WO2004056786A2 - Pyrimidine derivates for the treatment of abnormal cell growth - Google Patents

Pyrimidine derivates for the treatment of abnormal cell growth Download PDF

Info

Publication number
WO2004056786A2
WO2004056786A2 PCT/IB2003/006055 IB0306055W WO2004056786A2 WO 2004056786 A2 WO2004056786 A2 WO 2004056786A2 IB 0306055 W IB0306055 W IB 0306055W WO 2004056786 A2 WO2004056786 A2 WO 2004056786A2
Authority
WO
WIPO (PCT)
Prior art keywords
indol
pyridin
bromo
diamine
pyrimidine
Prior art date
Application number
PCT/IB2003/006055
Other languages
French (fr)
Other versions
WO2004056786A3 (en
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Priority to JP2004561885A priority Critical patent/JP2006515298A/en
Priority to BR0317435-2A priority patent/BR0317435A/en
Priority to CA002510848A priority patent/CA2510848A1/en
Priority to MXPA05006420A priority patent/MXPA05006420A/en
Priority to EP03780443A priority patent/EP1578732A2/en
Priority to AU2003288603A priority patent/AU2003288603A1/en
Publication of WO2004056786A2 publication Critical patent/WO2004056786A2/en
Publication of WO2004056786A3 publication Critical patent/WO2004056786A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • This invention relates to novel pyrimidine derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals
  • This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds
  • a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene ( ⁇ _e., a gene which, on activation, leads to the formation of malignant tumor cells)
  • ⁇ _e a gene which, on activation, leads to the formation of malignant tumor cells
  • oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation
  • the overexpression of a normal proto oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype
  • Receptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation
  • receptor tyrosine kinases include c-erbB-2, c-met, t ⁇ e-2, PDGFr, FGFr, and VEGFR It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer It has also been shown that epidermal growth factor receptor (EGFR), which possesses tyrosine kinase activity, is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells For example, erbstatin, a tyrosine kinase inhibitor, selectively attenuates
  • selective inhibitors of certain receptor tyrosine kinases are useful in the treatment of abnormal cell growth, in particular cancer, in mammals
  • selective inhibitors of certain non-receptor tyrosine kinases such as FAK (focal adhesion kinase), lck, src, abl or serine/threonine kinases (e g cyclm dependent kinases)
  • FAK is also known as the Protein-Tyrosme Kinase 2, PTK2
  • FAK a cytoplasmic, non-receptor tyrosine kinase
  • FAK was subsequently found to be a tyrosine kinase that localizes to focal adhesions, which are contact points between cultured cells and their underlying substratum and sites of intense tyrosine phosphorylation.
  • FAK is phosphorylated and, thus, activated in response to extracellular matrix (ECM)-binding to integrins.
  • ECM extracellular matrix
  • World Patent Application WO 92/20642 (published November 26, 1992), refers to certain bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation.
  • World Patent Applications WO96/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), WO 97/30034 (published August 21 , 1997), WO 98/02434 (published January 22, 1998), WO 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), also refer to substituted bicyclic heteroaromatic derivatives as tyrosine kinase inhibitors that are useful for the same purpose.
  • the present invention provides for novel pyrimidine derivatives which are selective inhibitors of the non-receptor tyrosine kinase, FAK, and are useful in the treatment of abnormal cell growth.
  • the present invention relates to a compound of the formula 1
  • R 1 has the following formula 2
  • each D is independently selected from the group consisting of CR -.8 and N, with the proviso that R 1 is linked to NH group through a ring carbon atom;
  • E and G are independently selected from the group consisting of N and C;
  • X, W and Q are independently selected from the group consisting of N, O, S, S0 2 , CO, NR 3 , CR 2 and CR 2 R 3 ;
  • Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, O, S, S0 2 , CO, NR 3 , CR 2 and CR 2 R 3 ;
  • A is present or absent, if present A is selected from the group consisting of O, S and NH and wherein B is present or absent, if present B is selected from the group consisting of
  • n is an integer from 1 to 3; wherein each R 2 is independently selected from the group consisting of H, alkyl,
  • NR 6 CONR 6 R 7 NHS0 2 R 6 , NR 6 S0 2 R 6 , with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom
  • said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C 6 alkyl, CN, NH 2 , NHR 10 , N(R 10 ) 2 , OR 10 , C C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalkyl, C0 2 R 11 , CONH 2 , CONHR 11 , and CONR 11 R 12 ; wherein each R 3 is independently selected from the group consisting of H, C C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalky
  • the compounds of formula 1 include those wherein E and G are independently selected from the group consisting of N and C; wherein X, W and Q are independently selected from the group consisting of N, O, CO, NR 3 , CR 2 and CR 2 R 3 ; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, O, CO, NR 3 , CR 2 and CR 2 R 3 .
  • the compounds of formula 1 include those wherein E and G are independently selected from the group consisting of N and C; wherein X, W and Q are independently selected from the group consisting of N, CO, NR 3 , CR 2 and CR 2 R 3 ; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, CO, NR 3 , CR 2 and CR 2 R 3 .
  • the compounds of formula 1 include those wherein E and G are C; wherein X, W and Q are independently selected from the group consisting of N, CO, NR 3 , CR 2 and CR 2 R 3 ; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, CO, NR 3 , CR 2 and
  • the compounds of formula 1 include those wherein E and G are C; wherein X, W and Q are independently selected from the group consisting of N, NR 3 , CR 2 and CR 2 R 3 ; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, NR 3 , CR 2 and CR 2 R 3 .
  • R 2 is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is selected from the group consisting of O and NH and wherein B is present or absent, if present B is selected from the group consisting of CO, S0 2 , and NR 6 , with the proviso that when A is O that B is absent.
  • Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is selected from the group consisting of CO, S0 2 , and NR 6 .
  • Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is selected from the group consisting of CO and NR .
  • the compounds of formula 1 include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is CO.
  • the compounds of formula ⁇ include those wherein A is present or absent, if present A is NH and wherein B is absent.
  • each R 2 is independently selected from the group consisting of H, d-C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalkyl, OC C 6 alkyl, OC 3 -C 7 cycloalkyl, OC 4 -C 7 heterocyloalkyl, NH 2 , NHR 6 , NR 6 R 7 , SR 6 , SOR 6 , S0 2 R 6 , C0 2 R 6 , CONH 2 , CONHR 6 , CONR 6 R 7 , NHCOR 6 , NR 6 CONR 6 , NHCONHR 6 , NR 6 CONHR 6 , NHCONR 6 R 7 , NR 6 CONR 6 R 7 , NHS0 2 R 6 , NR 6 S0 2 R 6 , with the proviso that O
  • each R 2 is independently selected from the group consisting of H, d-C 6 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 7 heterocycloalkyl, OC C 6 alkyl, OC 3 -C 7 cycloalkyl, OC 4 -C 7 heterocyloalkyl, NH 2 , NHR 6 , NR 6 R 7 , with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C 6 alkyl, CN, NH 2 , NHR 10 , N(R 10 ) 2 , OR 10 , d-C 6 alkyl, C 3 -C 7
  • R 5 is selected from the group consisting of H, Br, Cl, CN, CF 3 , CH 2 F, CHF 2 , S0 2 CH 3 , CONH 2 , and C 6 H 5 .
  • R 5 is selected from the group consisting of H, Br, Cl, CN, CF 3 , CH 2 F, CHF 2 , S0 2 CH 3 , and CONH 2 .
  • Other specific embodiments of the compounds of formula 1 include those selected from the group consisting of: 5-Bromo-N 2 -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N 4 -p-tolyl-pyrimidine-2,4- diamine;
  • 55--BBrroommoo--NN 44 ((22--pphh ⁇ enyl-cyclopropyl)-N 2 -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diiaammiinnee;;
  • N 4 (2-Benzo[1 ,3]dioxol-5-yl-ethyl)-5-bromo-N 2 -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine; 5-Bromo-N 4 -(3-phenyl-propyl)-N 2 -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
  • This invention also relates to a method for the treatment of abnormal cell growth in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1 , as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth.
  • the abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms
  • the method comprises comprising administering to a mammal an amount of a compound of formula 1 that is effective in treating said cancer solid tumor.
  • the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder cancer.
  • said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.
  • This invention also relates to a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of formula 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
  • an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
  • This invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, comprising an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.
  • said abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms
  • the invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth in combination with a pharmaceutically acceptable carrier and an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.
  • an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.
  • This invention also relates to a method for the treatment of a disorder associated with angiogenesis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating said disorder.
  • Such disorders include cancerous tumors such as melanoma; ocular disorders such as age-related macular degeneration, presumed ocular histoplasmosis syndrome, and retinal neovascularization from proliferative diabetic retinopathy; rheumatoid arthritis; bone loss disorders such as osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and osteoporosis induced by glucocorticoid treatment; coronary restenosis; and certain microbial infections including those associated with microbial pathogens selected from adenovirus, hantaviruses, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and group A Streptococcus.
  • This invention also relates to a method of (and to a pharmaceutical composition for) treating abnormal cell growth in a mammal which comprise an amount of a compound of formula 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents, which amounts are together effective in treating said abnormal cell growth.
  • Anti-angiogenesis agents such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound of formula 1 in the methods and pharmaceutical compositions described herein.
  • MMP-2 matrix-metalloprotienase 2
  • MMP-9 matrix-metalloprotienase 9
  • COX-II cyclooxygenase II
  • Examples of useful COX-II inhibitors include CELEBREXTM (alecoxib), valdecoxib, and rofecoxib.
  • Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No.
  • MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP- .
  • MMP- 2 and/or MMP-9 are those that selectively inhibit MMP- 2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1 , MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
  • MMP-1 matrix-metalloproteinases
  • MMP-3 matrix-metalloproteinases
  • MMP inhibitors useful in combination with the compounds of the present invention are AG-3340, RO 32-3555, RS 13-0830, and the compounds recited in the following list:
  • the compounds of formula 1 can also be used in combination with signal transduction inhibitors, such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTINTM (Genentech, Inc. of South San Francisco, California, USA).
  • signal transduction inhibitors such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTINTM (Genentech, Inc. of South San Francisco, California, USA).
  • EGFR inhibitors are described in, for example in WO 95/19970 (published July 27, 1995), WO 98/14451 (published April 9, 1998), WO 98/02434 (published January 22, 1998), and United States Patent 5,747,498 (issued May 5, 1998).
  • EGFR-inhibiting agents include, but are not limited to, CI-1033 (Pfizer Inc.), the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, New York, USA), the compounds ZD- 1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc.
  • VEGF inhibitors for example CP-547,632 and AG-13736 (Pfizer, Inc.), SU-5416 and SU-6668 (Sugen Inc. of South San Francisco, California, USA), can also be combined with a compound of formula 1.
  • VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT International Application PCT/IB99/00797 (filed May 3, 1999), in WO 95/21613 (published August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent 5,834,504 (issued November 10, 1998), WO 98/50356 (published November 12, 1998), United States Patent 5,883,113 (issued March 16, 1999), United States Patent 5,886,020 (issued March 23, 1999), United States Patent 5,792,783 (issued August 11 , WO 99/10349 (published March 4, 1999), WO 97/32856 (published September 12, 1997), WO 97/22596 (published June 26, 1997), WO 98/54093 (published December 3, 1998), WO 98/02438 (published January 22, 1998), WO 99/16755 (published April 8, 1999), and WO 98/02437 (published January 22, 1998), all of which are herein incorporated by reference in their
  • VEGF inhibitors include IM862 (Cytran Inc. of Kirkland, Washington, USA); anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, California; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California).
  • ErbB2 receptor inhibitors such as CP-724,714 (Pfizer, Inc.), GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) and 2B-1 (Chiron), may be administered in combination with a compound of formula 1.
  • Such erbB2 inhibitors include those described in WO 98/02434 (published January 22, 1998), WO 99/35146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 1998), WO 97/13760 (published April 17, 1997), WO 95/19970 (published July 27, 1995), United States Patent 5,587,458 (issued December 24, 1996), and United States Patent 5,877,305 (issued March 2, 1999), each of which is herein incorporated by reference in its entirety.
  • ErbB2 receptor inhibitors useful in the present invention are also described in United States Provisional Application No. 60/117,341 , filed January 27, 1999, and in United States Provisional Application No. 60/117,346, filed January 27, 1999, both of which are herein incorporated by reference in their entirety.
  • antiproliferative agents that may be used with the compounds of the present invention include inhibitors of HDI (CI-994, Pfizer Inc.), MEK (CI-1040, Pfizer Inc.), the enzyme farnesyl protein transferase and the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following United States patent applications: 09/221946 (filed December 28, 1998); 09/454058 (filed December 2, 1999); 09/501163 (filed February 9, 2000); 09/539930 (filed March 31 , 2000); 09/202796 (filed May 22, 1997); 09/384339 (filed August 26, 1999); and 09/383755 (filed August 26, 1999); and the compounds disclosed and claimed in the following United States provisional patent applications: 60/168207 (filed November 30, 1999); 60/170119 (filed December 10, 1999); 60/177718 (filed January 21 , 2000); 60/168217 (filed November 30, 1999), and 60/200834 (filed May 1 , 2000).
  • a compound of formula 1 may also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors described in the references cited in the "Background" section, supra.
  • CTLA4 cytotoxic lymphocite antigen 4
  • anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors described in the references cited in the "Background" section, supra.
  • Specific CTLA4 antibodies that can be used in the present invention include those described in United States Provisional Application 60/113,647 (filed December 23, 1998) which is herein incorporated by reference in its entirety.
  • abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that proliferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs..
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • halo includes fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.
  • alkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic (including mono- or multi-cyclic moieties) or branched moieties. It is understood that for said alkyl group to include cyclic moieties it must contain at least three carbon atoms.
  • cycloalkyl as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having cyclic (including mono- or multi-cyclic) moieties.
  • alkenyl as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon double bond.
  • alkynyl as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon triple bond.
  • aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
  • alkoxy as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.
  • 4 to 10 membered heterocyclic includes aromatic and non-aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system.
  • Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
  • the heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties.
  • An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
  • An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl.
  • Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6- tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • a group derived from pyrrole may be C- attached or N-attached where such is possible.
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • -(CR 1 R 2 ) m - and (CR 16 R 17 ) k moieties, and other similar moieties, as indicated above, may vary in their definition of R 1 , R 2 , R 16 and R 17 for each iteration of the subscript (ie, m, k, etc) above 1.
  • -(CR 1 R 2 ) m - may include -CH 2 C(Me)(Et)- where m is 2.
  • phrases "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention.
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • the acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [Le., 1 ,1'-methylene-bis-(2-hydroxy-3- naphthoate)] salts.
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.
  • Certain functional groups contained within the compounds of the present invention can be substituted for bioisosteric groups, that is, groups which have similar spatial or electronic requirements to the parent group, but exhibit differing or improved physicochemical or other properties. Suitable examples are well known to those of skill in the art, and include, but are not limited to moieties described in Patini et al., Chem. Rev, 1996, 96, 3147-3176 and references cited therein.
  • the compounds of the present invention have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms.
  • This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them.
  • the compounds of formula 1 may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.
  • the subject invention also includes isotopically-labelled compounds, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 4 C, 15 N, 18 0, 17 0, 35 S, 18 F, and 36 CI, respectively
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention
  • Certain isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are
  • This invention also encompasses pharmaceutical compositions containing and methods of treating bacterial infections through administering prodrugs of compounds of the formula 1
  • Compounds of formula 1 having free ammo, amido, hydroxy or carboxylic groups can be converted into prodrugs
  • Prodrugs include compounds wherein an ammo acid residue, or a polypeptide chain of two or more (e g , two, three or four) ammo acid residues is covalently joined through an amide or ester bond to a free ammo, hydroxy or carboxylic acid group of compounds of formula 1
  • the ammo acid residues include but are not limited to the 20 naturally occurring ammo acids commonly designated by three letter symbols and also includes 4- hydroxyproline, hydroxylysme, demosme, isodemosme, 3-methylh ⁇ st ⁇ d ⁇ ne, norva n, beta-alanine, gamma-aminobutync acid, citrulline homocysteine, homose ⁇ ne, ornithine and me
  • ester optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed.
  • Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
  • the compounds of formula 1 can be prepared using the following synthetic scheme 1.
  • the substituents in scheme 1 have the same meaning as the substituents defined for formula 1.
  • the substituent Lg in the compounds of formulas 2 and 4 is a leaving group. Leaving groups are well-known to those of ordinary skill in the art. Applicants also direct the reader's attention to the Experimental section for particular examples of leaving group employed in the preparation of the compounds of the present invention.
  • starting materials may be purchased and used directly or alternatively, starting materials can be prepared by one skilled in the art utilizing known procedures obtained from standard chemistry references (such as, Organic Synthesis (McGraw Hill) Michael Smith). It is understood that starting materials may be optionally protected as to not interfere with a desired chemical reaction (see Protecting Groups in Organic Synthesis (Wiley-lnterscience), Green and Wutts). Subsequent de-protection of potentially interfering functional group may be effected at a later appropriate time to obtain the necessary desired material.
  • a pyrimidine of the general formula I may be purchased or prepared from known materials by one skilled in the art.
  • Lg is defined as a displaceable leaving group that includes halogens and sulfonyl groups.
  • a pyrimidine of formula 2 may be reacted together with a compound of formula 3, optionally in the presence of a suitable base and optionally in the presence of a suitable inert solvent and at a temperature range of OoC to 150°C.
  • Suitable bases employed may be the following but not limited to (i) organic bases, for example triethylamine, or diisopropylethylamine and (ii) inorganic bases such as potassium carbonate or cesium carbonate.
  • the reaction may be performed neat or carried out in a suitable inert solvent.
  • Suitable inert solvents are but not limited to tetrahydrofuran, 1 ,4- dioxane, dimethylformamide, n-methyl pyrrolidin-2-one, ethanol, butanol, dichloromethane, or acetonitrile.
  • pyrimidine of formula 4 may be reacted together with amine compounds of formula IV optionally in the presence of a suitable base and optionally in the presence of a suitable inert solvent and at a temperature range of 0°C to 150°C conveniently at or near reflux to obtain compounds of formula 6.
  • the reaction may be performed neat or optionally carried out in a suitable inert solvent.
  • suitable inert solvents are but not limited to tetrahydrofuran, 1,4-dioxane, dimethylformamide, n-methyl pyrrolidin-2-one, ethanol, butanol, dichloromethane, dimethyl sulfoxide or acetonitrile.
  • the compounds of the present invention may have asymmetric carbon atoms.
  • Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
  • the compounds of formulas 1 that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of formula 1 from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • Those compounds of formula 1 that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula 1.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
  • the compounds of the present invention are potent inhibitors of the FAK protein tyrosine kinases, and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer), antitumor (e.g., effective against solid tumors), antiangiogenesis (e.g., stop or prevent proliferationation of blood vessels) in mammals, particularly in humans.
  • antiproliferative agents e.g., anticancer
  • antitumor e.g., effective against solid tumors
  • antiangiogenesis e.g., stop or prevent proliferationation of blood vessels
  • the compounds of the present invention are useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplastic conditions such as benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH). It is, in addition, expected that a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies.
  • cancer is selected from lung cancer, bone cancer, pancreatic cancer, gastric, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, gynecological, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, squamous cell, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal
  • cancer is selected a solid tumor, such as, but not limited to, breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder.
  • a solid tumor such as, but not limited to, breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder.
  • the compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions or activation or signalling events related to various protein tyrosine kinases, are involved.
  • Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases are involved.
  • the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.
  • the in vitro activity of the compounds of formula 1 may be determined by the following procedure. More particularly, the following assay provides a method to determine whether compounds of the formula 1 inhibit the tyrosine kinase activity of the catalytic construct
  • the assay is an ELISA-based format, measuring the inhibition of poly-glu-tyr phosphorylation by FAK(410-689).
  • the assay protocol has three parts: I. Purification and cleavage of His-FAK(410-689) II. FAK410-689 (a.k.a. FAKcd) Activation
  • -FAK(410-689) 3 tubes of frozen aliquots at 150ul/tube for a total of 450ul at 1.48 mg/ml (660ug) -His-Src(249-524): -0.74 mg/ml stock in 10mM HEPES, 200mM (NH4)2S04 -Src reaction buffer (Upstate Biotech): 100 mM Tris-HCI pH7.2, 125mM MgCI 2 , 25 mM MnCI 2 ,
  • ImM DTT -ATP 150m M stock -MgCI 2 : 1 M Stock -DTT: 1 M stock Reagents for FAKcd Kinase ELISA
  • the signal is typically 0.8-1.0 OD units.
  • the values are reported as ICso s , uM concentration.
  • FAK Inducible cell-based ELISA Final Protocol Materials: Reacti-Bind Goat Anti-Rabbit Plates 96-well (Pierce Product#15135ZZ @115.00 USD)
  • Inhibition of the kinase-dependent autophosphorylation at Y397 results in a reduced absorbance signal at OD 450 .
  • the signal is typically 0.9 to 1.5 OD 450 units with the noise falling in the range of 0.08 to 0.1 OD 450 units.
  • the values are reported as IC 50 S, uM concentration.
  • control wells may be coated with 3.5 ug/ml of control Capture antibody (Whole Rabbit IgG molecules) prepared in SuperBlock TBS. Wash off excess FAKpY397 antibody 3 times using buffer. Block Anti-FAKpY397 coated plate(s) with 200 ul per well of 3%BSA 0.5%Tween Blocking buffer for 1 hour at room temperature on the plate shaker.
  • RIPA lysis buffer 50 mM Tris-HCI, pH7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCI, 1 mM EDTA, 1 mM Na3V04, 1 mM NaF, and one CompleteTM EDTA-free protease inhibitor pellet per 50 ml solution.
  • TBS-T wash buffer To the coated plate, remove blocking buffer and wash 3 times using TBS-T wash buffer. Using a 96-well automated microdispenser, transfer 100 ul of whole cell-lysate (from step 6) to the Goat Anti-Rabbit FAKpY397 coated plate(s) to capture phosphoFAKY397 proteins. Shake at room temperature for 2 hours. Wash off unbound proteins 3 times using TBS-T wash buffer. Prepare 0.5 ug/ml (1 :2000 dilution) of UBI ⁇ FAK detection antibody in 3%BSA/0.5% Tween blocking buffer. Dispense 100 ul of UBI ⁇ FAK solution per well and shake for 30 minutes at room temperature. Wash off excess UBI ⁇ FAK antibody 3 times using TBS-T wash buffer.
  • administering can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
  • an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
  • the active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No.
  • mitotic inhibitors for example vinblastine
  • alkylating agents for example cis-platin, carboplatin and cyclophosphamide
  • anti-metabolites for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No.
  • the pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
  • the pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
  • Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
  • Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents.
  • the pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • excipients such as citric acid
  • disintegrants such as starch, alginic acid and certain complex silicates
  • binding agents such as sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
  • Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules.
  • Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
  • diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
  • the mixture was stirred under nitrogen and then heated to 110° C for sixteen hours.
  • the reaction was cooled and was then dissolved in a solution of 5% methanol- dichloromethane and extracted with 1 N NaOH.
  • the organic and aqueous layers were separated and the aqueous layer was further extracted with additional 5% methanol- dichloromethane.
  • the organic layers were combined, washed with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure.
  • Example 1D The title compound was made in a manner similar to Example 1D. It was isolated in a manner similar to Example 1D. It was isolated in a manner similar to Example 1D.
  • the title compound was synthesized by dissolving 4-[5-(4-Benzylamino-5-bromo- pyrimidin-2-ylamino)-1 H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester into 5.00 mL dichloromethane and cooling to 0° C. To this was added 10.0 mL Trifluoroacetic acid. The red solution was allowed to slowly warm to room temperature and stir under N2 for two hours. 5.00 mL ethyl acetate was added. Filtration of the resulting precipitate gave the title compound as a white solid. C 24 H 23 BrN 6 .
  • the mixture was stirred under nitrogen and then heated to 110° C for sixteen hours.
  • the reaction was cooled and was then dissolved in a solution of 5% methanol- dichloromethane and extracted with 1 N NaOH.
  • the organic and aqueous layers were separated and the aqueous layer was further extracted with additional 5% methanol- dichloromethane.
  • the organic layers were combined, washed with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure.
  • Example 37A 5-Bromo-N 4 -(2-phenyl-cvclopropyl)-N 2 -r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5- vn-pyrimidine-2.4-diamine (homo-chiral)
  • Example 37B
  • This adsorbed compound was purified via column chromatography (97.8:2:0.2 CHCI 3 :CH 3 OH:NH 4 OH) over silica to isolate the major product. During evaporation of the major fractions, a white precipitate is noted. Filtration of this precipitate prior to mLete evaporation afforded the title compound in 6% yield as a white solid.
  • Example 9 The title compound was made in a 1% yield in a manner described in Example 9. It was characterized as a white solid isolated as its free base after purifying the TFA salt over silica (93:7:0.7 CHCI 3 :CH 3 OH:NH 4 OH). d ⁇ N ? .
  • Example 1 D The title compound was made in a manner similar to Example 1 D and deprotected according to the procedure of Example 1 E in a 38% yield.
  • the compound was characterized as an off-white solid and isolated as its HCI salt.
  • Example 1A It was characterized as an oily, yellow solid without purification.
  • Example 1D and 1E The title compound was made in a 2% yield via the manner described in Example 1D and 1E. It was characterized as an off white solid isolated as its free base after purifying the HCI salt over silica (93:7:0.7 CHCI 3 :CH 3 OH:NH 4 OH). C 24 H 24 BrN 7 . HPLC ret.
  • Example 60A 5-(5-Bromo-4-[2-(3-chloro-phenyl)-ethylamino1-pyrimidin-2-ylamino ⁇ -1 ,3-dihvdro-indol- 2-one
  • Example 84 6- ⁇ 5-Bromo-4-r(thiophen-2-ylmethyl)-amino1-pyrimidin-2-ylamino ⁇ -1 ,3-dihvdro-indol-2- one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-thiophen-2-ylmethyl-amine (CqH7BrCIN 3 S).

Abstract

The invention relates to compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, n, A and B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (1) and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (1). The invention also relates to methods of preparing the compounds of formula (1).

Description

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Background of the Invention This invention relates to novel pyrimidine derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds
It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (ι_e., a gene which, on activation, leads to the formation of malignant tumor cells) Many oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation Alternatively, the overexpression of a normal proto oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype
Receptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation
Other receptor tyrosine kinases include c-erbB-2, c-met, tιe-2, PDGFr, FGFr, and VEGFR It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer It has also been shown that epidermal growth factor receptor (EGFR), which possesses tyrosine kinase activity, is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells For example, erbstatin, a tyrosine kinase inhibitor, selectively attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma which expresses epidermal growth factor receptor tyrosine kinase
(EGFR) but is without effect on the growth of another carcinoma which does not express the EGF receptor Thus, selective inhibitors of certain receptor tyrosine kinases, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals In addition to receptor tyrosine kinses, selective inhibitors of certain non-receptor tyrosine kinases, such as FAK (focal adhesion kinase), lck, src, abl or serine/threonine kinases (e g cyclm dependent kinases, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals FAK is also known as the Protein-Tyrosme Kinase 2, PTK2
Convincing evidence suggests that FAK, a cytoplasmic, non-receptor tyrosine kinase, plays an essential role in cell-matrix signal transduction pathways (Clark and Brugge 1995 Scιence_268 233-239) and its aberrant activation is associated with an increase in the metastatic potential of tumors (Owens et al. 1995, Cancer Research 55: 2752-2755). FAK was originally identified as a 125 kDa protein highly tyrosine-phosphorylated in cells transformed by v-Src. FAK was subsequently found to be a tyrosine kinase that localizes to focal adhesions, which are contact points between cultured cells and their underlying substratum and sites of intense tyrosine phosphorylation. FAK is phosphorylated and, thus, activated in response to extracellular matrix (ECM)-binding to integrins. Recently, studies have demonstrated that an increase in FAK mRNA levels accompanied invasive transformation of tumors and attenuation of the expression of FAK (through the use of antisense oligonucleotides) induces apoptosis in tumor cells (Xu et al. 1996, Cell Growth and Diff. 7: 413-418). In addition to being expressed in most tissue types, FAK is found at elevated levels in most human cancers, particularly in highly invasive metastases.
Various compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. Five European patent publications, namely EP 0 566 226 A1 (published October 20, 1993), EP 0 602 851 A1 (published June 22, 1994), EP 0 635 507 A1 (published January 25, 1995), EP 0 635498 A1 (published January 25, 1995), and EP 0 520 722 A1 (published December 30, 1992), refer to certain bicyclic derivatives, in particular quinazoline derivatives, as possessing anti-cancer properties that result from their tyrosine kinase inhibitory properties.
Also, World Patent Application WO 92/20642 (published November 26, 1992), refers to certain bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation. World Patent Applications WO96/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), WO 97/30034 (published August 21 , 1997), WO 98/02434 (published January 22, 1998), WO 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), also refer to substituted bicyclic heteroaromatic derivatives as tyrosine kinase inhibitors that are useful for the same purpose.
Accordingly, a need exists for additional selective inhibitors of certain receptor and non- receptor tyrosine kinases, useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention provides for novel pyrimidine derivatives which are selective inhibitors of the non-receptor tyrosine kinase, FAK, and are useful in the treatment of abnormal cell growth. Summary of the Invention The present invention relates to a compound of the formula 1
Figure imgf000004_0001
1 or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R1 has the following formula 2
Figure imgf000004_0002
wherein each D is independently selected from the group consisting of CR -.8 and N, with the proviso that R1 is linked to NH group through a ring carbon atom; wherein E and G are independently selected from the group consisting of N and C; wherein X, W and Q are independently selected from the group consisting of N, O, S, S02, CO, NR3, CR2 and CR2R3; wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, O, S, S02, CO, NR3, CR2 and CR2R3; wherein A is present or absent, if present A is selected from the group consisting of O, S and NH and wherein B is present or absent, if present B is selected from the group consisting of
CO, S02, and NR6, with the proviso that when A is O or S that B is absent; wherein n is an integer from 1 to 3; wherein each R2 is independently selected from the group consisting of H,
Figure imgf000004_0003
alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OC C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl,
NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2,
S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7,
NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein each R3 is independently selected from the group consisting of H, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, CONR6R7 or R2 and R3 taken together with the carbon atom they are linked to can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring, wherein each methylene group present in said 3-7 membered cycloalkyl ring and said 4-7 membered heterocycloalkyl ring may be optionally replaced by a C=0 group, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, CrC6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein R4 is selected from the group consisting of H, CrC6 alkyl, C3-C7 cycloalkyl, C4- C7 heterocycloalkyl, C6-C10 aryl, and 5-10 membered heteroaryl, the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 subsitutents independently selected from the group consisting of H, halo, OH, N02, Cr C6 alkyl, C(R6)=CR6R7, C≡CR6, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OCrC6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, C=N-OH, C=N-0(C C6 alkyl), NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom; wherein R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, S02CH3, CONH2, cyclopropyl, cyclobutyl, C6H5> CONHR6, CONR6R7, C02R6, C(R9)=C(R9)2, and C≡CR9; wherein each R6 is independently selected from the group consisting of H,
Figure imgf000005_0001
alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-C10 aryl, and 5-10 membered heteroaryl, said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, CrC6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein each R7 is independently selected from the group consisting of H, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, and 5-10 membered heteroaryl, said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Ci-Ce alkyl, CN, NH2, NHR10, N(R10)2, OR10, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12; wherein each R8 is independently selected from the group consisting of H, halo, cyano, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OC C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, said alkyl, cycloalkyl, and heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR3, N(R3)2, OR3, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, and CONR6R7; wherein each R9 is independently selected from the group consisting of H, CF3, and d- C6 alkyl, said d-C6 alkyl is optionally substituted by 1 to 6 halo atoms; wherein each R10 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, CONR11R12, SOR11, S02R11, S02NH2, S02NHR11, S02NR11R12; said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR13, N(R13)2, OR13, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, and CONR14R15 wherein each R11 is independently selected from the group consisting of H, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-C10 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-Cβ alkyl, CN, NH2, NHR13, N(R13)2, OR13, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, and CONR14R15; wherein each R12 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-C10 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NHR13, N(R13)2, OR13, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, and CONR1 R15; wherein each R13 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, CONR14R15, SOR14, S02R14, S02NH2, S02NHR14, S02NR14R15; wherein each R14 is independently selected from the group consisting of H, CrCβ alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-C10 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NH d-C6alkyl, N(C C6alkyl)2, 0-C C6 alkyl; and wherein each R15 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cιo aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NH d-C6alkyl, N(d-C6alkyl)2, 0-C C6 alkyl.
In one preferred embodiment of the compounds of formula 1 , include those wherein E and G are independently selected from the group consisting of N and C; wherein X, W and Q are independently selected from the group consisting of N, O, CO, NR3, CR2 and CR2R3; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, O, CO, NR3, CR2 and CR2R3.
In another preferred embodiment of the compounds of formula 1 , include those wherein E and G are independently selected from the group consisting of N and C; wherein X, W and Q are independently selected from the group consisting of N, CO, NR3, CR2 and CR2R3; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, CO, NR3, CR2 and CR2R3.
In a more preferred embodiment of the compounds of formula 1 , include those wherein E and G are C; wherein X, W and Q are independently selected from the group consisting of N, CO, NR3, CR2 and CR2R3; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, CO, NR3, CR2 and
CR2R3.
In a most preferred embodiment of the compounds of formula 1 , include those wherein E and G are C; wherein X, W and Q are independently selected from the group consisting of N, NR3, CR2 and CR2R3; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, NR3, CR2 and CR2R3.
In one specific embodiment of the compounds of formula 1 , include those wherein R2 is selected from the group consisting of:
Figure imgf000008_0001
In another specific embodiment of the compounds of formula 1 , include those wherein R2 is selected from the group consisting of:
Figure imgf000008_0002
In another specific embodiment of the compounds of formula 1 , include those wherein R2 is selected from the group consisting of:
Figure imgf000009_0001
Figure imgf000009_0002
Figure imgf000009_0003
Figure imgf000009_0005
Figure imgf000009_0007
Figure imgf000009_0006
Figure imgf000009_0004
Specific embodiments of the compounds of formula 1 include those wherein R2 is selected from the group consisting of: -9-
Figure imgf000010_0001
Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is selected from the group consisting of O and NH and wherein B is present or absent, if present B is selected from the group consisting of CO, S02, and NR6, with the proviso that when A is O that B is absent.
Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is selected from the group consisting of CO, S02, and NR6. Specific embodiments of the compounds of formula 1 include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is selected from the group consisting of CO and NR .
In one preferred embodiment of the compounds of formula 1, include those wherein A is present or absent, if present A is NH and wherein B is present or absent, if present B is CO.
In a more preferred embodiment of the compounds of formula Λ include those wherein A is present or absent, if present A is NH and wherein B is absent.
In a most preferred embodiment of the compounds of formula include those wherein A is NH and wherein B is absent. Specific embodiments of the compounds of formula Λ include those each R2 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OC C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, CrC6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; and wherein each R3 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, CONR6R7 or R2 and R3 taken together with the carbon atom they are linked to can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring, wherein each methylene group present in said 3-7 membered cycloalkyl ring and said 4-7 membered heterocycloalkyl ring may be optionally replaced by a C=0 group, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 .
Specific embodiments of the compounds of formula 1 include those each R2 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OC C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, NH2, NHR6, NR6R7, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; and wherein each R3 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, CONR6R7 or R2 and R3 taken together with the carbon atom they are linked to can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring, wherein each methylene group present in said 3-7 membered cycloalkyl ring and said 4-7 membered heterocycloalkyl ring may be optionally replaced by a C=0 group, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 .
Specific embodiments of the compounds of formula 1 include those R4 is selected from the group consisting of H, C C6 alkyl, C6-C10 aryl, and 5-10 membered heteroaryl, the alkyl, aryl and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 subsitutents independently selected from the group consisting of H, halo, OH, N02, d-C6 alkyl, C(R6)=CR6R7, C≡CR6, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, Od-C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, C=N-OH, C=N-0(C C6 alkyl), NH2, NHR6, NR6R7, SR6, SOR6, S02R6, COzR6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6 NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom.
Specific embodiments of the compounds of formula 1 include those R4 is selected from the group consisting of H, C C6 alkyl, and C6-C10 aryl, wherein the alkyl, and aryl moieties of the foregoing groups are optionally substituted by 1 to 3 subsitutents independently selected from the group consisting of H, halo, OH, N02, C C6 alkyl, C(R6)=CR6R7, C≡CR6, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OCrC6 alkyl, 0C3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, C=N-OH, C=N-0(C C6 alkyl), NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom.
Specific embodiments of the compounds of formula 1 include those R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, SOzCH3, CONH2, C6H5, CONHR6, CONR6R7, C02R6, C(R9)=C(R9)2, and C≡CR9.
Specific embodiments of the compounds of formula 1 include those R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, S02CH3, CONH2, and C6H5.
Specific embodiments of the compounds of formula 1 include those R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, S02CH3, and CONH2. Other specific embodiments of the compounds of formula 1 include those selected from the group consisting of: 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-p-tolyl-pyrimidine-2,4- diamine;
5-Bromo-N4-pyridin-2-yl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
N4-Benzyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine- 2,4-diamine;
5-Bromo-N4-(1 R-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N -(1rac-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(1 S-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 4-({5-Bromo-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-ylamino]-pyrimidin-4- ylamino}-methyl)-benzenesulfonamide
5-Bromo-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]-N4-(4-trifluoromethyl- benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-methoxy-benzyl)-N -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(4-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-naphthalen-1-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-fluoro-3-trifluoromethyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)- 1H-indol-5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(3-fluoro-5-trifluoromethyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)- 1 H-indol-5-yl]-pyhmidine-2,4-diamine;
5-Bromo-N4-(4-phenoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3,4-difluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(3-trifluoromethoxy- benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-chloro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]-N4-thiophen-2-ylmethyl- pyrimidine-2,4-diamine;
5-Bromo-N4-furan-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-(2-methyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3-methyl-benzyl)-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(4-methyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
N -Biphenyl-2-ylmethyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; N4-Biphenyl-3-ylmethyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-methoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyhmidine-2,4-diamine;
5-Bromo-N4-(3-methoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyhmidine-2,4-diamine;
3-({5-Bromo-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-ylamino]-pyrimidin-4- ylam ino}-methyl)-N-methyl-benzam ide
5-Bromo-N4-(2-chloro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-phenethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine-
2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-4-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-3-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(3-fluoro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-ρyridin-4-yl)-1 H-indol-
5-yl]-pyrimidine-2,4-diamine;
55--BBrroommoo--NN44--((22--pphh<enyl-cyclopropyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diiaammiinnee;;
55--BBrroommoo--NN --((22--pphh«enyl-cyclopropyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; (homo-chiral) 5-Bromo-N4-(2-phenyl-cyclopropyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; (homo-chiral)
5-Bromo-N4-[2-(4-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine; 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-thiophen-2-yl- ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(2-fluoro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(2-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(2-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine;
N4-(2-Benzo[1 ,3]dioxol-5-yl-ethyl)-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine; 5-Bromo-N4-(3-phenyl-propyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2-chloro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-(4-Benzylamino-5-bromo-pyrimidin-2-ylamino)-1 ,3-dihydro-indol-2-one; 5-[5-Bromo-4-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(3-phenyl-propylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-(2-methanesulfonyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyhmidine-2,4-diamine;
N4-Benzyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine-2,4-diamine; N4-Benzyl-N4-methyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine-
2,4-diamine;
N4-Methyl-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
[4-(2-Phenyl-morpholin-4-yl)-pyrimidin-2-yl]-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-amine
5-Methyl-N -(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N2-(3-piperidin-4-yl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4- diamine; 5-Bromo-N2-[1 -methanesulfonyl-3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-
(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-[1 -methanesulfonyl-3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4- pyridin-2-yl-pyrimidine-2,4-diamine; 5-Bromo-N2-(2-pyridin-2-yl-ethyl)-N4-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
3-{4-(2-Pyridin-2-yl-ethylamino)-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- ylamino]-pyrimidin-5-yl}-acrylic acid; ethyl ester; 5-{5-Bromo-4-[2-(3-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-
2-one;
5-Bromo-N4-[2-(3-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(3-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-Bromo-N4-[2-(4-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine; 5-{5-Bromo-4-[2-(3-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-Bromo-N4-[2-(3-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H- indol-5-yl]-pyrimidine-2,4-diamine;
5-[5-Bromo-4-(2-o-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-o-tolyl-ethyl)- pyrimidine-2,4-diamine;
5-[5-Bromo-4-(2-m-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-m-tolyl-ethyl)- pyrimidine-2,4-diamine; 5-[5-Bromo-4-(2-p-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-p-tolyl-ethyl)- pyrimidine-2,4-diamine;
[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-acetic acid;
5-{5-Bromo-4-[2-(3-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one;
5-[4-(2-Biphenyl-4-yl-ethylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
5-{5-Bromo-4-[2-(3-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one; 5-{5-Bromo-4-[2-(2-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-
2-one;
5-{5-Bromo-4-[2-(2-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; 5-{5-Bromo-4-[2-(4-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-{5-Bromo-4-[2-(4-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one; 5-{5-Bromo-4-[2-(2-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-
2-one;
5-[5-Bromo-4-(3-phenyl-allylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-{5-Bromo-4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one; 6-{5-Bromo-4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 6-[5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 5-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 6-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 6-[5-Bromo-4-ι 2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-ι 2-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-ι 3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one; 6-[5-Bromo-4-ι 3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-ι 4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Bromo-4-i 4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Bromo-4 2-methoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4- 3-methoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4' 3-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol-
2-one; 5-[5-Bromo-4 (thiazol-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-{5-Bromo-4 (5-methanesulfonyl-thiophen-2-ylmethyl)-amino]-pyhmidin-2-ylamino}-
1 ,3-dihydro-indol-2-one; 5-[5-Bromo-4-(2,3-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(2,3-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 6-[5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-
2-one;
5-Chloro-N2-(1-methyl-1H-indol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine;
5-Chloro-N2-(1H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine; 5-Chloro-N2-(1-methyl-1H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
6-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Chloro-N2-(1H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Chloro-N2-(1H-indazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1 -yl)-acetic acid; tert-butyl ester;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-2-yl)-acetic acid; tert-butyl ester;
6-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
N2-(1-Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4- diamine;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; tert-butyl ester; N4-Pyridin-2-ylmethyl-N2-quinolin-5-yl-5-trifluoromethyl-pyrimidine-2,4-diamine;
2-(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-N-(2- methoxy-ethyl)-acetamide;
6-{5-Chloro-4-[(3-methyl-pyhdin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; (6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1 -yl)-acetic acid;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid; tert-butyl ester;
N2-(1 H-lndazol-6-yl)-N4-pyhdin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine;
(5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; tert-butyl ester;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid;
(5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid;
5-{5-Chloro-4-[(3-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; 5-[5-Chloro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[5-Bromo-4-(2-methoxy-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-{5-Chloro-4-[(4-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-(4-Benzylamino-5-chloro-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one; 5-Bromo-N2-(1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 H-indol-4-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine; N2-(1 H-lndazol-5-yl)-N4-pyhdin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1,3-dihydro- benzoimidazol-2-one; 5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1,3-dihydro- benzoimidazol-2-one;
5-{4-[(Pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-benzoimidazol-2- one;
5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-benzoimidazol-2-one; 5-Bromo-N2-(1 H-indazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyhmidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(2-Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine2,4-diamine;
N2-(1 H-Benzoimidazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-Benzoimidazol-5-yl)-5-bromo-N4-(2-pyridin-2-yl-ethyl)-pyhmidine-2,4-diamine; 3-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-yl]-3H-benzoimidazol-5-ylamine
N2-(1 H-Benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4- diamine;
N2-(2-Methyl-1 H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-
2,4-diamine;
5-Bromo-N2-(2,3-dihydro-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4- diamine;
N2-(2,3-Dihydro-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(1-Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2,3-dihydro-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Fluoro-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine; 5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-7-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indazol-4-yl)-N4-pyhdin-2-ylmethyl-pyrimidine-2,4-diamine;
6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-6-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-5-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-5-yl-pyrimidine-2,4-diamine; 6-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-8-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-8-yl-pyrimidine-2,4-diamine; 5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 H-indole-2-carboxylic acid; ethyl ester;
6-[5-Bromo-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one; 5-Bromo-N2-(1 H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine;
5-Bromo-N2-(1 H-indazol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-3H-isobenzofuran-1- one;
N2-Benzothiazol-6-yl-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-2-methyl-1 H-indole-3- carbonitrile
5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1 H-indazol-5-yl)-pyrimidine- 2,4-diamine;
N2-(1-Benzyl-1H-indol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1H-indol-5-yl)-pyrimidine-2,4- diamine;
N2-(1-Benzyl-1 H-indazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 -methyl-1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; 5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-cyclohexylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
1 -{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3- (1 ,2,3,6-tetrahydro-pyridin- 4-yl)-1 H-indol-5-ylamine
1-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3-(1 ,2,3,6-tetrahydro-pyridin- 4-yl)-1 H-indol-5-ylamine
5-Fluoro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Chloro-N2-(1H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one; 5-Fluoro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Chloro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Fluoro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-[5-Fluoro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Chloro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-[5-Chloro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-{5-Methoxy-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Methoxy-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 5-[5-Methoxy-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-
2-one;
5-{5-Bromo-4-[(cyclohex-1-enylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-[5-Bromo-4-(methyl-pyridin-2-ylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 5-[5-Bromo-4-(cyclohexylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one;
2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile 5-{5-Methyl-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
N2-(1 H-lndazol-5-yl)-5-methyl-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Fluoro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Chloro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-4-(2-trifluoromethyl-benzylamino)- pyrimidine-5-carbonitrile 5-{4-[Methyl-(2-pyridin-2-yl-ethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-cyclohex-1 -enylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine; 5-[5-Trifluoromethyl-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one;
6-{2-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-4-ylamino}-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(piperidin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[4-(1 -Acetyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
2-(2-Oxo-2,3-dihydro-1 H-indol-6-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile
5-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one;
6-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one;
4-[5-Bromo-2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine- 1 -carboxylic acid; tert-butyl ester; 5-[5-Bromo-4-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one;
5-[5-Bromo-4-(piperidin-3-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
4-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine- 1 -carboxylic acid; ethylamide 3-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine-
1 -carboxylic acid; ethylamide
5-[4-(1-Benzoyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one;
6-[4-(3-Methanesulfonyl-benzylamino)-5-methoxy-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1,3- dihydro-indol-2-one;
6-[4-(3-Methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[4-(1-Benzenesulfonyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one;
5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one; 6-{5-Chloro-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
6-{5-Chloro-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one; 6-{5-Bromo-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
6-{5-Bromo-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one;
5-[5-Fluoro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-{5-Bromo-4-[(1-hydroxy-cyclohexylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; and pharmaceutically acceptable salt, prodrug, hydrate or solvate of the aforementioned compounds. This invention also relates to a method for the treatment of abnormal cell growth in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1 , as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth. In one embodiment of this method, the abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In one embodiment the method comprises comprising administering to a mammal an amount of a compound of formula 1 that is effective in treating said cancer solid tumor. In one preferred embodiment the solid tumor is breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder cancer. In another embodiment of said method, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis. This invention also relates to a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of formula 1 , or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
This invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, comprising an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier. In one embodiment of said composition, said abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said pharmaceutical composition, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.
The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating abnormal cell growth in combination with a pharmaceutically acceptable carrier and an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens. This invention also relates to a method for the treatment of a disorder associated with angiogenesis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that is effective in treating said disorder. Such disorders include cancerous tumors such as melanoma; ocular disorders such as age-related macular degeneration, presumed ocular histoplasmosis syndrome, and retinal neovascularization from proliferative diabetic retinopathy; rheumatoid arthritis; bone loss disorders such as osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and osteoporosis induced by glucocorticoid treatment; coronary restenosis; and certain microbial infections including those associated with microbial pathogens selected from adenovirus, hantaviruses, Borrelia burgdorferi, Yersinia spp., Bordetella pertussis, and group A Streptococcus. This invention also relates to a method of (and to a pharmaceutical composition for) treating abnormal cell growth in a mammal which comprise an amount of a compound of formula 1, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents, which amounts are together effective in treating said abnormal cell growth.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors, MMP-9 (matrix-metalloprotienase 9) inhibitors, and COX-II (cyclooxygenase II) inhibitors, can be used in conjunction with a compound of formula 1 in the methods and pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7, 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 98/34918 (published August 13, 1998), WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO 98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931 ,788 (published July 28, 1999), WO 90/05719 (published May 331 , 1990), WO 99/52910 (published October 21 , 1999), WO 99/52889 (published October 21 , 1999), WO 99/29667 (published June 17, 1999), PCT International Application No. PCT/IB98/01113 (filed July 21 , 1998), European Patent Application No. 99302232.1 (filed March 25, 1999), Great Britain patent application number 9912961.1 (filed June 3, 1999), United States Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863,949 (issued January 26, 1999), United States Patent 5,861 ,510 (issued January 19, 1999), and European Patent Publication 780,386 (published June 25, 1997), all of which are herein incorporated by reference in their entirety. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP- . More preferred, are those that selectively inhibit MMP- 2 and/or MMP-9 relative to the other matrix-metalloproteinases (i.e. MMP-1 , MMP-3, MMP-4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).
Some specific examples of MMP inhibitors useful in combination with the compounds of the present invention are AG-3340, RO 32-3555, RS 13-0830, and the compounds recited in the following list:
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclopentyl)-amino]- propionic acid;
3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3- carboxylic acid hydroxyamide; (2R, 3R) 1-[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl- piperidine-2-carboxylic acid hydroxyamide;
4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-cyclobutyl)-amino]- propionic acid;
4-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide;
3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-3-carboxylic acid hydroxyamide; (2R, 3R) 1-[4-(4-fluoro-2-methyl-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl- piperidine-2-carboxylic acid hydroxyamide;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamoyl-1-methyl-ethyl)- aminoj-propionic acid;
3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4-hydroxycarbamoyl-tetrahydro-pyran-4-yl)- amino]-propionic acid;
3-exo-3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3- carboxylic acid hydroxyamide;
3-endo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1]octane-3- carboxylic acid hydroxyamide; and 3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxylic acid hydroxyamide; and pharmaceutically acceptable salts, solvates and prodrugs of said compounds.
The compounds of formula 1 , and the pharmaceutically acceptable salts, solvates and prodrugs thereof, can also be used in combination with signal transduction inhibitors, such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN™ (Genentech, Inc. of South San Francisco, California, USA).
EGFR inhibitors are described in, for example in WO 95/19970 (published July 27, 1995), WO 98/14451 (published April 9, 1998), WO 98/02434 (published January 22, 1998), and United States Patent 5,747,498 (issued May 5, 1998). EGFR-inhibiting agents include, but are not limited to, CI-1033 (Pfizer Inc.), the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, New York, USA), the compounds ZD- 1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, New Jersey, USA), and OLX-103 (Merck & Co. of Whitehouse Station, New Jersey, USA), VRCTC-310 (Ventech Research) and EGF fusion toxin (Seragen Inc. of Hopkinton, Massachusettes).
VEGF inhibitors, for example CP-547,632 and AG-13736 (Pfizer, Inc.), SU-5416 and SU-6668 (Sugen Inc. of South San Francisco, California, USA), can also be combined with a compound of formula 1. VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT International Application PCT/IB99/00797 (filed May 3, 1999), in WO 95/21613 (published August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent 5,834,504 (issued November 10, 1998), WO 98/50356 (published November 12, 1998), United States Patent 5,883,113 (issued March 16, 1999), United States Patent 5,886,020 (issued March 23, 1999), United States Patent 5,792,783 (issued August 11 , 1998), WO 99/10349 (published March 4, 1999), WO 97/32856 (published September 12, 1997), WO 97/22596 (published June 26, 1997), WO 98/54093 (published December 3, 1998), WO 98/02438 (published January 22, 1998), WO 99/16755 (published April 8, 1999), and WO 98/02437 (published January 22, 1998), all of which are herein incorporated by reference in their entirety. Other examples of some specific VEGF inhibitors are IM862 (Cytran Inc. of Kirkland, Washington, USA); anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, California; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California).
ErbB2 receptor inhibitors, such as CP-724,714 (Pfizer, Inc.), GW-282974 (Glaxo Wellcome pic), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) and 2B-1 (Chiron), may be administered in combination with a compound of formula 1. Such erbB2 inhibitors include those described in WO 98/02434 (published January 22, 1998), WO 99/35146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published January 22, 1998), WO 97/13760 (published April 17, 1997), WO 95/19970 (published July 27, 1995), United States Patent 5,587,458 (issued December 24, 1996), and United States Patent 5,877,305 (issued March 2, 1999), each of which is herein incorporated by reference in its entirety. ErbB2 receptor inhibitors useful in the present invention are also described in United States Provisional Application No. 60/117,341 , filed January 27, 1999, and in United States Provisional Application No. 60/117,346, filed January 27, 1999, both of which are herein incorporated by reference in their entirety.
Other antiproliferative agents that may be used with the compounds of the present invention include inhibitors of HDI (CI-994, Pfizer Inc.), MEK (CI-1040, Pfizer Inc.), the enzyme farnesyl protein transferase and the receptor tyrosine kinase PDGFr, including the compounds disclosed and claimed in the following United States patent applications: 09/221946 (filed December 28, 1998); 09/454058 (filed December 2, 1999); 09/501163 (filed February 9, 2000); 09/539930 (filed March 31 , 2000); 09/202796 (filed May 22, 1997); 09/384339 (filed August 26, 1999); and 09/383755 (filed August 26, 1999); and the compounds disclosed and claimed in the following United States provisional patent applications: 60/168207 (filed November 30, 1999); 60/170119 (filed December 10, 1999); 60/177718 (filed January 21 , 2000); 60/168217 (filed November 30, 1999), and 60/200834 (filed May 1 , 2000). Each of the foregoing patent applications and provisional patent applications is herein incorporated by reference in their entirety.
A compound of formula 1 may also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors described in the references cited in the "Background" section, supra. Specific CTLA4 antibodies that can be used in the present invention include those described in United States Provisional Application 60/113,647 (filed December 23, 1998) which is herein incorporated by reference in its entirety. "Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that proliferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs..
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. The term "halo", as used herein, unless otherwise indicated, includes fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro and chloro.
The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, cyclic (including mono- or multi-cyclic moieties) or branched moieties. It is understood that for said alkyl group to include cyclic moieties it must contain at least three carbon atoms.
The term "cycloalkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having cyclic (including mono- or multi-cyclic) moieties.
The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon double bond.
The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl groups, as defined above, having at least one carbon-carbon triple bond.
The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
The term "alkoxy", as used herein, unless otherwise indicated, includes -O-alkyl groups wherein alkyl is as defined above.
The term "4 to 10 membered heterocyclic", as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one or more heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4 to 10 atoms in its ring system. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems and ring systems substituted with one or more oxo moieties. An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6- tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1 ,3- dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3- azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups, as derived from the compounds listed above, may be C- attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
The term "Me" means methyl, "Et" means ethyl, and "Ac" means acetyl. In the definition of X1 above, the -(CR1R2)m- and (CR16R17)k moieties, and other similar moieties, as indicated above, may vary in their definition of R1, R2, R16 and R17 for each iteration of the subscript (ie, m, k, etc) above 1. Thus, -(CR1R2)m- may include -CH2C(Me)(Et)- where m is 2.
The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of the present invention. The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of are those that form non-toxic acid addition salts, Le., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [Le., 1 ,1'-methylene-bis-(2-hydroxy-3- naphthoate)] salts. The compounds of the present invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.
Certain functional groups contained within the compounds of the present invention can be substituted for bioisosteric groups, that is, groups which have similar spatial or electronic requirements to the parent group, but exhibit differing or improved physicochemical or other properties. Suitable examples are well known to those of skill in the art, and include, but are not limited to moieties described in Patini et al., Chem. Rev, 1996, 96, 3147-3176 and references cited therein.
The compounds of the present invention have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the compounds of the present invention, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment that may employ or contain them. The compounds of formula 1 may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof. The subject invention also includes isotopically-labelled compounds, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 4C, 15N, 180, 170, 35S, 18F, and 36CI, respectively Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays Tπtiated, i e , 3H, and carbon-14, i e , 14C, isotopes are particularly preferred for their ease of preparation and detectabihty Further, substitution with heavier isotopes such as deuterium, i e , 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances Isotopically labelled compounds of formula of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent
This invention also encompasses pharmaceutical compositions containing and methods of treating bacterial infections through administering prodrugs of compounds of the formula 1 Compounds of formula 1 having free ammo, amido, hydroxy or carboxylic groups can be converted into prodrugs Prodrugs include compounds wherein an ammo acid residue, or a polypeptide chain of two or more (e g , two, three or four) ammo acid residues is covalently joined through an amide or ester bond to a free ammo, hydroxy or carboxylic acid group of compounds of formula 1 The ammo acid residues include but are not limited to the 20 naturally occurring ammo acids commonly designated by three letter symbols and also includes 4- hydroxyproline, hydroxylysme, demosme, isodemosme, 3-methylhιstιdιne, norva n, beta-alanine, gamma-aminobutync acid, citrulline homocysteine, homoseπne, ornithine and methionine sulfone Additional types of prodrugs are also encompassed For instance, free carboxyl groups can be denvatized as amides or alkyl esters Free hydroxy groups may be denvatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115 Carbamate prodrugs of hydroxy and ammo groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups Deπvatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl 04/056786
-32-
ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
Detailed Description Of The Invention The compounds of formula 1 can be prepared using the following synthetic scheme 1. The substituents in scheme 1 have the same meaning as the substituents defined for formula 1. The substituent Lg in the compounds of formulas 2 and 4 is a leaving group. Leaving groups are well-known to those of ordinary skill in the art. Applicants also direct the reader's attention to the Experimental section for particular examples of leaving group employed in the preparation of the compounds of the present invention.
Figure imgf000033_0001
Scheme 1
Necessary starting materials may be purchased and used directly or alternatively, starting materials can be prepared by one skilled in the art utilizing known procedures obtained from standard chemistry references (such as, Organic Synthesis (McGraw Hill) Michael Smith). It is understood that starting materials may be optionally protected as to not interfere with a desired chemical reaction (see Protecting Groups in Organic Synthesis (Wiley-lnterscience), Green and Wutts). Subsequent de-protection of potentially interfering functional group may be effected at a later appropriate time to obtain the necessary desired material. A pyrimidine of the general formula I may be purchased or prepared from known materials by one skilled in the art. Lg is defined as a displaceable leaving group that includes halogens and sulfonyl groups.
Using methods known in the literature by one skilled in the art, a pyrimidine of formula 2 may be reacted together with a compound of formula 3, optionally in the presence of a suitable base and optionally in the presence of a suitable inert solvent and at a temperature range of OoC to 150°C. Suitable bases employed may be the following but not limited to (i) organic bases, for example triethylamine, or diisopropylethylamine and (ii) inorganic bases such as potassium carbonate or cesium carbonate. The reaction may be performed neat or carried out in a suitable inert solvent. Examples of suitable inert solvents are but not limited to tetrahydrofuran, 1 ,4- dioxane, dimethylformamide, n-methyl pyrrolidin-2-one, ethanol, butanol, dichloromethane, or acetonitrile. Followed by the next reaction in which pyrimidine of formula 4 may be reacted together with amine compounds of formula IV optionally in the presence of a suitable base and optionally in the presence of a suitable inert solvent and at a temperature range of 0°C to 150°C conveniently at or near reflux to obtain compounds of formula 6. The reaction may be performed neat or optionally carried out in a suitable inert solvent. Examples of suitable inert solvents are but not limited to tetrahydrofuran, 1,4-dioxane, dimethylformamide, n-methyl pyrrolidin-2-one, ethanol, butanol, dichloromethane, dimethyl sulfoxide or acetonitrile.
Compounds of formula 6, if optional protecting groups are present would be removed using standard techniques well-known to those of ordinary skill in the art, see for example, Protecting Groups in Organic Synthesis (Wiley-lnterscience), Green and Wutts. These methods are known to those skilled in the art and include a) removal of a protecting group by methods outlined in T. W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", Second Edition, John Wiley and Sons, New York, 1991 ; b) displacement of a leaving group (halide, mesylate, tosylate, etc) with a primary or secondary amine, thiol or alcohol to form a secondary or tertiary amine, thioether or ether, respectively; c) treatment of phenyl (or substituted phenyl) carbamates with primary of secondary amines to form the corresponding ureas as in Thavonekham, B et. al. Synthesis (1997), 10, p1189; d) reduction of propargyl or homopropargyl alcohols or N-BOC protected primary amines to the corresponding E-allylic or E-homoallylic derivatives by treatment with sodium bis(2-methoxyethoxy)aluminum hydride (Red-AI) as in Denmark, S. E.; Jones, T. K. J. Org. Chem. (1982) 47, 4595-4597 or van Benthem, R. A. T. M.; Michels, J. J.; Speckamp, W. N. Synlett (1994), 368-370; e) reduction of alkynes to the corresponding Z-alkene derivatives by treatment hydrogen gas and a Pd catalyst as in Tomassy, B. et. al. Synth. Commun. (1998), 28, p1201 f) treatment of primary and secondary amines with an isocyanate, acid chloride (or other activated carboxylic acid derivative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding urea, amide, carbamate or sulfonamide; g) reductive amination of a primary or secondary amine using R1CH(0); and h) treatment of alcohols with an isocyanate, acid chloride (or other activated carboxylic acid de vative), alkyl/aryl chloroformate or sulfonyl chloride to provide the corresponding carbamate, ester, carbonate or sulfonic acid ester.
The compounds of the present invention may have asymmetric carbon atoms. Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
The compounds of formulas 1 that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of formula 1 from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
Those compounds of formula 1 that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula 1. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the present invention may include mono, di or tri-salts in a single compound.
The compounds of the present invention are potent inhibitors of the FAK protein tyrosine kinases, and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer), antitumor (e.g., effective against solid tumors), antiangiogenesis (e.g., stop or prevent proliferationation of blood vessels) in mammals, particularly in humans. In particular, the compounds of the present invention are useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplastic conditions such as benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH). It is, in addition, expected that a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies. In one preferred embodiment of the present invention cancer is selected from lung cancer, bone cancer, pancreatic cancer, gastric, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, gynecological, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, squamous cell, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain, pituitary adenoma, or a combination of one or more of the foregoing cancers.
In a more preferred embodiment cancer is selected a solid tumor, such as, but not limited to, breast, lung, colon, brain, prostate, stomach, pancreatic, ovarian, skin (melanoma), endocrine, uterine, testicular, and bladder.
The compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions or activation or signalling events related to various protein tyrosine kinases, are involved. Such disorders may include those of neuronal, glial, astrocytal, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases are involved. In addition, the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.
The in vitro activity of the compounds of formula 1 may be determined by the following procedure. More particularly, the following assay provides a method to determine whether compounds of the formula 1 inhibit the tyrosine kinase activity of the catalytic construct
FAK(410-689). The assay is an ELISA-based format, measuring the inhibition of poly-glu-tyr phosphorylation by FAK(410-689).
The assay protocol has three parts: I. Purification and cleavage of His-FAK(410-689) II. FAK410-689 (a.k.a. FAKcd) Activation
III. FAKcd Kinase ELISA
Materials: -Ni-NTA agarose (Qiagen) -XK-16 column (Amersham-Pharmacia) -300 mM Imidizole
-Superdex 200 HiLoad 16/60 prep grade column (Amersham Biotech.) -Antibody: Anti-Phosphotyrosine HRP-Conjugated Py20 (Transduction labs). -FAKcd: Purified and activated in house
-TMB Microwell Peroxidase Substrate (Oncogene Research Products #CL07) -BSA: Sigma #A3294
-Tween-20: Sigma #P1379 -DMSO: Sigma #D-5879 -D-PBS: Gibco #14190-037.
Reagents for Purification: -Buffer A: 50mM HEPES pH 7.0,
500mM NaCI, O.l mM TCEP
CompleteTM protease inhibitor cocktail tablets (Roche) -Buffer B: 25mM HEPES pH 7.0, 400mM NaCI
O.lmM TCEP. -Buffer C: 10mM HEPES pH 7.5, 200mM Ammonium Sulfate O.l mM TCEP. Reagents for Activation
-FAK(410-689): 3 tubes of frozen aliquots at 150ul/tube for a total of 450ul at 1.48 mg/ml (660ug) -His-Src(249-524): -0.74 mg/ml stock in 10mM HEPES, 200mM (NH4)2S04 -Src reaction buffer (Upstate Biotech): 100 mM Tris-HCI pH7.2, 125mM MgCI2, 25 mM MnCI2,
2mM EDTA, 250 uM Na3V04, 2 mM DTT -Mn2+/ATP cocktail (Upstate Biotech) 75mM MnCI2
500 uM ATP 20mM MOPS pH 7.2 1mM Na3V04
25mM α-glycerol phosphate 5mM EGTA
ImM DTT -ATP: 150m M stock -MgCI2: 1 M Stock -DTT: 1 M stock Reagents for FAKcd Kinase ELISA
-Phosphorylation Buffer:
50mM HEPES, pH 7.5, 125mM NaCI, 48mM MgCI2 -Wash Buffer: TBS + 0.1% Tween-20.
-Blocking Buffer:
Tris Buffer Saline, 3% BSA,
0.05% Tween-20, filtered. -Plate Coating Buffer:
50mg/ml Poly-Glu-Tyr (Sigma #P0275) in Phosphate buffer Saline (DPBS). -ATP: 0.1 M ATP in H20 or HEPES, pH7. Note: ATP Assay Buffer:
Make up as 75 uM ATP in PBS, so that 80 ul in 120 ul reaction volume=50uM final ATP concentration.
I. Purification of His-FAKcd(410-689) 1. Resuspend 130 g baculovirus cell paste containing the over expressed His- FAKcd410-689 recombinant protein in 3 volumes (400ml) of Buffer A,
2. Lyse cells with one pass on a microfluidizer
3. Remove cell debris by centrifugation at 40C for 35 minutes at 14,000 rpm in a Sorval SLA-1500 rotor.
4. Transfer the supernatant to a clean tube and add 6.0 ml of Ni-NTA agarose (Qiagen)
5. Incubate the suspension with gentle rocking at 40°C for 1 hour
6. Centrifuge suspension at 700 x g in a swinging bucket rotor. 7. Discard the supernatant and resuspend the agarose beads in 20.0 ml of Buffer A
8. Transfer the beads to an XK-16 column (Amersham-Pharmacia) connected to a FPLCTM.
9. Wash the agarose-beads with 5 column volumes of Buffer A and elute off the column with a step gradient of Buffer A containing 300mM Imidizole. 10. Perform a buffer exchange of the eluted fractions into Buffer B
11. Following buffer exchange, pool the fractions and add thrombin at a 1 :300 (w/w) ratio and incubated overnight at 13°C to remove the N-terminal His-tag (His- FAK410-698 -* FAK410-689 (a.k.a. FAKcd)).
12. Add the reaction mixture back onto the Ni-NTA column equilibrated with Buffer A and collect the flow-through.
13. Concentrate the flow-through down to 1.7 ml and load directly onto a Superdex 200 HiLoad 16/60 prep grade column equilibrated with Buffer C. The desired protein elutes between 85 - 95 ml.
14. Aliquot the FAKcd protein and store frozen at -80°C II. FAK activation
1. To 450ul of FAK(410-689) at 1.48 mg/ml (660ug) add the following:
30ul of 0.037 mg/ml (1 uM) His-Src(249-524) 30ul of 7.5 mM ATP
12ul of 20 mM MgCI2 10ul Mn2+/ATP cocktail (UpState Biotech.)
4ul of 6.7mM DTT 60ul Src Reaction Buffer (UpState Biotech.)
2. Incubate Reaction for at least 3 hours at room temperature
At time to, almost all of the FAK(410-689) is singly phosphorylated. The second phosphorylation is slow. At t120 (t = 120 minutes), add 10ul of 150 mM ATP. T0 = (Start) 90% singly phosphorylated FAK(410-689) (1 P04) T43 = (43 min) 65% singly phosphorylated (1 P04), 35% doubly phosphorylated (2
P04)
T90 = (90 min) 45% 1 P04, 55% 2 P04 T150 = 15% 1 P04, 85% 2 P04 T210 = <10% 1 P04, >90% 2 P04 desalted sample
3. Add 180 ul aliquots of the desalted material to NiNTA spin column and incubate on spin column
4. Spin at 10k rpm (microfuge), for 5 min to isolate and collect flow through (Activated FAK(410-689)) and remove His-Src (captured on column) 111. FAKcd Kinase ELISA
1. Coat 96-well Nunc MaxiSorp plates with poly-glu-tyr (pGT) at 10 ug/well: Prepare
10 ug/ml of pGT in PBS and aliquot 100 ul/well. Incubate the plates at 37°C overnight, aspirate the supernatant, wash the plates 3 times with Wash Buffer, and flick to dry before storing at 4°C. 2. Prepare compound stock solutions of 2.5 mM in 100% DMSO. The stocks are subsequently diluted to 60X of the final concentration in 100% DMSO, and diluted
1 :5 in Kinase Phosphorylation Buffer. 3. Prepare a 75 uM working ATP solution in Kinase phosphorylation buffer. Add 80 ul to each well for a final ATP concentration of 50 uM. 4. Transfer 10 ul of the diluted compounds (0.5log serial dilutions) to each well of the pGT assay plate, running each compound in triplicates on the same plate.
5. Dilute on ice, FAKcd protein to 1 :1000 in Kinase Phosphorylation Buffer. Dispense 30 ul per well.
6. Note: Linearity and the appropriate dilution must be pre-determined for each batch of protein. The enzyme concentration selected should be such that quantitation of the assay signal will be approximately 0.8-1.0 at OD450, and in the linear range of the reaction rate.
7. Prepare both a No ATP control (noise) and a No Compound Control (Signal):
8. (Noise) One blank row of wells receives 10 ul of 1 :5 diluted compounds in DMSO, 80ul of Phosphorylation buffer (minus ATP), and 30 ul FAKcd solution.
9. (Siganl) Control wells receive 10 ul of 1 :5 diluted DMSO (minus Compound) in Kinase phosphorylation buffer, 80 ul of 75 uM ATP, and 30 ul of 1 :1000 FAKcd enzyme.
10. Incubate reaction at room temperature for 15 minutes with gentle shaking on a plate shaker.
11. Terminate the reaction by aspirating off the reaction mixture and washing 3 times with wash buffer. 12. Dilute phospho-tyrosine HRP-conjugated (pY20HRP) antibody to 0.250ug/ml (1 :1000 of Stock) in blocking buffer. Dispense 100 ul per well, and incubate with shaking for 30min. at R.T.
13. Aspirate the supernatant and wash the plate 3 times with wash buffer. 14. Add 100 ul per well of room temperature TMB solution to initiate color development. Color development is terminated after approximately 15-30 sec. by the addition of 100ul of 0.09M H2S04 per well. 15. The signal is quantitated by measurement of absorbance at 450nm on the BioRad microplate reader or a microplate reader capable of reading at OD450. 16. Inhibition of tyrosine kinase activity would result in a reduced absorbance signal.
The signal is typically 0.8-1.0 OD units. The values are reported as ICsos, uM concentration.
FAK Inducible cell-based ELISA: Final Protocol Materials: Reacti-Bind Goat Anti-Rabbit Plates 96-well (Pierce Product#15135ZZ @115.00 USD)
FAKpY397 rabbit polyclonal antibody (Biosource #44624 @315.00 USD) ChromePure Rabbit IgG, whole molecule (Jackson Laboratories #001-000-003 @60/25mg USD)
UBI ccFAK clone 2A7 mouse monoclonal antibody (Upstate#05-182 @ 289.00 USD) Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG (Jackson Labs #115-035-146
@95/1.5ml USD)
SuperBlock TBS (Pierce Product#37535ZZ @99 USD) Bovine Serum Albumin (Sigma #A-9647 @117.95/100 g USD) TMB Peroxidase substrate (Oncogene Research Products #CL07-100ml @40.00 USD)
Na3V04 Sodium Orthovanadate (Sigma #S6508 @43.95/50g USD) MTT substrate (Sigma # M-2128 @25.95/500mg USD)
Growth Media: DMEM+10%FBS, P/S, Glu, 750 ug/ml Zeocin and 50 ug/ml Hygromycin (Zeocin InVitrogen #R250-05 @ 725 USD and Hygromycon InVitrogen #R220-05 @ 150 USD)
Mifepristone InVitrogen # H110-01 @ 125 USD
CompleteTM EDTA-free Protease Inhibitor pellet Boehringer Mannheim #1873580 FAK cell-based Protocol for selectivity of kinase-dependent phosphoFAKY397 Procedure An inducible FAK cell-based assay in ELISA format for the screening of chemical matter to identify tyrosine kinase specific inhibitors was developed. The cell-based assay exploits the mechanism of the GeneSwitchTM system (InVitrogen) to exogenously control the expression and phosphorylation of FAK and the kinase-dependent autophosphorylation site at residue Y397.
Inhibition of the kinase-dependent autophosphorylation at Y397 results in a reduced absorbance signal at OD450. The signal is typically 0.9 to 1.5 OD450 units with the noise falling in the range of 0.08 to 0.1 OD450 units. The values are reported as IC50S, uM concentration.
On day 1 , grow A431»FAKwt in T175 flasks. On the day prior to running the FAK cell- assay, seed A431»FAKwt cells in growth media on 96-well U-bottom plates. Allow cells to sit at 37°C, 5% C02 for 6 to 8 hours prior to FAK induction. Prepare Mifepristone stock solution of 10 uM in 100 % Ethanol. The stock solution is subsequently diluted to 10 X of the final concentration in Growth Media. Transfer 10 ul of this dilution (final concentration of 0.1 nM Mifepristone) into each well. Allow cells to sit at 37°C, 5% C02 overnight (12 to 16 hours). Also, prepare control wells without Mifepristone induction of FAK expression and phosphorylation.
On day 2, coat Goat Anti-Rabbit plate(s) with 3.5 ug/ml of phosphospecific FAKpY397 polyclonal antibody prepared in SuperBlock TBS buffer, and allow plate(s) to shake on a plate shaker at room temperature for 2 hours. Optionally, control wells may be coated with 3.5 ug/ml of control Capture antibody (Whole Rabbit IgG molecules) prepared in SuperBlock TBS. Wash off excess FAKpY397 antibody 3 times using buffer. Block Anti-FAKpY397 coated plate(s) with 200 ul per well of 3%BSA 0.5%Tween Blocking buffer for 1 hour at room temperature on the plate shaker. While the plate(s) are blocking, prepare compound stock solutions of 5 mM in 100 % DMSO. The stock solutions are subsequently serially diluted to 100X of the final concentration in 100% DMSO. Make a 1 :10 dilution using the 100X solution into growth media and transfer 10 ul of the appropriate compound dilutions to each well containing either the FAK induced or uninduced control A431 cells for 30 minutes at 37°C, 5% C02. Prepare RIPA lysis buffer (50 mM Tris-HCI, pH7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCI, 1 mM EDTA, 1 mM Na3V04, 1 mM NaF, and one CompleteTM EDTA-free protease inhibitor pellet per 50 ml solution). At the end of 30 minutes compound treatment, wash off compound 3 times using TBS-T wash buffer. Lyse cells with 100 ul/well of RIPA buffer.
To the coated plate, remove blocking buffer and wash 3 times using TBS-T wash buffer. Using a 96-well automated microdispenser, transfer 100 ul of whole cell-lysate (from step 6) to the Goat Anti-Rabbit FAKpY397 coated plate(s) to capture phosphoFAKY397 proteins. Shake at room temperature for 2 hours. Wash off unbound proteins 3 times using TBS-T wash buffer. Prepare 0.5 ug/ml (1 :2000 dilution) of UBI αFAK detection antibody in 3%BSA/0.5% Tween blocking buffer. Dispense 100 ul of UBI αFAK solution per well and shake for 30 minutes at room temperature. Wash off excess UBI αFAK antibody 3 times using TBS-T wash buffer. Prepare 0.08 ug/ml (1 :5000 dilution) of secondary Anti-Mouse Peroxidase (Anti-2MHRP) conjugated antibody. Dispense 100 ul per well of the Anti-2MHRP solution and shake for 30 minutes at room temperature. Wash off excess Anti-2MHRP antibody 3 times using TBS-T wash buffer. Add 100 ul per well of room temperature TMB substrate solution to allow for color development. Terminate the TMB reaction with 100 ul per well of TMB stop solution (0.09M H2S04) and quantitate the signal by measurement of absorbance at 450 nm on the BioRad microplate reader. Additional FAK cell assays are hereby incorporated by reference from Pfizer Attorney
Docket No. PC11699 entitled "INDUCIBLE FOCAL ADHESION KINASE CELL ASSAY".
.Administration of the compounds of the present invention (hereinafter the "active compound(s)") can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyi)-N- methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as Nolvadex™ (tamoxifen) or, for example anti-androgens such as Casodex™ (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'- (trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Easter, Pa., 15th Edition (1975).
The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art. General Methods Method A General method for introduction of a group at C-4
(5-Bromo-2-chloro-pyrim id in-4-yl)-p-tolyl-am ine
Figure imgf000045_0001
A mixture of 5-Bromo-2,4-dichloropyrimidine (5.00 g, 22.0 mmol), di-isopropyl ethylamine (3.91 mL, 22.4 mmol) and p-toluidine (2.40 g, 22.4 mmol) in n-butanol (50.0 mL) was heated to 105°C under nitrogen for three hours. The reaction was allowed to cool to room temperature. The resulting mixture was poured into ethyl acetate and extracted with 1 N NaOH. The aqueous layer was removed and the organic layer was washed with water, dried over magnesium sulfate, filtered and evaporated under reduced pressured. To the resulting oily residue, diethyl ether was added and the mixture was then cooled to 0° C. HCI (4.0 M in dioxane) was added dropwise. The resulting white solid was filtered and dried. The salt was suspended in a mixture of water and ethyl acetate. The pH of the aqueous layer was then adjusted to 9 with 1 N NaOH and extracted. The aqueous layer was further extracted with ethyl acetate. The organic layers were combined, dried over magnesium sulfate, filtered and evaporated under reduced pressure to afford 5-Bromo-2-chloro-pyrimidin-4-yl)-p-tolyl-amine (3.62 g, 55%) as a white solid: CnHgBrCINa. GC/MS: ret. Time = 4.65 min, m/z 296/298/300; g.l.c. purity: 100%; TLC Rf 0.58 (20% Ethyl acetate/hexanes); 1H NMR (d6-DMSO) δ 9.21 (s, 1 H), 8.39 (s, 1 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.4 Hz, 2 H), 2.27 (s, 3 H) ppm. Method B
General method for introduction of a group at C-4 (2-Chloro-5-fluoro-pyrimidin-4-yl)-pyridin-2-ylmethyl-amine To a solution of 5-fluoro-2,4-dichloropyrimidine (1.5 g; 9 mmol) in THF (25 mL) was added triethylamine (1.1 eq), followed by dropwise addition of 2-(aminomethyl)pyridine (0.973 g; 1 eq). After stirring for one hour the reaction was concentrated and taken up in ethyl acetate, washed with saturated NaHC03, dried over Na2S04, and the solvent removed. The resulting solid was re-crystallized from ethyl acetate and hexanes as a white solid (1.74g; 81 %): 1H NMR (CDCI3, 400 MHz) δ 4.84 (d, J = 4.7 Hz, 2H), 7.07 (bs, 1 H), 7.35 (t, J = 5.1 Hz, 1H), 7.44 (d, J = 7.8, 1 H), 7.82 (t, J = 7.6, 1H), 7.95 (d, J = 2.5 Hz, 1 H), 8.63 (d, J = 5.0 Hz, 1H); HPLC ret. Time: 4.228 min. LRMS (M+): 239.0, 241.0. Method C
General method for introduction of a group at C-4
Using method B, replace the THF solvent with 1 ,4-dioxane as solvent.
Method D General method for introduction of a group at C-4
5-Fluoro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
(2-Chloro-5-fluoro-pyrimidin-4-yl)-pyridin-2-ylmethyl-amine (100 mg; 0.4 mmol) and 5- aminoindazole (56 mg; 1 eq) were combined and heated at 160° C for 30 minutes. After cooling to room temperature, methanol (1 mL) was added and stirred for 15 minutes, followed by filtration gave the product as a brown solid (29 mg; 21 %): 1H NMR (CD3OD, 400 MHz) δ 4.80 (s, 2H), 7.34 (m, 3H), 7.43 (d, J = 7.8 Hz, 1 H), 7.8 (m, 2H), 7.87 (s, 1 H), 7.90 (s, 1 H), 8.54 (d, J = 5 Hz, 1 H); HPLC ret. time: 3.916 min. LRMS (M+): 336.1.
Method E
General method for introduction of C-2 Group 5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1.3-dihvdro-indol-2-one
153 mg (0.490 mmol) (5-Bromo-2-chloro-pyrimidin-4-yl)-phenethyl-amine was taken into 0.5 mL 1 ,4 dioxane with 0.14 mL (1.00 mmol) diisopropylethylamine and 80 mg (0.539 mmol) 5-amino-1 ,3-dihydro-indol-2-one. The reaction was allowed to heat to 110° C for sixteen hours. The resulting brown glass was taken into 92.3:7:0.7 CHCI3:CH3OH:NH4OH and washed with 1 N sodium hydroxide. The organic layer was dried over magnesium sulfate and evaporated directly onto silica gel. This adsorbed compound was purified via column chromatography (97.8:2:0.2 CHCI3:CH3OH:NH4OH) over silica to isolate the major product. The title compound was isolated as a white solid. C20H18BrN5O: MS: 424.2/426.2 (MH+); H NMR (D6-DMSO) 10.20 (s, 1 H), 9.01 (s, 1 H), 7.93 (s, 1 H), 7.52 (s, 1 H), 7.44 (d, J = 8.4 Hz, 1 H), 7.28 - 7.16 (m, 5 H), 6.97 (m, 1 H), 6.65 (d, J = 8.3 Hz, 1 H), 3.56 (m, 2 H), 3.31 (s, 2 H), 2.82 (t, J = 7.9 Hz, 2 H) ppm.
Method F
General method for introducing both C-2 and C-4 amines ("One Pot Method")
4-(5-[5-Bromo-4-(4-trifluoromethyl-benzylamino)-pyrimidin-2-ylaminol-1 H-indol-3-yl)- 3.6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester
To a stirred solution of 5-bromo-2,4-dichloropyhmidine (0.222 g, 0.98 mmol) in THF (3 mL) under nitrogen was added triethylamine (0.42 mL, 3 mmol) followed by dropwise addition of p-trifluoromethylbenzyl amine (0.175 g,1 mmol). After three hours the THF was removed under reduced pressure. To the resulting residue was added dioxane (1 mL) followed by 4-(5- Amino-1 H-indol-3-yl)-3,6-dihydro-2H-pyhdine-1 -carboxylic acid tert-butyl ester (0.345 g 1.1 mmol). The mixture was stirred under nitrogen and then heated to 110° C for sixteen hours. The reaction was cooled and was then dissolved in a solution of 5% methanol- dichloromethane and extracted with 1 N NaOH. The organic and aqueous layers were separated and the aqueous layer was further extracted with additional 5% methanol- dichloromethane. The organic layers were combined, washed with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by silica gel chromotography (30% ethyl acetate in hexanes) to give 4-{5-[5- Bromo-4-(4-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1H-indol-3-yl}-3,6-dihydro-2H- pyridine-1 -carboxylic acid tert-butyl ester (150 mg, 23%):
Method G
TFA General de-protection Method
5-Bromo-N2-r3-(1 ,2.3.6-tetrahvdro-pyridin-4-yl)-1H-indol-5-vn-N4-(4-trifluoromethyl- benzyl)-pyrimidine-2.4-diamine t fluoro acetate salt
To a stirred solution of 4-{5-[5-Bromo-4-(4-trifluoromethyl-benzylamino)-pyrimidin-2- ylamino]-1 H-indol-3-yl}-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester (0.15 g) in dichloromethane (2 mL) at 0° C under nitrogen was added trifluoroacetic acid (4 mL). The cooling bath was removed and the reaction mixture was stirred for four hours. The reaction was concentrated under reduced pressure. To the resulting residue was added ethyl acetate (2 mL) followed by concentrating to an oily residue. The ethyl acetate concentration sequence was repeated three times. The resulting residue was suspended in ethyl acetate follow by addition of diethyl ether to precipitate 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-N4-(4-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine trfluoroacetate salt (0.129 g, 86%) as a white solid: C25H22BrF3N6. MS: 542.9/544.7 (MH+). 1H NMR (D6-DMSO) δ 11.31 (s, 1 H), 8.82 (s, 2 H), 8.08 (s, 1 H), 7.88 (s, 1 H), 7.53 (s, 3 H), 7.36 (s, 2 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.16 (d, J = 8.3 Hz, 1 H), 6.05 (bs, 1 H), 4.58 (s, 2 H), 3.75-3.65 (bs, 2 H), 3.35-3.25 (bs, 2 H), 2.70-2.60 (bs, 2 H) ppm
Method H HCI General de-protection Method
5-Bromo-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yll-N4-p-tolyl-pyrimidine- 2.4-diamine hydrochloride salt
To a stirred solution of 4-[5-(5-Bromo-4-p-tolylamino-pyrimidin-2-ylamino)-1 H-indol-3- yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (0.1 g, 0.174 mmol) and methanol (3 mL) cooled to 0° C under nitrogen was added HCI in dioxane (0.2 mL of a 4 M solution). The cooling bath was removed and the reaction was allowed to stir for 6 hours. The mixture was concentrated under reduced pressure and the resultant residue was triturated with dichloromethane. The solid was filtered, washed with dichloromethane and dried to give 5- Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-p-tolyl-pyrimidine-2,4-diamine hydrochloride salt (0.076 g, 85%) as a white solid: C24H23BrN6. MS: 475.0/477.0 (MH+); 1H NMR (D6-DMSO) δ 10.98 (s, 1 H), 9.01 (s, 1 H), 8.28 (s, 1 H), 8.12 (s, 1 H), 7.89 (s, 1 H), 7.50 - 7.58 (m, 3 H), 7.41 (d, J = 8.7 Hz, 1 H), 7.29 (s, 1 H), 7.18 (d, J = 8.7 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 2 H), 6.02 (s, 1 H), 4.03 (m, 2 H), 2.47 (m, 2 H), 2.35 (m, 2 H), 2.23 (s, 3 H) ppm. Example 1 5-Bromo-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-p-tolyl-pyrimidine-2,4- diamine
A. 5-Bromo-2-chloro-pyrimidin-4-yl)-p-tolyl-amine
Figure imgf000048_0001
A mixture of 5-Bromo-2,4-dichloropyrimidine (5.00 g, 22.0 mmol), di-isopropyl ethylamine (3.91 mL, 22.4 mmol) and p-toluidine (2.40 g, 22.4 mmol) in n-butanol (50.0 mL) was heated to 105°C under nitrogen for three hours. The reaction was allowed to cool to room temperature. The resulting mixture was poured into ethyl acetate and extracted with 1 N NaOH. The aqueous layer was removed and the organic layer was washed with water, dried over magnesium sulfate, filtered and evaporated under reduced pressured. To the resulting oily residue, diethyl ether was added and the mixture was then cooled to 0° C. HCI (4.0 M in dioxane) was added dropwise. The resulting white solid was filtered and dried. The salt was suspended in a mixture of water and ethyl acetate. The pH of the aqueous layer was then adjusted to 9 with 1N NaOH and extracted. The aqueous layer was further extracted with ethyl acetate. The organic layers were combined, dried over magnesium sulfate, filtered and evaporated under reduced pressure to afford 5-Bromo-2-chloro-pyrimidin-4-yl)-p-tolyl-amine (3.62 g, 55%) as a white solid: CnH9BrCIN3. GC/MS: ret. Time = 4.65 min, m/z 296/298/300; g.l.c. purity: 100%; TLC Rf 0.58 (20% Ethyl acetate/hexanes); 1H NMR (d6-DMSO) δ 9.21 (s, 1 H), 8.39 (s, 1 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.16 (d, J = 8.4 Hz, 2 H), 2.27 (s, 3 H) ppm.
B. 4-(5-Nitro-1 H-indol-3-yl)-3.6-dihvdro-2H-pyridine-1 -carboxylic acid tert-butyl ester
Figure imgf000048_0002
To 600 mL of HPLC-grade methanol was added 60.0 g (1.11 mol) sodium methoxide portion-wise. The resulting white slurry was allowed to stir for ten minutes before adding 30.0 g (185 mmol) 5-nitroindole. This allowed to stir for an additional ten minutes before adding 92.2 g (463 mmol) 4-Oxo-pipehdine-1 -carboxylic acid tert-butyl ester. After waiting ten minutes, the reaction temperature was ramped to 85° C which was maintained for thirty-two hours. The black reaction solution was cooled to 0° C and 250 mL distilled water was added drop-wise under nitrogen via an equalizing pressure addition funnel. The methanol was removed under reduced pressure. To the aqueous residue was added 1.50 L dichloromethane. The organic layer was separated. The pH of the aqueous was adjusted to 9.00 using sodium hydroxide. Dichloromethane was added and the two layers were filtered through diatomaceous earth to alleviate emulsion. The organic layer was separated and combined with the original organic. The combined organic layers were dried over magnesium sulfate. Partial evaporation of the dried organics resulted in a yellow-orange slurry. Filtration of this solid followed by washing with 5:1 diethyl etherdichloromethane afforded 49.98 g (146 mmol, 79%) of the title compound as a yellow solid. MS: 244.1 (M-Boc H+); TLC Rf: 0.31 (40% ethyl acetate/hexanes); 1H NMR (D6-DMSO) δ 11.90 (s, 1 H), 8.68 (s, 1H), 7.99 (d, J = 8.8 z, \ H), 7.68 (s, 1 H), 7.53 (d, J = 8.8 Hz, 1 H), 6.17 (s, 1 H), 4.04 (m, 2 H), 3.54 (m, 1 H), 2.47 (m, 2H), 1.40 (s, 9 H) ppm.
C. 4-(5-Amino-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester
Figure imgf000049_0001
To a solution of 400 mL dioxane, 300 mL ethanol, and 200 mL distilled water was added ten grams of 4-(5-Nitro-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert- butyl ester. To this was added 8.13 g (146 mmol) powdered iron (0) and 6.23 g (116 mmol) ammonium chloride. The reaction was heated to 70° C under nitrogen with the iron eventually becoming a conglomerate around the magnetic stir bar. After three hours, the reaction was removed from the heating source allowed to cool to room temperature and filtered. The filtrate was evaporated under reduced pressure. The aqueous residue was partitioned with ethyl acetate, dried over magnesium sulfate and filtered. Evaporation of the filtrate afforded the title compound as a tan glassy foam which darkens upon exposure to air. C18H23N302: 8.57 g (27.3 mmol, 94%): MS 214.1 (M-Boc H+); TLC Rf: 0.18 (40% Ethyl acetate : hexanes); 13C NMR (D6-DMSO) δ 154.6, 142.5, 131.3, 126.1 , 123.4, 115.4, 114.9, 112.6, 112.5, 104.2, 79.3, 44.0, 43.8, 41.5, 28.8, 28.3 ppm; 1H NMR (D6-DMSO) δ 10.71 (s, 1 H), 7.24 (s, 1 H), 7.09 (d, J = 8.4 Hz, 1 H), 7.04 (s, 1 H), 6.53 (d, J = 8.4 Hz, 1 H), 6.00 (s, 1 H), 4.54 (s, 2H), 4.54 (m, 2 H), 4.05 (m, 2 H), 3.56 (m, 2 H), 2.51 (m, 2 H), 1.45 (s, 9 H) ppm. D. 4-r5-(5-Bromo-4-p-tolylamino-pyrimidin-2-ylamino)-1 H-indol-3-yl1-3,6-dihvdro-
2H-pyridine-1 -carboxylic acid tert-butyl ester
Figure imgf000050_0001
2.32 g (7.77 mmol) (5-Bromo-2-chloro-pyrimidin-4-yl)-p-tolyl-amine was taken into 21.0 mL dioxane with 2.92 g (2.92 mmol) 4-(5-Amino-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1- carboxylic acid tert-butyl ester and 1.30 mL (9.32 mmol) triethyl amine. The reaction was heated to 100° C for sixteen hours. The reaction was allowed to cool to room temperature, and the dioxane was removed under reduced pressure. The brown residue was taken into ethyl acetate and 1 N sodium hydroxide mixture. Aqueous work-up gave approximately 3 g brown tar. This brown tar was purified to give 2.43 g (4.21 mmol, 54%) white solid.
C29H31BrN602 : MS: 575.0/577.0 (MH+); 1H NMR (D6-DMSO) δ 11.00 (s, 1 H), 9.01 (s, 1 H),
8.28 (s, 1 H), 8.13 (s, 1 H), 7.93 (s, 1 H), 7.53 (d, J = 8.3 Hz, 2 H), 7.35 (s, 1 H), 7.34 (d, J =
8.8 Hz, 1 H), 7.19 (d, J = 8.8 Hz, 1 H), 7.02 (d, J = 8.3 Hz, 2 H), 5.93 (s, 1 H), 3.89 (m, 2 H),
3.50 (m, 2 H), 3.14 (m, 2 H), 2.21 (s, 3 H), 1.39 (s, 9 H) ppm; TLC Rf 0.32 (40% ethyl acetate in hexanes).
E. 5-Bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-p-tolyl-
Pyrimidine-2.4-diamine
Figure imgf000050_0002
To a stirred solution of 4-[5-(5-Bromo-4-p-tolylamino-pyrimidin-2-ylamino)-1 H-indol-3- yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (0.1 g, 0.174 mmol) and methanol (3 mL) cooled to 0° C under nitrogen was added HCI in dioxane (0.2 mL of a 4 M solution). The cooling bath was removed and the reaction was allowed to stir for 6 hours. The mixture was concentrated under reduced pressure and the resultant residue was triturated with dichloromethane. The solid was filtered, washed with dichloromethane and dried to give 5- Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-p-tolyl-pyrimidine-2,4-diamine hydrochloride salt (0.076 g, 85%) as a white solid: C24H23BrN6. MS: 475.0/477.0 (MH+); 1H NMR (D6-DMSO) δ 10.98 (s, 1 H), 9.01 (s, 1 H), 8.28 (s, 1 H), 8.12 (s, 1 H), 7.89 (s, 1 H), 7.50 - 7.58 (m, 3 H), 7.41 (d, J = 8.7 Hz, 1 H), 7.29 (s, 1 H), 7.18 (d, J = 8.7 Hz, 1 H), 7.03 (d, J = 8.3 Hz, 2 H), 6.02 (s, 1 H), 4.03 (m, 2 H), 2.47 (m, 2 H), 2.35 (m, 2 H), 2.23 (s, 3 H) ppm. Example 2 5-Bromo-N4-pyridin-2-yl-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-pyridin-2-yl-amine
Figure imgf000051_0001
The title compound was prepared from 2-aminopyridine in a 10% yield as a yellow solid in a manner similar to Example 1A. C9H6BrCIN4. GC/MS: ret. time = 4.19 min. m/z 284/286/288, 205/207, 169, 78; 1H NMR (D6-DMSO) δ 9.06 (bs, 1 H), 8.57 (s, 1 H), 8.38 (d, J = 4.6 Hz, 1 H), 7.93-7.86 (m, 2 H), 7.20 (dd, J = 4.6, 6.2 Hz, 1 H) ppm. B. 5-Bromo-N4-pyridin-2-yl-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yl1- pyrimidine-2,4-diamine
Figure imgf000051_0002
The title compound was made in a manner similar to Examples 1D and 1E. The compound was isolated as its HCI salt in a 29% yield as a yellow solid. C22H20BrN7. MS: 462.1/464.1 (MH+). 1H NMR (CD3OD) δ 8.37 (s, 1 H), 8.2 - 7.8 (m, 4 H), 7.53 (m, 2 H), 7.29 (m, 2 H), 6.18 (bs, 1 H), 4.93 - 4.80 (m, 2 H), 3.87 - 3.48 (m, 2 H), 3.00 - 2.80 (m, 2 H) ppm.
Example 3 5-Bromo-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yll- pyrimidine-2,4-diamine A. (5-Bromo-2-chloro-pyrimidin-4-yl)-pyridin-2-ylmethyl-amine
Figure imgf000051_0003
The title compound was made in 82% yield as a yellow oil that solidifies on standing. C10H8BrCIN4. GC/MS ret. time = 4.67 min. m/z 298/300/302, 219/221 , 107. 1H NMR (CDCI3) δ 8.64 (d, J = 4.7 Hz, H), 8.19 (s, 1 H), 7.78 (t, J = 7.8 Hz, 1 H), 7.41 - 7.29 (m, 3H), 4.82 (d, J = 4.7 Hz, 2 H) ppm. B. 5-Bromo-N4-pyridin-2-ylmethyl-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-
5-yll-pyrimidine-2.4-diamine
Figure imgf000052_0001
The title compound was made in a manner similar to Example 1 D and 1 E in 14% yield isolated as a free based white solid. C23H22BrN7. MS: 447.0/449.0 (MH+), 1H NMR (D6-
DMSO) δ 10.85 (s, 1 H), 8.91 (s, 1 H), 8.50 (s, 1 H), 8.01-8.00 (m, 2 H), 7.68 (t, J = 6.4 Hz, 1
H), 7.42 (t, J = 5.7 Hz, H), 7.28 - 7.20 (m, 4 H), 7.09 (d, J = 8.3 Hz, 1 H), 6.07 (s, 1 H), 4.70
(d, J = 5.7Hz, 2 H), 3.40 - 3.30 (m, 2 H), 2.90 - 2.87 (m, 2 H), 2.50 - 2.40 (m, 2 H) ppm.
Example 4 N4-Benzyl-5-bromo-N2-[3-(1.2,3.6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yll-pyrimidine-
2,4-diamine
A. Benzyl-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
Figure imgf000052_0002
The title compound was synthesized in a manner similar to Example 1A. It was isolated in an 85% yield as a yellow solid. Cn^BrCINs. MS 296.1/298.0 (MH+). 1H NMR (CDCI3) δ 8.19 (s, 1 H), 7.45 - 7.30 (m, 5 H), 5.85 (bs, 1 H), 4.74 (d, J = 5.6 Hz, 2 H) ppm.
B. 4-r5-(4-Benzylamino-5-bromo-pyrimidin-2-ylamino)-1 H-indol-3-yll-3,6-dihvdro-
2H-pyridine-1 -carboxylic acid tert-butyl ester
Figure imgf000052_0003
The title compound was made in a manner similar to Example 1D. It was isolated in a
65% yield after chromatography (30% EtOAc in hexanes) as a white solid. C29H31BrN602. MS: 575.0/576.8 (MH+). 1H NMR (D6-DMSO) δ 10.95 (s, 1 H), 8.92 (s, 1 H), 8.14 (s, 1 H), 7.96 (s, 1 H), 7.48-7.14 (m, 9 H), 6.02 (s, 1 H), 4.61 (d, J = 6.2 Hz, 2 H), 4.01-3.98 (m, 2 H), 3.51-3.48 (m, 2 H), 2.47-2.45 (m, 2 H), 1.38 (s, 9H) ppm. C. N4-Benzyl-5-bromo-N2-f3-(1 ,2.3.6-tetrahvdro-Pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000053_0001
The title compound was synthesized by dissolving 4-[5-(4-Benzylamino-5-bromo- pyrimidin-2-ylamino)-1 H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester into 5.00 mL dichloromethane and cooling to 0° C. To this was added 10.0 mL Trifluoroacetic acid. The red solution was allowed to slowly warm to room temperature and stir under N2 for two hours. 5.00 mL ethyl acetate was added. Filtration of the resulting precipitate gave the title compound as a white solid. C24H23BrN6. MS: 475.0/476.8 (MH+). 1H NMR (CD3OD) δ 11.05 (s, 1 H), 7.88 (s, 1 H), 7.81 (s, 1 H), 7.49 (s, 1 H), 7.45 (d, J = 8.7Hz, 1 H), 7.36-7.13 (m, 8 H), 6.15 (bs, 1 H), 4.64 (bs, 2 H), 3.90-3.80 (bs, 2 H), 3.49-3.43 (bs, 2 H), 2.85-2.83 (bs, 2H) ppm..
Example 5
5-Bromo-N4-(1 R-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-vH- pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(1 R-phenyl-ethyl)-amine
Figure imgf000053_0002
The title compound was made in a manner similar to Example 1A. It was isolated as an orange solid in a nearly quantitative yield. C^HnBrCINa. MS: 312.1/314.1 (MH+). 1H NMR (CDCIa) δ 8.11 (s, 1 H), 7.37 - 7.14 (m, 5 H), 5.71 (d, J = 7.4 Hz, 1 H), 5.35 (dt, J = 7.4, 6.7 Hz, 1 H), 1.60 (d, J = 6.7 Hz, 3 H) ppm. B. 5-Bromo-N4-(1 R-phenyl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-vn-pyrimidine-2.4.-diamine
Figure imgf000054_0001
The title compound was made in a manner similar to Example 1 D and deprotected similarly to Example 4C to give the desired material as its TFA salt in a 18% yield (tan solid). C25H25BrN6. MS 489.0/491.1 (MH+); 1H NMR (D6-DMSO) δ 11.37 (s, 1 H), 8.91 (s, 1 H), 8.11 (s, 1 H), 7.94 (s, 1 H), 7.57 (s, 1 H), 7.40 (d, J = 8.8 Hz, 1 H), 7.30 - 7.22 (m, 7 H), 6.12 (s, 1 H), 4.06 (bs, 1 H), 3.77 - 3.75 (bs, 2 H), 3.38-3.36 (bs, 2 H), 2.76-2.75 (bs, 2 H), 1.57 (d, J = 6.8 Hz, 3 H) ppm.
Example 6 5-Bromo-N4-(1rac-phenyl-ethyl)-N2-[3-(1 ,2,3.6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(1rac-phenyl-ethyl)-amine
Figure imgf000054_0002
The title compound was made in a manner similar to Example 1A. It was isolated as an orange solid in nearly quantitative yield. C^HnBrCINa. MS: 312.1/314.1 (MH+). 1H NMR (CDCI3) δ 8.11 (s, 1 H), 7.37 - 7.14 (m, 5 H), 5.71 (d, J = 7.4 Hz, 1 H), 5.35 (dt, J = 7.4, 6.7 Hz, 1 H), 1.60 (d, J = 6.7 Hz, 3 H) ppm
B. 5-Bromo-N4-(1rac-phenyl-ethyl)-N2-[3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-yll-pyrimidine-2,4-diamine
Figure imgf000054_0003
-54-
The title compound was made in a manner similar to Example 1D and deprotected similarly to Example 4C to give the desired material as its TFA salt in a 27% yield (tan solid). C25H25BrN6. MS 489.0/491.1 (MH+); 1H NMR (d6-DMSO) J511.37 (s, 1 H), 8.91 (s, 1 H), 8.11 (s, 1 H), 7.94 (s, 1 H), 7.57 (s, 1 H), 7.40 (d, J = 8.8 Hz, 1 H), 7.30 - 7.22 (m, 7 H), 6.12 (s, 1 H), 4.06 (bs, 1 H), 3.77 - 3.75 (bs, 2 H), 3.38-3.36 (bs, 2 H), 2.76-2.75 (bs, 2 H), 1.57 (d, J = 6.8 Hz, 3 H) ppm.
Example 7
5-Bromo-N4-(1 S-phenyl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(1 S-phenyl-ethyl)-amine
Figure imgf000055_0001
The title compound was made in a manner similar to Example 1 A. It was isolated as an yellow solid in a 84% yield. Ci2HnBrCIN3. MS: 312.1/314.1 (MH+). 1H NMR (CDCI3) d 8.11 (s, 1 H), 7.37 - 7.14 (m, 5 H), 5.71 (d, J = 7.4 Hz, 1 H), 5.35 (dt, J = 7.4, 6.7 Hz, 1 H), 1.60 (d, J = 6.7Hz, 3 H) ppm
B. 5-Bromo-N4-(1 S-phenyl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-vπ-pyrimidine-2.4-diamine
Figure imgf000055_0002
The title compound was made in a manner similar to Example 1 D and deprotected similarly to Example 4C to give the desired material as its TFA salt in a 15% yield (tan solid). C25H25BrN6. MS 489.0/491.1 (MH+); 1H NMR (d6-DMSO) $11.37 (s, 1 H), 8.91 (s, 1 H), 8.11 (s, 1 H), 7.94 (s, 1 H), 7.57 (s, 1 H), 7.40 (d, J = 8.8 Hz, 1 H), 7.30 - 7.22 (m, 7 H), 6.12 (s, 1 H), 4.06 (bs, 1 H), 3.77 - 3.75 (bs, 2 H), 3.38-3.36 (bs, 2 H), 2.76-2.75 (bs, 2 H), 1.57 (d, J = 6.8 Hz, 3 H) ppm. 04/056786
-55-
Example 8 4-((5-Bromo-2-r3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-ylamino1-pyrimidin-4- ylaminoj-methvP-benzenesulfonamide
A. 4-f(5-Bromo-2-chloro-pyrimidin-4-ylamino)-methvn-benzenesulfonamide
Figure imgf000056_0001
The title compound was made in a manner similar to Example 1 A. It was isolated in a 30% yield as a white solid which fell out of solution upon work-up. CnH10BrCIN4θ2S. MS 375/377/378 (MH+). 1H NMR (d6-DMSO) δ 8.26 (s, 1 H), 7.74 (d, J = 8.6 Hz, 2 H), 7.42 (d, J = 8.6 Hz, 2 H), 4.59 (s, 2 H) ppm.
B. 4-((5-Bromo-2-f3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-ylamino1- pyrimidin-4-ylamino}-methyl)-benzenesulfonamide
Figure imgf000056_0002
The title compound was made in a manner similar to Example 1 D and deprotected similarly to Example 4C. It was isolated as its free base after column chromatography (93:7:0.7 CHCI3:CH3OH:NH4OH) as a brown solid in a 2% yield. C24H24BrN7θ2S. MS: 554.1/556.0 (MH+). 1H NMR (CD3OD) δ(CD3OD) δ 7.89 (s, 1 H), 7.68 (d, J = 8.3 Hz, 2 H), 7.31 (d, J = 8.3 Hz, 2 H), 7.26-7.22 (m, 2 H), 7.16-7.10 (m, 2H), 6.69 (d, J = 8.7 Hz, Λ H), 6.16 (bs, 1 H), 4.61 (bs, 2 H), 3.59-3.57 (bs, 2 H), 3.30 - 3.21 (bs, 2 H), 2.55 - 2.53 (bs, 2 H) ppm.. Example 9 5-Bromo-N2-[3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-(4-trifluoromethyl- benzyl)-pyrimidine-2.4-diamine
Figure imgf000057_0001
To a stirred solution of 5-bromo-2,4-dichloropyrimidine (0.222 g, 0.98 mmol) in THF (3 mL) under nitrogen was added triethylamine (0.42 mL, 3 mmol) followed by dropwise addition of p-trifluoromethylbenzyl amine (0.175 g,1 mmol). After three hours the THF was removed under reduced pressure. To the resulting residue was added dioxane (1 mL) followed by 4-(5- Amino-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester (0.345 g 1.1 mmol). The mixture was stirred under nitrogen and then heated to 110° C for sixteen hours. The reaction was cooled and was then dissolved in a solution of 5% methanol- dichloromethane and extracted with 1 N NaOH. The organic and aqueous layers were separated and the aqueous layer was further extracted with additional 5% methanol- dichloromethane. The organic layers were combined, washed with brine, dried over magnesium sulfate, filtered and evaporated under reduced pressure. The resulting residue was purified by silica gel chromotography (30% ethyl acetate in hexanes) to give 4-{5-[5- Bromo-4-(4-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 H-indol-3-yl}-3,6-dihydro-2H- pyridine-1 -carboxylic acid tert-butyl ester (150 mg, 23%): (MS: 642.9/644.73 MH+). This material was then taken directly to the next reaction. To a stirred solution of 4-{5-[5-Bromo-4- (4-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 H-indol-3-yl}-3,6-dihydro-2H-pyridine-1- carboxylic acid tert-butyl ester (0.15 g) in dichloromethane (2 mL) at 0° C under nitrogen was added trifluoroacetic acid (4 mL). The cooling bath was removed and the reaction mixture was stirred for four hours. The reaction was concentrated under reduced pressure. To the resulting residue was added ethyl acetate (2 mL) followed by concentrating to an oily residue. The ethyl acetate concentration sequence was repeated three times. The resulting residue was suspended in ethyl acetate follow by addition of diethyl ether to precipitate 5-Bromo-N2- [3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(4-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine trfluoroacetate salt (0.129 g, 86%) as a white solid: C25H22BrF3N6. MS: 542.9/544.7 (MH+). H NMR (D6-DMSO) δ 11.31 (s, 1 H), 8.82 (s, 2 H), 8.08 (s, 1 H), 7.88 (s, 1 H), 7.53 (s, 3 H), 7.36 (s, 2 H), 7.28 (d, J = 8.3 Hz, 1 H), 7.16 (d, J = 8.3 Hz, 1 H), , 6.05 (bs, 1 H), 4.58 (s, 2 H), 3.75-3.65 (bs, 2 H), 3.35-3.25 (bs, 2 H), 2.70-2.60 (bs, 2 H) ppm Example 10 5-Bromo-N4-(4-methoxy-benzyl)-N2-f3-(1 ,2.3.6-tetrahydro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000058_0001
The title compound was synthesized according to the procedure of Example 9. It was isolated in a 21 % yield as a white solid TFA salt. C25H25BrN60. MS: 505.0/506.8 (MH+); 1H NMR (D6-DMSO) δ 11.33 (s, 1 H), 8.84 (s, 2 H), 8.06 (s, 1 H), 7.95 (s, 1 H), 7.53 (s, 1 H), 7.35 (d, J = 7.9 Hz, 1 H), 7.23 (d, J = 7.9 Hz, 1 H), 7.10 (s, 2 H), 6.74 (s, 1 H), 6.73 (s, 1 H), 6.06 (s, 1 H), 4.26 (s, 2 H), 3.69 (s, 2 H), 3.66 (s, 3 H), 3.30 (s, 2 H), 2.68 (s, 2 H) ppm.
Example 11
5-Bromo-N4-(4-fluoro-benzv))-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2.4-diamine
Figure imgf000058_0002
The title compound was synthesized according to the procedure of Example 9. It was isolated in a 12% overall yield as an off-white TFA salt. C24H22BrFN6. MS: 492.9/494.9
(MH+); 1H NMR (D6-DMSO) δ 11.26 (s, 1 H), 8.78 (s, 2 H), 8.03 (s, 1 H), 7.95 (s, 1 H), 7.51
(s, 1 H), 7.31-7.23 (m, 3 H), 7.02 (s, 2 H), 6.05 (s, 1 H), 4.50 (s, 2 H), 3.70 (s, 2 H), 3.29 (s, 2
H), 2.68 (s, 2 H) ppm.
Example 12 5-Bromo-N -(3-flύoro-benzyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vπ- pyrimidine-2,4-diamine
Figure imgf000058_0003
The title compound was synthesized in a manner similar to Example 9 in a 20% yield. It was isolated as an off-white solid TFA salt. C24H22BrFN6. MS: 492.9/494.9 (MH+); H NMR (D6-DMSO) δ 11.33 (s, 1 H), 8.66 (s, 2 h), 8.40-8.20 (bs, 1 H), 8.11 (s, 1 H), 7.98 (s, 1 H), 7.57 (s, 1 H), 7.33-7.30 (m, 3 H), 7.10-7.07 (m, 3 H), 6.11 (s, 1 H), 4.60 (d, J = 5.6 Hz, 2 H), 3.77 (s, 2 H), 3.37 (s, 2 H), 2.73 (s, 2 H) ppm.
Example 13
5-Bromo-N4-naphthalen-1 -ylmethyl-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5- vn-pyrimidine-2,4-diamine
Figure imgf000059_0001
The title compound was made in a manner described in Example 9 in a 16% yield. The isolated TFA salt was characterized as an off-white solid. C28H25BrN6. MS: 525.1/527.1 (MH+); 1H NMR (D6-DMSO) δ 11.21 (s, 1 H), 8.76 (s, 2 H), 8.15 (d, J = 9.2 Hz, 1 H), 8.06 (s, 1 H), 7.93 (d, J - 8.0 Hz, 1 H), 7.89 (s, 1 H), 7.79 (d, J = 7.8 Hz, 1 H), 7.54-7.46 (m, 3 H), 7.34 (s, 1 H), 7.28 (s, 1 H), 7.14 (d, J = 8.4 Hz, 1 H), 6.98 (bs, 1 H), 6.02 (s, 1 H), 5.04 (s, 2 H), 3.67 (s, 2 H), 3.28 (s, 2 H), 2.65 (s, 2 H) ppm.
Example 14
5-Bromo-N4-(4-fluoro-3-trifluoromethyl-benzyl)-N2-[3-(1.2.3.6-tetrahvdro-pyridin-4-yl)- 1 H-indol-5-yll-pyrimidine-2,4-diamine
Figure imgf000059_0002
The title compound was made in a manner described in Example 9 in a 12% overall yield. The isolated TFA salt was characterized as an off-white solid. C25H21BrF4N6. MS: 560.8/562.4 (MH+); 1H NMR (D6-DMSO) δ11.31 (s, 1 H), 8.87 (s, 2 H), 8.24 (bs. 1 H), 8.11 (s, 1 H), 8.01 (s, 1 H), 7.72 (s, 1 H), 7.56 (s, 2 H), 7.36-7.29 (m, 3 H), 6.18 (s, 1 H), 4.62 (d, J = 5.6 Hz, 2 H), 3.79 (s, 2 H), 3.39 (s, 2 H), 2.74 (s, 2 H) ppm. 4/056786
-59-
Example 15 5-Bromo-N4-(3-fluoro-5-trifluoromethyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-
1H-indol-5-vπ-pyrimidine-2,4-diamine
Figure imgf000060_0001
The title compound was synthesized in a manner described in Example 9 in a 16% overall yield. It was characterized as an off-white solid as its TFA salt. C25H21BrF4N6. MS: 561.4/563.2 (MH+), 1H NMR (D6-DMSO) δ 11.26 (s, 1 H), 8.82 (s, 2 H), 8.21 (bs, 1 H), 8.07 (s, 1 H), 7.94 (s, 1 H), 7.46-7.35 (m, 3 H), 7.24 (s, 1 H), 7.20 (s, 2 H), 6.06 (s, 1 H), 4.61 (d, J = 5.4 Hz, 2 H), 3.74 (s, 2 H), 3.30 (s, 2 H), 2.68 (s, 2 H) ppm.
Example 16
5-Bromo-N4-(4-phenoxy-benzyl)-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4- -vyll))--11 HH--indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000060_0002
The title compound was synthesized in a 9% overall yield in a manner described in Example 9. It was characterized as an off-white solid isolated as its TFA salt. C30H27BrN6O. 567.0/568.6 (MH+); 1H NMR (CD3OD) δ 7.89 (s, 1 H), 7.84 (s, 1 H), 7.48 (s, 1 H), 7.47 (d, J = 7.5 Hz, 1 H), 7.31 (dd, J = 7.5, .3 Hz, 2 H), 7.17 (d, J = 8.7 Hz, 1 H), 7.15 (bs, 2 H), 7.08 (t, J = 7.5 Hz, 1 H), 6.90 (d, J = 8.3 Hz, 2 H), 6.79 (s, 2 H), 6.15 (s, 1 H), 4.57 (s, 2 H), 3.80 (s, 2 H), 3.42 (s, 2 H), 2.82 (s, 2 H) ppm. Example 17 5-Bromo-N4-(3.4-difluoro-benzyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000061_0001
The title compound was synthesized in a 19% overall yield in a manner described in Example 9. It was characterized as an off-white solid isolated as its TFA salt. C24H21BrF2N6: 510.9/513 .0 (MH+); 1H NMR (D6-DMSO) δ 11.26 (s, 1 H), 8.87 (bs, 2 H), 8.09 (s, 2 H), 8.00 (s, 1 H), 7.56 (s, 1 H), 7.33 (m, 3 H), 7.10 (s, 1 H), 6.11 (s, 1 H), 4.54 (s, 2 H), 3.78 (s, 2 H), 3.35 (s, 2 H), 2.74 (s, 2 H) ppm.
Example 18
5-Bromo-N2-r3-(1.2,3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-(3-trifluoromethoxy- benzyl)-pyrimidine-2,4-diamine
Figure imgf000061_0002
The title compound was synthesized in a 8% ovrall yield in a manner described in Example 9. It was characterized as an off-white solid isolated as its TFA salt. C25H22BrF3N60. 559.0/561.0 (MH+); 1H NMR (D6-DMSO) δ 11.28 (s, 1 H), 8.81 (bs, 2 H), 8.08 (s, 1 H), 8.01 (s, 1 H), 7.55 (s, 1 H), 7.50 (bs, 1 H), 7.40-7.21 (m, 6 H), 6.10 (s, 1 H), 4.63 (s, 2 H), 3.77 (s, 2 H), 3.37 (s, 2 H), 2.73 (s, 2 H) ppm. Example 19 5-Bromo-N4-(4-chloro-benzyl)-N2-f3-(1.2,3.6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yn- pyrimidine-2,4-diamine
Figure imgf000062_0001
The title compound was synthesized in a 20% overall yield in a manner described in Example 9 from 4-chlorobenzyl amine. It was characterized as an off-white solid isolated as its TFA salt. C24H22BrCIN6. MS: 508.9/510.9/513.0 (MH+); 1H NMR (D6-DMSO) δ 11.27 (s, 1 H), 8.85 (bs, 2 H), 8.09 (s, 1 H), 7.98 (s, 1 H), 7.56 (s, 1 H), 7.32-7.29 (m, 6 H), 6.10 (s, 1 H), 4.55 (s, 2 H), 3.77 (s, 2 H), 3.36 (s, 2 H), 2.74 (s, 2 H) ppm.
Example 20
5-Bromo-N2-f3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yll-N4-thiophen-2-ylmethyl- pyrimidine-2,4-diamine
Figure imgf000062_0002
The title compound was synthesized in a 12% overall yield in a manner described in Example 9 from 2-methylaminothiophene. It was characterized as an off-white solid isolated as its TFA salt. C22H21BrN6S. MS: 481.0/483.0 (MH+); 1H NMR (D6-DMSO) δ 11.24 (s, 1 H), 8.77 (s, 2 H), 8.04 (s, 2 H), 7.49 (s, 1 H), 7.32 (s, 3 H), 6.87 (m, 2 H), 6.05 (s, 1 H), 4.71 (s, 2 H), 3.69 (s, 2 H), 3.29 (s, 2 H), 2.67 (s, 2 H) ppm. Example 21 5-Bromo-N4-furan-2-ylmethyl-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2,4-diamine
Figure imgf000063_0001
The title compound was made in a manner similar to Example 9. It was isolated in a
1% yield as an off-white solid characterized as its free base. C22H21BrN60. MS: 465.1/467.1 (MH+)
Example 22 5-Bromo-N4-(2-methyl-benzyl)-N2-f3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2,4-diamine
Figure imgf000063_0002
C25H25BrN6
Example 23 5-Bromo-N4-(3-methyl-benzyl)-N2-[3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000063_0003
C25H25BrN6. Example 24 5-Bromo-N4-(4-methyl-benzyl)-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000064_0001
C25H25BrN6.
Example 25 5-Bromo-N4-(2-fluoro-benzyl)-N2-r3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000064_0002
C24H22BrFN6.
Example 26 N4-Biphenyl-2-ylmethyl-5-bromo-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000064_0003
C3oH27BrN6. Example 27 N4-Biphenyl-3-ylmethyl-5-bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000065_0001
Example 28 5-Bromo-N4-(2-methoxy-benzyl)-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000065_0002
C25H25BrN60.
Example 29 5-Bromo-N4-(3-methoxy-benzyl)-N2-r3-(1 ,2.3.6-tetrahvdro-pyridin-4-yl)-1H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000065_0003
C25H25BrN60. Example 30 3-((5-Bromo-2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-ylamino1-pyrimidin-4- ylamino)-methyl)-N-methyl-benzamide
Figure imgf000066_0001
C26H26BrN70.
Example 31
5-Bromo-N4-(2-chloro-benzyl)-N2-[3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2,4-diamine
Figure imgf000066_0002
C24H22BrCIN6.
Example 32 5-Bromo-N4-phenethyl-N2-r3-(1.2.3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-vn-pyrimidine- 2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-phenethyl-amine
Figure imgf000066_0003
A 5.00 g (22.0 mmol) sample of 5-bromo-2,4-dichloropyrimidine was taken into 40.0 mL tetrahydrofuran with 7.80 mL (44.8 mmol) diisopropylethylamine. 3.53 g (22.4 mmol) phenethyl amine was added drop-wise with a white precipitate noted upon addition. After addition mLetion, the reaction mixture was allowed to stir at ambient temperature under nitrogen for three hours. The volatiles were removed under reduced pressure, and the resulting residue was partitioned between 1 N sodium hydroxide and ethyl acetate. Aqueous work-up afforded the title compound as 5.93 g (19.0 mmol, 95%) of a pale yellow, oily solid. CuHnBrCINa: GC/MS: ret. Time: 4.77 min.: m/z 311/313/315, 220/222/224, 104; 1H NMR (CDCI3) δ 8.09 (s, 1 H), 7.34 - 7.30 (m, 2 H), 7.28 - 7.18 (m, 3 H), 5.53 (bs, 1 H), 3.75 (t, J = 6.4 Hz, 2 H), 2.92 (t, J = 6.4 Hz, 2 H) ppm.
B. 4-f5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1 H-indol-3-vπ-3.6- dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester
Figure imgf000067_0001
The title compound was made in a 35% yield in a manner similar to Example 1 D using
(5:bromo-2-chloro-pyrimidin-4-yl)-phenethyi-amine. C3oH33BrN602: MS 589.1/591.1 (MH+); 1H NMR (D6-DMSO): δ 11.00 (s, 1 H), 8.92 (s, 1 H), 7.94 (s, 1 H), 7.40 (d, J = 8.4 Hz, 1 H), 7.34 (s, 1 H), 7.22 (d, J = 8.4 Hz, 1 H), 7.18 - 7.07 (m, 6 H), 6.90 (m, 1 H), 6.02 (s, 1 H), 3.98 (m, 2 H), 3.56 (m, 2 H), 3.45 (m, 2 H), 2.76 (t, J = 7.6 Hz, 2 H), 2.42 (m, 2 H), 1.38 (s, 9 H) ppm.
C. 5-Bromo-N4-phenethyl-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2,4-diamine
Figure imgf000067_0002
832 mg (1.70 mmol) 4-[5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1 H-indol- 3-yl]-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester was taken into 2.00 mL dichloromethane and cooled to 0° C. 4.00 mL trifluoroacetic acid was slowly added. The red reaction mixture was allowed to stir under nitrogen and slowly warm to ambient temperature over three hours. The volatiles were removed under reduced pressure. Ethyl acetate was added and evaporated an additional three times until a nearly clear yellow oil remained. Ethyl acetate was added (app. 1 mL) and stirred. Diethyl ether was added until a white precipitate was noted. Filtration of this precipitate afforded 716 mg of the title compound isolated as its Trifluoroacetate salt. C25H25BrN6: MS: 489.1/491.1 (MH+); 1H NMR (D6-DMSO): δ 11.45 (s, 1 H), 10.32 (s, 1 H), 8.92 (s, 1 H), 8.31 (s, 1 H), 8.16 (s, 1 H), 7.91 (s, 1 H), 7.57 (s, 1 H), 7.40 (d, J = 8.3 Hz, 1 H), 7.27 (d, J = 8.3 Hz, 1 H), 7.11 - 6.90 (m, 5 H), 6.19 (bs, 1 H), 3.68 (m, 2 H), 3.46 (m, 2 H), 3.24 (m, 2 H), 2.71 - 2.66 (m, 4 H) ppm.
Example 33 5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-vn-1 H-indol-5-yll- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-pyridin-2-yl-ethyl)-amine
The title compound was made in a manner similar to Example 32A. It was isolated in an 83% yield as a tan solid. CnH10BrCIN4. MS 313.0/315.0/317.0 (MH+); 1H NMR (D6- DMSO) δ 8.53 (d, J = 4.9 Hz, 1 H), 8.26 (s, 1 H), 7.92 (t, J = 5.5 Hz, 1 H), 7.73 (t, J = 7.6 Hz, 1 H), 7.30-7.23 (m, 2 H), 3.78-3.62 (m, 2 H), 3.07-3.02 (m, 2 H) ppm.
B. 5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-r3-(1.2,3.6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-yll-pyrimidine-2,4-diamine
Figure imgf000068_0001
The title compound was synthesized in a manner similar to Example 32B and deprotected similarly to Example 21 C. It was made in a 40% yield and isolated as a white solid, TFA salt. C24H24BrN7. MS: 490.0/491.8 (MH+); 1H NMR (D6-DMSO) δ 11.41 (s, 1 H), 8.89 (s, 2H), 8.59 (s, 1 H), 8.29-8.00 (m, 2H), 7.91 (s, 2 H), 7.56-7.50 (m, 2H), 7.38 (d, J = 8.3 Hz, 1 H), 7.35-7.20 (m, 2 H), 6.07 (bs, 1 H), 3.98-3.72 (bs, 4 H), 3.37-3.30 (bs, 2 H), 3.10-3.00 (bs, 2 H), 2.67-2.46 (bs, 2 H) ppm.
Example 34
5-Bromo-N4-(2- -ppyyrriiddiinn--44--yyll--eetthhvyll])-N2-r3-(1 ,2,3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- Pyrimidine-2.4-diamine
Figure imgf000068_0002
The title compound was made in a 30% yield in the same manner as Example 9 using 4-(2-ethylamino)pyridine. It was noted to be a white solid, isolated as its TFA salt. C24H24BrN7. MS: 490.0/492.0 (MH+); 1H NMR (D6-DMSO) 011.37 (s, 1 H),8.85 (s, 1 H), 8.50 (s, 2 H), 8.10 (s, 1 H), 7.94 (s, 1 H), 7.54 (s, 1 H), 7.37 (d, J = 8.7 Hz, J H), 7.35 (bs, 1 H), 7.26 (d, J = 9.1 Hz, 1 H), 6.06 (bs, 1 H), 3.75-3.65 (bs, 2 H), 3.60-3.50 (bs, 2 H), 3.35-3.25 (bs, 2 H), 3.00-2.90 (bs, 2 H), 2.70-2.60 (bs, 2H) ppm.
Example 35
5-Bromo-N4-(2-pyridin-3-yl-ethyl)-N2-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn- pyrimidine-2.4-diamine
Figure imgf000069_0001
The title compound was made in a 23% overall yield starting from 3(2- ethylamino)pyridine, following the procedure of Example 9. The compound was noted to be an off-white solid isolated as its TFA salt. C24H24BrN7. MS: 490.2/492.2 (MH+); 1NMR (De- DMSO) δ 11.37 (s, 1 H), 8.82 (s, 2H), 8.53 (s, 1 H), 8.49 (s, 1 H), 8.09 (s, 1 H), 8.00 (bs, 1 H), 7.97 (s, 1 H), 7.66 (bs, 1 H), 7.54 (s, 1 H), 7.39 (bs, 1 H), 7.37 (d, J = 8.8 Hz, 1 H), 7.26 (d, J = 8.3 Hz, 1 H), 6.07 (bs, 1 H), 3.70 (s, 2 H), 3.55(s, 2 H), 3.28(s, 2 H), 2.88 (s, 2 H), 2.70-2.60 (bs, 2 H) ppm..
Example 36 5-Bromo-N4-f2-(3-fluoro-phenyl)-ethvn-N2-F3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol- 5-vn-pyrimidine-2.4-diamine
Figure imgf000069_0002
The title compound was isolated in a 4% yield as a white solid according to the procedure of Example 9. It was isolated as its free base after purifying over silica gel (93:7:0.7
CHCl3:CH3OH:NH4OH). C25H24BrFN6. MS: 507.0/508.8 (MH+); 19F NMR (Dβ-DMSO) δ - 114.0 ppm. 1H NMR (D6-DMSO) δ 10.90 (s, 1 H), 8.92 (s, 1 H), 8.08 (s, 1 H), 7.93 (s, 1 H), 7.41 (dd, J = 1.6, 8.7 Hz, 1 H), 7.32 (s, 1 H), 7.27 (s, 1 H), 7.21-7.19 (m, 2 H), 6.99-6.88 (m, 4 H), 6.08 (s, 1 H), 3.59-3.53 (m, 2 H), 3.31 (s, 2 H), 2.85-2.82 (m, 4 H), 2.32 (s, 2 H) ppm.
Example 37 5-Bromo-N4-(2-phenyl-cyclopropyl)-N2-r3-(1,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5- vn-pyhmidine-2.4-diamine
Figure imgf000070_0001
The title compound was synthesized in a 13% overall yield in a manner described in
Example 1. C26H25BrN6. 501.0/503.0 (MH+); 1H NMR (D6-DMSO) δ 11.28 (s, 1 H), 8.90 (bs,
2 H), 8.11 (s, 1 H), 7.90 (bs, 1 H), 7.86 (s, 1 H), 7.55 (s, 1 H), 7.43 (d, J = 8.1 Hz, 1 H), 7.21- 7.09 (m, 6 H), 6.08 (s, 1 H), 3.77 (s, 2 H), 3.34 (m, 3 H), 2.73 (s, 2 H), 2.25 (m, 1 H), 1.58 (m,
1 H), 1.20 (m, 1 H) ppm.
Example 37A 5-Bromo-N4-(2-phenyl-cvclopropyl)-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5- vn-pyrimidine-2.4-diamine (homo-chiral) Example 37B
5-Bromo-N4-(2-phenyl-cvclopropyl)-N2-[3-(1 ,2,3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5- vπ-pyrimidine-2.4-diamine (homo-chiral)
Example 38 5-Bromo-N4-f2-(4-chloro-phenyl)-ethvn-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-vn-pyrimidine-2,4-diamine
Figure imgf000070_0002
The title compound was isolated in a 10% overall yield in a manner described by Example 9 from 4-chlorophenethyl amine. It was characterized as an off-white solid isolated as its TFA salt. C25H24BrCIN6. MS: 522.9/524.9/527.0 (MH+); 1H NMR (D6-DMSO) δ 11.37 (s, 1 H), 8.79 (s, 2 H), 8.07 (s, 1 H), 7.93 (s, 1 H), 7.56 (s, 1 H), 7.37 (d, J = 8.8 Hz, 1 H), 7.30 (s, 1 H), 7.13 (bs, 2 H), 6.97 (s, 2 H), 6.06 (s, 1 H), 3.69 (s, 2 H), 3.34 (s, 2 H), 3.26 (s, 2 H), 2.67 (m, 4 H) ppm.
Example 39 5-Bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn-N4-(2-thiophen-2-yl- ethyl)-pyrimidine-2.4-diamine
Figure imgf000071_0001
The title compound was isolated in 13% overall yield in a manner described by Example 9 from 2-ethylaminothiophene. It was characterized as an off-white solid isolated as its TFA salt. C23H23BrN6S. MS: 495.1/497.1 (MH+); 1H NMR (D6-DMSO) δ 11.38 (s, 1 H), 8.86 (s, 2 H), 8.11 (s, 1 H), 8.00 (s, 1 H), 7.57 (s, 1 H), 7.39 (s, 2 H), 7.35 (d, J = 5.3 Hz, 1 H), 6.94 (m, 1 H), 6.78 (s, 1 H), 6.11 (s, 1 H), 3.75 (s, 2 H), 3.62 (s, 2 H), 3.34 (s, 2 H), 3.09 (s, 2 H), 2.72 (s, 2 H) ppm.
Example 40
5-Bromo-N4-r2-(2-fluoro-phenyl)-ethyll-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol- 5-yll-pyrimidine-2,4-diamine
Figure imgf000071_0002
The title compound was made in a 12% yield in a manner described in Example 9. It was characterized as an off-white solid isolated as its HCI salt. C25H24BrFN6. MS: 507.0/508.9 (MH+); 1HNMR (D6-DMSO) δ 11.43 (s, 1 H), 10.37 (s, 1 H), 9.20 (s, 2 H), 8.53 (bs, 1 H), 8.20 (bs, 1 H), 7.90 (s, 1 H), 7.57 (s, 1 H), 7.41 (s, 1 H), 7.18-7.06 (m, 3 H), 6.89 (bs, 1 H), 6.06 (s, 1 H), 3.66 (s, 2 H), 3.46 (s, 2 H), 3.23 (s, 2 H), 2.80 (s, 2 H), 2.67 (s, 2 H) ppm. Example 41 5-Bromo-N4-f2-(2-chloro-phenyl)-ethvn-N2-f3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol- 5-vπ-pyrimidine-2.4-diamine
Figure imgf000072_0001
The title compound was made in a 20% yield in a manner described in Example 9. It was characterized as an off-white solid and isolated as its HCI salt. C25H24BrCIN6. MS: 523.1/525.1/527.1 (MH+); 1HNMR (D6-DMSO) δ 11.45 (s, 1 H), 10.37 (s, 1 H), 9.17 (bs, 2 H), 8.54 (s, 1 H), 8.28 (s, 1 H), 7.87 (s, 1 H), 7.57 (s, 1 H), 7.42 (d, J = 8.7 Hz, 1 H), 7.33 (d, J = 7.5 Hz, 1 H), 722-1 M (m, 2 H), 6.98 (bs, 1 H), 6.06 (s, 1 H), 3.66 (s, 2 H), 3.52 (s, 2 H), 3.22 (s, 2 H), 2.90 (s, 2 H), 2.67 (s, 2 H) ppm.
Example 42
5-Bromo-N4-f2-(2-methoxy-phenyl)-ethvn-N2-[3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine
Figure imgf000072_0002
The title compound was made in a 6% yield in a manner described in Example 9. It was characterized as an off-white solid and isolated as its HCI salt. C26H27BrN60. MS: 519.0/520.9 (MH+); 1HNMR (D6-DMSO) δ 11.47 (s, 1 H), 10.46 (s, 1 H), 9.28 (bs, 2 H), 8.56 (s, 1 H), 7.90 (s, 1 H), 7.57 (s, 1 H), 7.41 (d, J = 8.8 Hz, 1 H), 7.20 (s, 1 H), 7.17 (s, 1 H), 6.85 (d, J = 7.9 Hz, 1 H), 6.65 (bs, 2 H), 6.05 (s, 1 H), 3.76 (s, 3 H), 3.65 (s, 2 H), 3.53 (s, 2 H), 3.20 (s, 2 H), 2.75 (s, 2 H), 2.67 (s, 2 H) ppm. Example 43 N -(2-Benzof1 ,3ldioxol-5-yl-ethyl)-5-bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-vn-1 H- indol-5-vn-pyrimidine-2.4-diamine
Figure imgf000073_0001
The title compound was made in a 4% yield in a manner described in Example 9. It was characterized as an off-white solid isolated as its HCI salt. C26H25BrN602. MS: 533.6/535.6 (MH+); 1HNMR (D6-DMSO) δ 11.47 (s, 1 H), 10.43 (s, 1 H), 9.29 (bs, 2 H), 8.53 (s, 1 H), 8.34 (s, 1 H), 7.88 (s, 1 H), 7.67 (s, 1 H), 7.42 (s, 1 H), 7.22 (s, 1 H), 6.60 (m, 2 H), 6.05 (s, 1 H), 3.63 (s, 2 H), 3.52 (s, 2 H), 3.45 (s, 2 H), 2.69 (m, 4 H) ppm.
Example 44
5-Bromo-N4-(3-phenyl-propyl)-N2-f3-(1 ,2,3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vπ- pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-phenyl-propyl)-amine
Figure imgf000073_0002
The title compound was made in a manner similar to Example 1A except performing the reaction at ambient temperature. It was isolated as a yellow oil which solidified upon standing in a 84% yield. MS: 324/326/328 (MH+); 1H NMR (CDCI3) δ 8.30 (s, 1 H), 7.37-7.23 (m, 5 H), 5.52 (s, 1 H), 3.57 (tt, J = 7.5, 7.3 Hz, 2 H), 2.77 (t, J = 7.5 Hz, 2 H), 2.04 (t, J = 7.3 Hz, 2 H) ppm. B. 5-Bromo-N4-(3-phenyl-propyl)-N2-r3-(1.2.3,6-tetrahvdro-pyridin-4-yl)-1H-indol-
5-y|]-pyrimidine-2,4-diamine
Figure imgf000074_0001
The title compound was isolated as its TFA salt following the procedure of Example 1 D and deprotecting according Example 4C in a 34% yield as a white solid. C26H27BrN6. MS: 503.2/505.1 (MH+); 1H NMR (D6-DMSO) δ 11.32 (s, 1 H), 8.90 (s, 1 H), 8.05 (s, 1 H), 7.93 (s, 1 H), 7.53 (s, 1 H), 7.35 (s, 2H), 7.21-7.05 (m, 7 H), 6.07 (bs, 1 H), 3.80-3.70 (bs, 2 H), 3.37- 3.31 (bs, 4 H), 2.70-2.60 (bs, 2 H), 2.47-2.46 (bs, 2 H), 2.00-1.90 (bs, 2 H).
Example 45
5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1 ,3-dihvdro-indol-2-one
A. 5-Nitro- ,3-dihydro-indol-2-one
Figure imgf000074_0002
C8H6N203: GC/MS ret. time: 4.12 min., m/z 178, 148, 104; 1H NMR (D6-DMSO) d 10.50 (s, 1 H), 8.11 (d, J = 8.7Hz, 1 H), 8.05 (s, 1 H), 6.94 (d, J = 8.7 Hz, 1 H), 3.59 (s, 2 H) ppm.
B. 5-Amino-1.3-dihydro-indol-2-one
Figure imgf000074_0003
To 250 mL acetic acid was added 7.00 g (39.3 mmol) 5-nitro-1 ,3-dihydro-indol-2-one and 418 mg (0.393 mmol) palladium on carbon. Exposed the reaction mixture to 40 psi H2 on parr shaker for 1.5 hours. The reaction was filtered through diatameceous earth, and the acetic acid was removed under reduced pressure. Cooled the reaction mixture to 0° C and added 10.0 mL of a 94.5:5:0.5 CHCI3:CH3OH:NH4OH solution. The solution was loaded onto a silica gel column and purified via chromatography (97.8:2.0:0.2 CHCI3:CH30H:NH40H) to give a white solid which was further crystallized using the eluent as the solvent to give 4.06 g (27.2 mmol, 69%) of the title compound as crystalline white needles. C8H9N20: C. 5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1,3-dihydro-indol-2-one
Figure imgf000075_0001
153 mg (0.490 mmol) (5-Bromo-2-chloro-pyrimidin-4-yl)-phenethyl-amine was taken into 500 DL 1 ,4 dioxane with 140 DL (1.00 mmol) diisopropylethylamine and 80 mg (0.539 mmol) 5-amino-1 ,3-dihydro-indol-2-one. The reaction was allowed to heat to 110° C for sixteen hours. The resulting brown glass was taken into 92.3:7:0.7 CHCI3:CH3OH:NH4OH and washed with 1 N sodium hydroxide. The organic layer was dried over magnesium sulfate and evaporated directly onto silica gel. This adsorbed compound was purified via column chromatography (97.8:2:0.2 CHCI3:CH3OH:NH4OH) over silica to isolate the major product. During evaporation of the major fractions, a white precipitate is noted. Filtration of this precipitate prior to mLete evaporation afforded the title compound in 6% yield as a white solid.
C2oH18BrN50: MS: 424.2/426.2 (MH+); 1H NMR (D6-DMSO) 10.20 (s, 1 H), 9.01 (s, 1 H),
7.93 (s, 1 H), 7.52 (s, 1 H), 7.44 (d, J = 8.4 Hz, 1 H), 7.28 - 7.16 (m, 5 H), 6.97 (m, 1 H), 6.65
(d, J = 8.3 Hz, 1 H), 3.56 (m, 2 H), 3.31 (s, 2 H), 2.82 (t, J = 7.9 Hz, 2 H) ppm. Example 46
5-f5-Bromo-4-(2-chloro-benzylamino)-pyrimidin-2-ylamino1-1.3-dihvdro-indol-2-one
Figure imgf000075_0002
C19H15BrCIN50. Example 47 5-(4-Benzylamino-5-bromo-pyrimidin-2-ylamino)-1.3-dihvdro-indol-2-one
Figure imgf000076_0001
C19H16BrN50
Example 48 5-f5-Bromo-4-(1-phenyl-ethylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one
Figure imgf000076_0002
C20H18BrN5O.
Example 49 5-[5-Bromo-4-(3-phenyl-propylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one
Figure imgf000076_0003
C21H20BrN5O. Example 50 5-Bromo-N -(2-methanesulfonyl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-
5-vπ-pyrimidine-2.4-diamine
Figure imgf000077_0001
The title compound was made in a 13% yield in a manner described in Example 9. It was characterized as an off-white solid isolated as it TFA salt. C20H23BrN6θ2S: MS: 491.1/493.1 (MH+); 1H NMR (D6-DMSO) δ 11.28 (s, 1 H), 8.84 (s, 2 H), 8.09 (s, 1 H), 7.95 (s, 1 H), 7.83 (s, 1 H), 7.52 (s, 1 H), 7.38 (s, 1 H), 7.36 (s, 1 H), 6.07 (s, 1 H), 3.75 (m, 4 H), 3.34 (m, 4 H), 2.90 (s, 3 H), 2.69 (m, 2 H) ppm. Example 51
N4-Benzyl-N2-f3-(1.2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-pyrimidine-2.4-diamine
Figure imgf000077_0002
250 mg (0.424 mmol) N4-Benzyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine trifluoroacetate was suspended in 12.7 mL cone. NH4OH. To this was added 0.636 g (9.73 mmol) zinc dust. The resulting slurry was heated to reflux for three hours. The gray mixture was filtered through diatomaceous earth. The filtrate was evaporated under reduced pressure to give the title compound in 39% yield isolated as a white solid. C24H24N6. MS: 397.2 (MH+); 1H NMR (CD3OD) δ 8.05 (s, 1 H), 7.66 (d, J = 5.8 Hz, 1 H), 7.30-7.17 (m, 7 H), 6.15 (s, 1 H), 5.87 (d, J = 5.8 Hz, 1 H), 4.55 (s, 2 H), 3.41 (s, 2 H), 3.05 (s, 2 H), 2.53 (s, 2 H) ppm. Example 52 N -Benzyl-N4-methyl-N2-[3-(1 ,2.3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yl1-pyrimidine- 2,4-diamine
Figure imgf000078_0001
The title compound was synthesized in a 4% overall yield in a manner similar to Example 9 using 2-4-dichloropyrimidine and N-methyl benzyl amine. It was characterized as an off-white solid isolated as its free base. C25H26N6. MS: 411.2 (MH+); 1H NMR (D6-DMSO) δ 10.85 (s, 1 H), 8.23 (s, 1 H), 7.88 (d, J = 5.8 Hz, 1 H), 7.35-7.15 (m, 9 H), 6.07 (s, 1 H), 6.04 (d, J = 5.8 Hz, 1 H), 4.78 (s, 2 H), 3.32 (s, 2 H), 3.13 (s, 2 H), 2.93 (m, 2 H), 2.47 (s, 3 H) ppm.
Example 53
N4-Methyl-N4-(2-Pyridin-2-yl-ethyl)-N2-r3-(1 ,2.3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vπ- pyrimidine-2,4-diamine
Figure imgf000078_0002
The title compound was made in a 1% yield in a manner described in Example 9. It was characterized as a white solid isolated as its free base after purifying the TFA salt over silica (93:7:0.7 CHCI3:CH3OH:NH4OH). d^N?. MS: 426.1 (MH+); 1H NMR (CD3OD) δ 8.37 (s, 1 H), 8.00 (s, 1 H), 7.76 (t, J = 7.5 Hz, 1 H), 7.44 (bs, 1 H), 7.33-7.15 (m, 5 H), 6.14 (s, 1 H), 5.97 (d, J = 5.8 Hz, 1 H), 5.94 (d, J = 7.5 Hz, 1 H), 3.87-3.78 (m, 2 H), 3.52-3.50 (m, 2 H), 3.11-3.06 (m, 2 H), 3.00 (s, 3 H), 2.97 (s, 2 H) ppm. Example 54 r4-(2-Phenyl-morpholin-4-yl)-pyrimidin-2-yll-f3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-yll-amine
Figure imgf000079_0001
The title compound was synthesized in a 9% overall yield in a manner described by
Example 9 using 2-phenylmorpholine and 2,4-dichloropyrimidine. It was characterized as an off-white solid isolated as its TFA salt. C27H28N60. MS: 453.3 (MH+); 1H NMR
Example 55 5-Methyl-N4-(2-pyridin-2-yl-ethyl)-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll- pyrimidine-2.4-diamine
Figure imgf000079_0002
C25H27N7
Example 56 5-Bromo-N2-(3-piperidin-4-yl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2.4- diamine
4-(5-Amino-1 H-indol-3-yl)-piperidine-1 -carboxylic acid tert-butyl ester
Figure imgf000079_0003
5.00 g 4-(5-Nitro-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester (14.6 mmol) was taken into 40.0 mL THF and 160 mL ethyl acetate 2/ 1.00 mL (5.74 mmol) diisopropylethylamine. 1.56 g (1.46 mmol) Pd/C was added. The reaction was shaken on a parr shaker under 3 atm H2 for 90 minutes. The reaction vessel was removed from pressure. It was filtered through a bed of diatomaceous earth and was washed thoroughly with ethyl acetate. The clear, colorless filtrate was evaporated under reduced pressure to give an impure white solid. The white solid was taken into a minimum amount of dichloromethane and tritrated with hexanes. Filtration afforded the title copound in 84% yield as a white solid. Cι8H25N3θ2. MS: 315.3, 216.1 (MH+); 1H NMR (D6-DMSO) δ 10.24 (s, 1 H), 6.99 (d, J = 8.3 Hz, 1 H), 6.87 (d, J = 2.1 Hz, 1 H), 6.66 (s, 1 H), 6.42 (dd, J = 2.1 Hz, 8.3 Hz, 1 H), 4.38 (s, 2 H), 4.00 (m, 2 H), 2.75 (m, 2 H), 2.47 (m, 2 H), 1.86 (m, 2 H), 1.46 (m, 2 H) ppm.
B. 5-Bromo-N2-(3-piperidin-4-yl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)- pyrimidine-2,4-diamine
The title compound was made in a manner similar to Example 1 D and deprotected according to the procedure of Example 1 E in a 38% yield. The compound was characterized as an off-white solid and isolated as its HCI salt.
Figure imgf000080_0001
C24H26BrN7. MS: 492.1/494.0 (MH+); 1H NMR (D6-DMSO) δ 11.11 (s, 1 H), 10.57 (s, 1 H), 9.16 (s, 1 H), 9.08 (s, 1 H), 8.69 (s, 1 H), 8.61 (s, 1 H), 8.32 (bs, 1 H), 8.17 (bs, 1 H), 7.74 (s, 2 H), 7.37 (d, J = 8.7 Hz, 1 H), 7.15 (s, 1 H), 7.11 (s, 1 H), 3.73 (s, 2 H), 3.26 (s, 4 H), 2.02 (s, 2 H), 1.88 (s, 2 H) ppm.
Example 57 5-Bromo-N2-f1-methanesulfonyl-3-(1 ,2,3.6-tetrahvdro-pyhdin-4-yl)-1 H-indol-5-vn-N4- (2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine A. 4-(1-Methanesulfonyl-5-nitro-1 H-indol-3-yl)-3,6-dihvdro-2H-pyridine-1- carboxylic acid tert-butyl ester
2.00 g (5.82 mmol) 4-(5-Nitro-1H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester was suspended in 15.0 mL toluene and 15.0 mL 15% sodium hydroxide solution and cooled to 0° C. To this was added 349 mg (0.874 mmol) nbu4N(HS04) tetra-n- butyl hydrogensulfate. 676 DL (8.74 mmol) methanesulfonyl chloride was slowly dropped in.
There was noted an immediate dissolution of the solids and a color change to red. Allowed the reaction to slowly warm to ambient temperature over sixteen hours. Reaction was regularly monitored and aliquots of 676 DL (8.74 mmol) methanesulfonyl chloride were added until complete disappearance of starting material by TLC. Ethyl acetate was added and the layers were separated. Aqueous work-up gave a yellow solid which was purified over silica (20%- 50% ethyl acetate in hexanes) to give the title compound in a 76% yield as a yellow solid. 1H NMR (D6-DMSO) δ 8.69 (d, J = 2.3 Hz, 1 H), 8.25 (dd, J = 9.1,2.3 Hz, 1 H), 8.05 (d, J = 9.1 Hz, 1 H), 7.84 (s, 1 H), 6.34 (s, 1 H), 4.06 (s, 2 H), 3.56 (s, 3 H), 3.55-3.53 (m, 2 H), 2.51 (s, 2 H), 1.41 (s, 9 H) ppm.
B. 4-(5-Amino-1-methanesulfonyl-1 H-indol-3-yl)-3,6-dihvdro-2H-pyridine-1- carboxylic acid tert-butyl ester
4-(1 -Methanesulfonyl-5-nitro-1 H-indol-3-yl)-3,6-dihydro-2H-pyridine-1 -carboxylic acid tert-butyl ester was reduced in a manner described in Example 1C in a 89% yield as an orange foam. 1H NMR (D6-DMSO) δ 7.48 (d, J = 9.0 Hz, 1 H), 7.33 (s, 1 H), 7.05 (s, 1 H),
6.66 (d, J = 9.0 Hz, 1 H), 6.16 (s, 1 H), 4.98 (s, 2 H), 4.02-3.96 ( , 2 H), 3.53-3.50 (m, 2 h), 3.23 (s, 3 H), 2.47-2.44 (m, 2 H), 1.40 (s, 9 H) ppm.
C. 5-Bromo-N2-f1 -methanesulfonyl-3-(1 ,2,3.6-tetrahydro-pyridin-4-yl)-1 H-indol-5- vπ-N4-(2-pyridin-2-yl-ethyl)-pyhmidine-2,4-diamine
Figure imgf000081_0001
The title compound was made in a manner 30% yield in a manner described in Example 1D and 1E. It was characterized as an off-white solid and isolated as its HCI salt.
Figure imgf000081_0002
MS: 568.0/569.9 (MH+); 1H NMR (D6-DMSO) δ 10.67 (bs, 1 H), 9.52 (s, 2 H), 8.64 (d, J = 5.4 Hz, 1 H), 8.44 (s, 1 H), 8.27 (s, 1 H), 8.18 (s, 2 H), 7.86 (d, J = 9.0 Hz, 1 H), 7.75-7.67 (m, 2 H), 7.52 (d, J = 9.0 Hz, 1 H), 6.29 (s, 1 H), 3.77 (s, 2 H), 3.48 (s, 3 H), 3.28 (s, 4 H), 2.73 (s, 2 H) ppm. Example 58 5-Bromo-N2-π-methanesulfonyl-3-(1 ,2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-vn-N4 PVridin-2-yl-pyrimidine-2,4-diamine
Figure imgf000082_0001
C23H22BrN702S.
Example 59
,4
5-Bromo-N -(2-pyridin-2-yl-ethyl)-N -r3-(1.2.3,6-tetrahvdro-pyridin-4-yl)-1H-indol-5-vπ- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-[3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol- 5-yll-amine
The title compound was made in a quantitative yield following the procedure of
Example 1A. It was characterized as an oily, yellow solid without purification. C17H15BrCIN5
MS: 503.1/505.1 (MH+); 1H NMR (CD3OD) δ 8.23 (s, 1 H), 8.14 (s, 1 H), 7.35 (d, J = 8.5 Hz, 1
H), 7.30 (s, 1 H), 7.22 (d, J = 8.5 Hz, 1 H), 6.14 (s, 1 H), 4.10 (s, 2 H), 3.64 (s, 2 H), 2.56 (s, 2 H), 1.48 (8, 9 H) ppm.
B. 5-Bromo-N2-(2-pyridin-2-yl-ethyl)-N4-f3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H- indol-5-vπ-pyrimidine-2,4-diamine
Figure imgf000082_0002
The title compound was made in a 2% yield via the manner described in Example 1D and 1E. It was characterized as an off white solid isolated as its free base after purifying the HCI salt over silica (93:7:0.7 CHCI3:CH3OH:NH4OH). C24H24BrN7. HPLC ret. time: 3.93 min.; MS: 490.0/492.1 (MH+); 1H NMR (CD3OD) δ 8.31 (s, 1 H), 7.94 (bs, 1 H), 7.87 (s, 1 H), 7.37- 7.32 (m, 4 H), 7.26 (dt, J = 9.0, 2.0 Hz, 1 H), 7.12 (s, 1 H), 6.16 (s, 1 H), 3.67 (s, 2 H), 3.43 (s, 2 H), 3.25-3.24 (m, 2 H), 2.84 (s, 2 H), 2.67 (s, 2 H) ppm. -82-
Example 60 3-(4-(2-Pyridin-2-yl-ethylamino)-2-r3-(1 ,2.3.6-tetrahvdro-pyridin-4-vi)-1H-indol-5- ylaminol-pyrimidin-5-yl)-acrylic acid ethyl ester
Figure imgf000083_0001
Example 60A 5-(5-Bromo-4-[2-(3-chloro-phenyl)-ethylamino1-pyrimidin-2-ylamino}-1 ,3-dihvdro-indol- 2-one
Example 61 5-Bromo-N4-r2-(3-chloro-phenyl)-ethyll-N2-f3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1H-indol-
5-vπ-pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-[2-(3-chloro-phenyl)-ethyll-amine fCι,HιnBrCI,N3)
Figure imgf000083_0002
Using method B, the title compound was isolated in a 79% yield (1.37 g, 3.95 mmol) as a white solid. GC/MS: ret. time = 5.30, m/z 345/347/349; 1H NMR (d6-DMSO) δ 8.20 (s, 1 H), 7.75 (t, 1 H), 7.29-7.12 (m, 4H), 3.56 (q, 2H), 2.84 (t, 2H) ppm. -83-
B. 5-(5-Bromo-4-f2-(3-chloro-phenyl)-ethylaminol-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one (C?nHi7BrCINgO)
Figure imgf000084_0001
The title compound was isolated as a brown solid in a 14% yield. MS: 459.9/461.2 (MH+). H NMR (d6-DMSO) δ: 10.19 (s, 1 H), 9.02 (s, 1H), 8.28 (s, 1 H), 7.93 (s, 1 H), 7.41 (dd, 1H), 7.30-7.22 (m, 3H), 7.13-7.11 (m, 1H), 6.98 (t, 1 H), 6.65 (d, 1H), 3.56 (q, 2H), 3.33 (s,1 H), 2.84 (t, 2H).
Example 62 5-Bromo-N4-r2-(3-chloro-phenyl)-ethyll-N -r3-(1 ,2.3,6-tetrahvdro-pyridin-4-yl)-1 H-indol- 5-yll-pyrim idine-2.4-diam ine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-[2-(3-chloro-phenyl)-ethvn-amine
Figure imgf000084_0002
The title compound was prepared according to method b and isolated in a 79% yield (1.37 g, 3.95 mmol) as a white solid (C12H10BrCI2N3): GC/MS: ret. time = 5.30, m/z 345/347/349; 1H NMR (d6-DMSO) δ 8.20 (s, 1 H), 7.75 (t, 1 H), 7.29-7.12 (m, 4H), 3.56 (q, 2H), 2.84 (t, 2H) ppm. 4/056786
-84-
B. 4-(6-(5-Bromo-4-f2-(3-chloro-phenyl)-ethylamino1-pyrimidin-2-ylamino)-1H- indol-3-yl)-3.6-dihvdro-2H-pyridine-1 -carboxylic acid tert-butyl ester.
Figure imgf000085_0001
The title compound was prepared according to method E (C30H32BrCINeO2): MS: 623.1/625.1 (MH+); 1H NMR (d6-DMSO) δ: 10.99 (s, 1H), 8.92 (s, 1H), 8.12 (s, 1H), 7.94 (s, 1H), 7.40-7.33 (m, 2H), 7.24-7.16 (m, 4H), 7.02-7.00 (m, H), 6.92 (t, 1 H), 6.02 (s, 1 H), 3.94 (s, 2H), 3.56 (q, 2H), 3.46 (m, 2H), 3.28 (s, 1 H), 2.81 (t, 2H), 1.38 (s, 9H) ppm.
C. 5-Bromo-N4-f2-(3-chloro-phenyl)-ethvn-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-
Figure imgf000085_0002
The title compound was prepared according to method G and isolated as the TFA salt in a 15% yield. MS: 522.9/525.1 (MH+). 1H NMR (CDCI3) δ: 12.16 (s, 1H), 9.67 (s, 2H), 8.90 (s, 1H), 8.75 (s, 2H), 8.34 (s, 1H), 8.19-8.13 (m, 2H), 8.03-7.94 (m, 3H), 7.72 (s, 1 H), 6.87 (s, 1H), 4.51 (s, 2H), 4.32 (s, 2H), 4.07 (s, 2H), 3.59 (s, 2H), 3.47 (s, 2H) ppm. Example 63 5- 5-Bromo-4-r2-(4-methoxy-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1 ,3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-r2-(4-methoxy-phenyl)-ethvn-amine.
Figure imgf000086_0001
The title compound was prepared according to method b and isolated as a light yellow, viscous oil in an 80% yield (C13H13BrCIN30). GC/MS: ret. time = 5.45. MS: 342.1/344.1/364.1 (MH+). 1H NMR (d6-DMSO) δ: 8.18 (s, 1 H), 7.70 (t, 1 H), 7.09 (d, 2H), 6.81 (d, 2H), 3.67 (s, 3H), 3.50 (q, 2H), 2.75 (t, 2H) ppm.
B. 5-(5-Bromo-4-f2-(4-methoxy-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1.3- dihvdro-indol-2-one (diHTnBrNsO?).
Figure imgf000086_0002
The title compound was prepared according to method E and isolated as a pink solid in a 40% yield. MS: 454.1/456.0 (MH+). 1H NMR (d6-DMSO) δ: 10.22 (s, 1 H), 9.01 (s, 1 H), 7.93 (s, 1 H), 7.51 (s, 1 H), 7.44 (d, 1 H), 7.07 (d, 2H), 6.95 (t, 1 H), 6.81 (d, 2H), 6.65 (d, 2H), 3.69 (s, 3H), 3.52 (q, 2H), 3.30 (s, 2H), 2.74 (t, 2H) ppm. 04/056786
-86-
Example 64 5-Bromo-N4-r2-(4-methoxy-phenyl)-ethyll-N -r3-(1.2.3,6-tetrahydro-pyridin-4-yl)-1H- indol-5-vn-pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-f2-(4-methoxy-phenyl)-ethyll-amine (CiaHiϋBrCINaO)
Figure imgf000087_0001
The title compound was isolated as a light yellow, viscous oil in an 80% yield. GC/MS: ret. time = 5.45 min. MS: 342.1/344.1/364.1 (MH+). 1H NMR (d6-DMSO) δ: 8.18 (s, 1 H), 7.70 (t, 1 H), 7.09 (d, 2H), 6.81 (d, 2H), 3.67 (s, 3H), 3.50 (q, 2H), 2.75 (t, 2H) ppm.
B. 5-Bromo-N4-[2-(4-methoxy-phenyl)-ethvn-N2-r3-(1 ,2,3,6-tetrahydro-pyridin-4-
Figure imgf000087_0002
The title compound was isolated as a tan solid in the TFA salt form in a 6.6% yield. MS: 520.4/522.3 (MH+). 1H NMR (d6-DMSO) δ: 11.36 (s, 1 H), 8.80, (s, 2H), 8.07 (s, 1 H), 7.94 (s, 1 H), 7.56 (s, 1 H), 7.38-7.32 (m, 2H), 6.83 (s, 2H), 6.65 (s, 2H), 6.06 (s, 1 H), 3.68-3.25 (m, 10H), 2.66 (s, 4H) ppm. Example 65 5-(5-Bromo-4-f2-(3-methoxy-phenyl)-ethylamino1-pyrimidin-2-ylamino)-1 ,3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-f2-(3-methoxy-phenyl)-ethvn-amine (CiaHiaBrCINaO)
Figure imgf000088_0001
The title intermediate compound was isolated as a colorless oil in an 84% yield. GC/MS: ret. time = 5.39 min, m/z = 341/343/345. 1H NMR (d6-DMSO) δ: 8.19 (s, 1H), 7.72 (t, 1 H), 7.16 (t, 1 H), 6.76-6.72 (m, 3H), 3.70 (s, 3H), 3.55 (q, 2H), 2.79 (t, 2H) ppm. B. 5-(5-Bromo-4-f2-(3-methoxy-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1,3- dihydro-indol-2-one (diHTnBrNgO?)
Figure imgf000088_0002
The title compound was isolated as a light pink solid in a 67% yield. MS: 454.1/456.1 (MH+). 1H NMR (de-DMSO) δ: 10.17 (s, 1H), 9.01 (s, 1 H), 7.93 (s, 1H), 7.54 (s, 1 H), 7.41 (1H), 7.17 (t, 1H), 6.95 (t, 1H), 6.76-6.72 (m, 3H), 6.64 (d, 1 H), 3.68 (s, 3H), 3.56 (q, 2H), 3.31 (s, 2H), 2.80 (t, 2H) ppm.
4/056786
-88-
Example 66 5-Bromo-N4-f2-(3-methoxy-phenyl)-ethvn-N2-f3-(1.2.3,6-tetrahydro-pyridin-4-yl)-1H- indol-5-vn-pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-f2-(3-methoxy-phenyl)-ethvn-amine ( ^BrCINgO)
Figure imgf000089_0001
The title intermediate compound was isolated as a colorless oil in an 84% yield. GC/MS: ret. time = 5.39 min, m/z = 341/343/345. 1H NMR (d6-DMSO) δ: 8.19 (s, 1H), 7.72 (t, 1H), 7.16 (t, 1H), 6.76-6.72 (m, 3H), 3.70 (s, 3H), 3.55 (q, 2H), 2.79 (t, 2H) ppm. B. 5-Bromo-N4-[2-(3-methoxy-phenyl)-ethvn-N2-f3-(1 ,2,3.6-tetrahvdro-pyridin-4- yl)-1 H-indol-5-vN-pyrimidine-2,4-diamine (dgHgjBrNgO)
Figure imgf000089_0002
The title compound was isolated as a tan solid in the TFA salt form in a 16% yield. MS: 519.2/521.1 (MH+). 1H NMR (d6-DMSO) δ: 11.45 (s, 1H), 8.82 (s, 2H), 8.08 (s, 1H), 8.00 (s, 1 H), 7.56 (s, 1H), 7.38 (s, 2H), 7.10 (t, 1H), 6.77-6.63 (m, 3H), 6.10 (s, 1H), 3.72-3.28 (m, 10H), 2.82-2.80 (m, 2H), 2.70 (s, 2H) ppm.
Example 67 5-[5-Bromo-4-(2-o-tolyl-ethylamino)-pyrimidin-2-ylaminol-1,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-o-tolyl-ethyl)-amine (d HisBrCINQ
Figure imgf000089_0003
The title intermediate was isolated as a white solid in a 79% yield. MS: 324.2/326.0/328.1 (MH-). 1H NMR (d6-DMSO) δ: 8.25 (s, 1H), 7.91 (t, 1 H), 7.18-7.10 (m, 4H), 3.56-3.51 (m, 2H), 2.88-2.82 (m, 2H), 2.37 (s, H) ppm.
B. 5-f5-Bromo-4-(2-o-tolyl-ethylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-
Figure imgf000090_0001
The title compound was isolated as a grey solid in a 28% yield. MS: 438.1/440.0 (MH+). 1H NMR (de-DMSO) δ: 10.20 (s, 1H), 9.03 (s, 1H), 7.97 (s, 1H), 7.56 (s, 1H), 7.46 (dd, 1 H), 7.13-7.04 (m, 5H), 6.67 (d, 1 H), 3.59-3.54 (m, 2H), 3.33 (s, 2H), 2.84 (t, 2H), 2.26 (s, 3H). Example 68
5-Bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1H-indol-5-yll-N4-(2-o-tolyl-ethyl)- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-o-tolyl-ethyl)-amine (C- H-nBrCINg)
Figure imgf000090_0002
The title intermediate was isolated as a white solid in a 79% yield. MS:
324.2/326.0/328.1 (MH-). 1H NMR (d6-DMSO) δ: 8.25 (s, 1 H), 7.91 (t, 1H), 7.18-7.10 (m, 4H), 3.56-3.51 ( , 2H), 2.88-2.82 (m, 2H), 2.37 (s, 1 H) ppm. B. 5-Bromo-N2-f3-(1.2.3,6-tetrahvdro-pyridin-4-ylV1H-indol-5-vn-N -(2-o-tolyl- ethyl)-pyrimidine-2.4-diamine (CggH^BrNg).
Figure imgf000091_0001
The title compound was isolated in the TFA salt form as a light yellow solid in a 21 % yield. HPLC ret. time = 5.53 min. MS: 502.9/505.1 (MH+). 1H NMR (d6-DMSO) δ: 11.36 (s, 1H), 8.82 (s, 2H), 8.10 (s, 1H), 7.98 (s, 1H), 7.57 (d, 1H), 7.40-7.32 (m, 2H), 7.08 (m, 2H), 6.95 (m, 2H), 6.09 (s, 1H), 3.70-3.27 (m, 7H), 2.79-2.70 (m, 4H), 2.16 (s, 3H) ppm.
Example 69 5-r5-Bromo-4-(2-m-tolyl-ethylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-m-tolyl-ethyl)-amine (C-^H BrClNg).
Figure imgf000091_0002
The title intermediate was isolated as a white solid in a 77% yield. MS: 326.1/328.1/330.1 (MH+). 1H NMR (d6-DMSO) δ: 8.25 (s, 1H), 7.79 (t, 1H), 7.19 (t, 1 H), 7.05- 7.00 (m, 3H), 3.61-3.54 (m, 2H), 2.82 (t, 2H), 2.29 (s, 3H) ppm.
B. 5-[5-Bromo-4-(2-m-tolyl-ethylamino)-pyrimidin-2-ylamino1-1.3-dihvdro-indol-2- one (diHgnBrNsO).
Figure imgf000091_0003
The title compound was isolated as a light pink solid in a 41% yield. MS: 438.1/440.0 (MH+). 1H NMR (de-DMSO) δ: 10.24 (s, 1H), 9.06 (s, 1H), 7.97 (s, 1H), 7.56 (s, 1H), 7.50 (d, 1 H), 7.20-7.15 (m, 1 H), 7.04-6.98 (m, 3H), 6.68 (d, 1 H), 3.58 (q, 2H), 3.33 (s, 2H), 2.82 (t, 2H), 2.27 (s, 3H) ppm.
Example 70 5-Bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N -(2-m-tolyl-ethyl)- pyrimidine-2,4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-m-tolyl-ethyl)-amine (C:!3H;ι3BrCIN3).
Figure imgf000092_0001
The title intermediate was isolated as a white solid in a 77% yield. MS: 326.1/328.1/330.1 (MH+). 1H NMR (d6-DMSO) δ: 8.25 (s, 1 H), 7.79 (t, 1H), 7.19 (t, 1H), 7.05- 7.00 (m, 3H), 3.61-3.54 (m, 2H), 2.82 (t, 2H), 2.29 (s, 3H) ppm.
B. 5-Bromo-N2-f3-(1.2.3.6-tetrahvdro-ρyridin-4-yl)-1 H-indol-5-vn-N4-(2-m-tolyl- ethyl)-pyrimidine-2.4-diamine (C2gH?7BrN ).
Figure imgf000092_0002
The title compound was isolated as a light yellow solid in a 21 % yield. HPLC ret. time = 5.61 min. MS: 503.2/505.2 (MH+). 1H NMR (d6-DMSO) δ: 11.36 (s, 1H), 8.83 (s, 2H), 8.10 (s, 1 H), 7.99 (s, 1 H), 7.56 (s, 1 H), 7.39 (s, 2H), 7.10-6.83 (m, 4H), 6.09 (s, 1 H), 3.72 (s, 2H), 3.53 (s, 2H), 3.27 (s, 3H), 2.79-2.69 (m, 4H), 2.19 (s, 3H) ppm. Example 71
5-[5-Bromo-4-(2-p-tolyl-ethylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one
A.
Figure imgf000093_0001
The title intermediate was isolated as a white solid in a 73% yield. MS:
326.1/328.0/330.0 (MH+). 1H NMR (d6-DMSO) δ: 8.23 (s, 1 H), 7.76 (t, 1 H), 7.10 (s, 4H), 3.56 (q, 2H), 2.82 (t, 2H), 2.27 (s, 3H) ppm.
B. 5-r5-Bromo-4-(2-p-tolyl-ethylamino)-pyrimidin-2-ylaminol-1.3-dihvdro-indol-2- one (diHgnBrNsO).
Figure imgf000093_0002
The title compound was isolated as a brown solid in a 14% yield. MS: 438.1/440.0/ (MH+). 1H NMR (de-DMSO) δ: 10.22 (s, 1 H), 9.05 (s, 1 H), 7.97 (s, 1 H), 7.55 (s, 1 H), 7.48 (dd, 1 H), 7.09 (s, 1 H), 6.99 (t, 1 H), 6.69 (d, 1 H), 4.03 (q, 2H), 3.33 (s, 2H), 2.81 (t, 2H), 2.23 (s, 3H) ppm.
Example 72 5-Bromo-N2-r3-(1 ,2,3,6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-(2-p-tolyl-ethvn- pyrimidine-2.4-diamine
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-p-tolyl-ethyl)-amine (Ci3Hi3BrCIN3).
Figure imgf000094_0001
The title intermediate was isolated as a white solid in a 73% yield. MS: 326.1/328.0/330.0 (MH+). 1H NMR (d6-DMSO) δ: 8.23 (s, 1 H), 7.76 (t, 1H), 7.10 (s, 4H), 3.56 (q, 2H), 2.82 (t, 2H), 2.27 (s, 3H) ppm.
B. 5-Bromo-N2-r3-(1.2.3.6-tetrahvdro-pyridin-4-yl)-1 H-indol-5-yll-N4-(2-p-tolyl- ethyl)-pyrimidine-2,4-diamine (C2gH27BrNfi). Br
Figure imgf000094_0002
The title compound was isolated as a yellow solid in the TFA salt form in a 13% yield. MS: 503.1/504.1 (MH+). 1H NMR (d6-DMSO) δ: 11.34 (s, 1 H), 8.77 (s, 2H), 8.05 (s, 1H), 7.95 (s, 1H), 7.54 (s, 1 H), 7.35 (s, 2H), 6.94-6.87 (m, 4H), 6.06 (s, 1 H), 3.68 (s, 4H), 3.46 (m, 2H), 3.24 (s, 2H), 2.66 (s, 3H), 2.21 (s, 3H) ppm.
Example 73 r5-Bromo-2-(2-oxo-2,3-dihvdro-1 H-indol-5-ylamino)-pyrimidin-4-ylaminol-acetic acid A. [5-Bromo-2-(2-oxo-2.3-dihvdro-1 H-indol-5-ylamino)-pyrimidin-4-ylaminol- acetic acid tert-butyl ester (CiaHTnBrNgOs).
Figure imgf000095_0001
The title intermediate was isolated as a light yellow solid in a 3.5% yield. MS: 434.1/436.1 (MH+). 1H NMR (d6-DMSO) δ: 10.18 (s, 1 H), 9.05 (s, 1 H), 7.98 (s, 1 H), 7.43-7.42 (m, 2H), 7.18 (t, 1 H), 6.65 (d, 1 H), 3.95 (d, 2H), 3.39 (s, 2H), 1.29 (s, 9H) ppm.
B. f5-Bromo-2-(2-oxo-2,3-dihvdro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino1-
Figure imgf000095_0002
The title compound was isolated as a brown solid. No yield determined. MS: 377.9/380.2 (MH+). 1H NMR (d6-DMSO) δ: 10.21 (s, 1 H), 9.10 (s, 1 H), 8.02 (s, 1 H), 7.59 (s, 1 H), 7.38 (dd, 1 H), 7.19 (t, 1 H), 6.69 (d, 1 H), 3.99 (d, 2H), 3.42 (s, 2H) ppm.
Example 74 5-(5-Bromo-4-[2-(3-trifluoromethyl-phenvh-ethylamino1-pyrimidin-2-ylamino)-1.3- dihydro-indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-r2-(3-trifluoromethyl-phenyl)-ethyll-amine (CigHinBrCIFjN .
Figure imgf000096_0001
The title intermediate was isolated as a white solid in an 84% yield. GC/MS: ret time = 4.65 min, m/z = 379/381/383. 1H NMR (d6-DMSO) δ: 8.25 (s, 1 H), 7.80 (t, 1 H), 7.65-7.52 (m, 4H), 3.65 (q, 2H), 2.98 (t, 2H) ppm. B. 5-(5-Bromo-4-f2-(3-trifluoromethyl-phenyl)-ethylaminol-pyήmidin-2-ylamino!-
Figure imgf000096_0002
The title compound was isolated as a pink solid in a 37% yield. MS: 492.2/493.5 (MS+). 1H NMR (de-DMSO) δ: 10.18 (s, 1 H), 9.00 (s, 1 H), 7.93 (s, 1 H), 7.54-7.47 (m, 5H), 7.39 (dd, 1 H), 6.96 (t, 1 H), 6.63 (d, 1 H), 3.60 (q, 2H), 3.35 (s, 2H), 2.95 (t, 2H) ppm.
Example 75 5-[4-(2-Biphenyl-4-yl-ethylamino)-5-bromo-pyrimidin-2-ylaminol-1.3-dihvdro-indol-2- one
A. (2-Biphenyl-4-yl-ethyl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
(d«HιgBrCIN2).
Figure imgf000097_0001
The title intermediate was isolated as a white solid in a 74% yield. GC/MS: ret. time = 6.94; m/z = 387/389/391. 1H NMR (d6-DMSO) δ: 8.24 (s, 1 H), 7.83 (t, 1 H), 7.65-7.58 (m, 4H), 7.45 (t, 2H), 7.33 (m, 3H), 3.62 (q, 2H), 2.90 (t, 2H) ppm. B. 5-f4-(2-Biphenyl-4-yl-ethylamino)-5-bromo-pyrimidin-2-ylaminol-1.3-dihvdro- indol-2-one (dgH^BrNgO)
Figure imgf000097_0002
The title compound was isolated as a gray solid in an 11 % yield. MS: 500.1/502.3 (MH+). 1H NMR (de-DMSO) δ: 10.25 (s, 1 H), 9.07 (s, 1 H), 7.99 (s, 1 H), 7.68-7.29 (m, 11 H), 7.07 (t, 1 H), 6.72 (d, 1 H), 3.64 (q, 2H), 3.39 (s, 2H), 2.91 (t, 2H) ppm. Example 76 5-(5-Bromo-4-[2-(3-fluoro-phenyl)-ethylamino1-pyrimidin-2-ylamino}-1 ,3-dihvdro-indol-
Figure imgf000098_0001
The title compound was isolated as a pink solid in a 52% yield. MS: 442.2/444.1 (MH+). 1H NMR (d6-DMSO) δ: 10.22 (s, 1 H), 9.05 (s, 1 H), 7.98 (s, 1 H), 7.57 (s, 1 H), 7.45 (dd, 1 H), 7.38-7.30 (m, 1 H), 7.08-7.00 (m, 4H), 6.69 (d, 1 H), 3.62 (q, 2H), 3.37 (s, 2H), 2.91 (t, 2H) ppm.
Example 77
5- 5-Bromo-4-r2-(2-chloro-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1 ,3-dihvdro-indol- 2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-f2-(2-chloro-phenyl)-ethyll-amine
(CijHinBrClgNa).
Figure imgf000098_0002
The title intermediate was isolated as a white solid in an 87% yield. GC/MS: ret. Time
= 5.22 min; m/z: 345/347/349. 1H NMR (d6-DMSO) δ: 8.19 (s, 1 H), 7.80 (t, 1 H), 7.39-7.35 (m, 1 H), 7.27-7.18 (m, 3H), 3.59 (q, 2H), 2.96 (t, 2H) ppm. B. 5-(5-Bromo-4-r2-(2-chloro-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1 ,3- dihvdro-indol^-one fdnHiTBrCINgO).
Figure imgf000099_0001
The title compound was isolated as pink solid in a 47% yield. MS: 458.1/460.0/462.1 (MH+). H NMR (d6-DMSO) δ: 10.17 (s, 1 H), 8.99 (s, 1 H), 7.93 (s, 1 H), 7.51 (s, 1 H), 7.43- 7.40 (m, 2H), 7.40-7.20 (m, 3H), 7.01 (t, 1 H), 6.63 (d, 1 H), 3.60 (q, 2H), 3.30 (s, 2H), 2.97 (t, 2H) ppm.
Example 78 5-(5-Bromo-4-[2-(2-methoxy-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1.3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-r2-(2-methoxy-phenyl)-ethyll-amine
(d^BrCINgO).
Figure imgf000099_0002
The title intermediate was isolated as a white solid in a 77% yield. GC/MS: ret. Time = 5.26 min; m/z: 341/343/345. 1H NMR (d6-DMSO) δ: 8.17 (s, 1 H), 7.63 (t, 1 H), 7.17-7.13 (m, 1 H), 7.07 (dd, 1 H), 6.93-6.90 (m, 1 H), 6,83-6.79 (m, 1 H), 3.75 (s, 3H), 3.53 (q, 2H), 2.81 (t, 2H) ppm. B. 5-(5-Bromo-4-f2-(2-methoxy-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1.3- dihvdro-indol-2-one (C iHynBrNgO?).
Figure imgf000100_0001
The title compound was isolated as a light pink solid in a 44% yield. MS: 454.1/456.0 (MH+). 1H NMR (de-DMSO) δ: 10.16 (s, 1 H), 8.99 (s, 1 H), 7.92 (s, 1 H), 7.53 (s, 1 H), 7.43 (dd, 1 H), 7.20-7.15 (m, 1 H), 7.09-7.07 (m, 1 H), 6.94-6.92 (m, 1 H), 6.87-6.81 (m, 2H), 6.62 (d, 1 H), 3.73 (s, 3H), 3.54 (q, 2H), 2.83 (t, 2H) ppm.
Example 79 5-{5-Bromo-4-[2-(4-fluoro-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1.3-dihvdro-indol- 2-one (dnH^BrFNgO).
Figure imgf000100_0002
The title compound was isolated as a pink solid in a 44% yield. MS: 442.1/444.0 (MH+). 1H NMR (de-DMSO) δ: 10.22 (s, 1 H), 9.04 (s, 1 H), 7.98 (s, 1 H), 7.55 (s, 1 H), 7.49- 7.46 (m, 1 H), 7.26-7.21 (m, 2H), 7.14-7.08 (m, 2H), 7.00 (t, 1 H), 6.69 (d, 1 H), 3.59 (q, 2H), 3.37 (s, 2H), 2.86 (t, 2H) ppm.
Example 80 5- 5-Bromo-4-[2-(4-chloro-phenyl)-ethylaminol-pyrimidin-2-ylamino}-1 ,3-dihvdro-indol- 2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-[2-(4-chloro-phenyl)-ethvn-amine (C^HjnBrCI^N,).
Figure imgf000100_0003
The title intermediate was isolated as a white solid in an 86% yield. GC/MS: ret. time = 5.36 min; m/z: 345/347/349. 1H NMR (d6-DMSO) δ: 8.25 (s, 1 H), 7.80-7.76 (t, 1 H), 7.38- 7.33 (m, 2H), 7.26-7.23 (m, 2H), 3.59 (q, 2H), 2.87 (t, 2H) ppm.
A. 5-(5-Bromo-4-[2-(4-chloro-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1 ,3- dihvdro-indol-2-one (C2nHi7BrCINgO).
Figure imgf000101_0001
The title compound was isolated as a pink solid in a 39% yield. MS: 458.1/460.0/462.1 (MH+). 1H NMR (d6-DMSO) δ: 10.19 (s, 1 H), 9.00 (s, 1 H), 7.93 (s, 1 H), 7.50 (s, 1 H), 7.46 (dd, 1 H), 7.31-7.29 (m, 2H), 7.19-7.17 (m, 2H), 6.96 (t, 1 H), 6.65 (d, 1 H), 3.54 (q, 2H), 3.34 (s, 2H), 2.82 (t, 2H) ppm.
Example 81 5-(5-Bromo-4-r2-(2-fluoro-phenyl)-ethylaminol-pyrimidin-2-ylamino)-1 ,3-dihvdro-indol- 2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-[2-(2-fluoro-phenyl)-ethyll-amine (C pH-inBrCIFN;).
Figure imgf000101_0002
The title intermediate was isolated as a white solid in an 84% yield. GC/MS: ret. time
= 4.67 m niinn;; mm//zz:: 332299//333311//333333.. 11HH NNMMRR ((dd66--DDMMSSOO)) δδ:: 8.23 (s, 1 H), 7.83 (t, 1 H), 7.30-7.23 (m, 2H), 7.18-7.10 (m, 2H), 3.62 (q, 2H), 2.92 (t, 2H) ppm. B. 5-(5-Bromo-4-[2-(2-fluoro-phenyl)-ethylamino1-pyrimidin-2-ylamino>-1 ,3- dihvdro-indol-2-one (C?nHi7BrFNgO).
Figure imgf000102_0001
The title compound was isolated as a pink solid in a 19% yield. MS: 442.0/444.0 (MH+). 1H NMR (de-DMSO) δ: 10.17 (s, 1 H), 9.00 (s, 1 H), 7.93 (s, 1 H), 7.52 (s, 1 H), 7.42 (dd, 1 H), 7.25-7.20 (m, 2H), 7.13-7.06 (m, 2H), 7.01 (t, 1 H), 6.64 (d, 1H), 3.58 (q, 2H), 3.32 (s, 2H), 2.88 (t, 2H) ppm.
Example 82 5-[5-Bromo-4-(3-phenyl-allylamino)-pyrimidin-2-ylaminol-1.3-dihvdro-indol-2-one A. (3-Phenyl-allyl)-carbamic acid di-tert-butyl ester (CigH NOA
Figure imgf000102_0002
The title intermediate was isolated as a light yellow oil in a 77% yield. GC/MS: ret. time = 4.28 min; m/z: 277 (MH-t-Bu), 234 (MH-BOC), 221 (MH-(t-Bu)2), 177 (MH-BOC-t-Bu), 132 (MH-BOC2), 116 (bp). 1H NMR (d6-DMSO) δ: 7.44-7.41 (m, 2H), 7.36-7.31 (m, 2H), 7.28- 7.23 (m, 1 H), 6.50 (d, 1 H), 6.25 (dt, 1 H), 4.26 (d, 2H), 1.46 (s, 18H). B. 3-Phenyl-allylamine (C9HnN).
Figure imgf000102_0003
The title intermediate in the crude form as a TFA salt was produced. GC/MS: ret. time = 1.54 min; m/z: 133. 1H NMR (d6-DMSO) δ: 7.98 (bs, 2H), 7.42-7.25 (m, 5H), 6.70 (d, 1 H), 6.23 (dt, 1 H), 3.62-3.57 (m, 2H) ppm. C. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-phenyl-allyl)-amine (OnH-nBrCINQ.
Figure imgf000103_0001
The title intermediate was isolated as a white solid in a 57% yield. GC/MS: ret. time = 5.43 min; m/z: 323/325/327. 1H NMR (d6-DMSO) δ: 8.29 (s, 1 H), 8.05 (t, 1 H), 7.45-7.22 (m, 5H), 6.55-6.50 (m, 1 H), 6.34 (dt, 1 H), 4.19-4.15 (m, 2H) ppm.
D. 5-r5-Bromo-4-(3-phenyl-allylamino)-pyrimidin-2-ylaminol-1.3-dihvdro-indol-2- one (CT H-igBrNgO).
Figure imgf000103_0002
The title compound was isolated as a pink solid in a 42% yield. MS: 436.1/438.0 (MH+). 1H NMR (d6-DMSO) δ: 10.20 (s, 1 H), 9.07 (s, 1 H), 8.01 (s, 1 H), 7.61 (s, 1 H), 7.48- 7.20 (m, 7H), 6.69 (d, 1 H), 6.54-6.36 (m, 2H), 4.18 (t, 2H), 3.39 (s, 2H) ppm.
Example 83 5- 5-Bromo-4-[(thiophen-2-ylmethyl)-aminol-pyrimidin-2-ylamino)-1.3-dihvdro-indol-2- one A.
Figure imgf000103_0003
The title intermediate was isolated as a white solid in an 88% yield. GC/MS: ret. time = 4.49 min; m/z: 303/305/307. 1H NMR (d6-DMSO) δ: 8.36 (t, 1 H), 8.26 (s, 1 H), 7.35 (dd, 1 H), 7.00-6.99 (m, 1 H), 6.93 (dd, 1 H), 4.67 (d, 2H) ppm. B. 5- 5-Bromo-4-f(thiophen-2-ylmethyl)-amino1-pyrimidin-2-ylamino)-1 ,3-dihydro- indol-2-one (drH- BrNgOS).
Figure imgf000104_0001
The title compound was isolated as a pink solid in a 29% yield. MS: 416.1/418.1 (MH+). 1H NMR (d6-DMSO) δ: 10.15 (S, 1 H), 9.05 (s, 1 H), 7.97 (s, 1 H), 7.57 (t, 1H), 7.51 (s, 1 H), 7.39-7.30 (m, 2H), 6.97-6.90 (m, 2H), 6.62 (d, 1 H), 4.71 (d, 2H), 3.35 (s, 2H) ppm.
Example 84 6-{5-Bromo-4-r(thiophen-2-ylmethyl)-amino1-pyrimidin-2-ylamino}-1 ,3-dihvdro-indol-2- one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-thiophen-2-ylmethyl-amine (CqH7BrCIN3S).
Figure imgf000104_0002
The title intermediate was isolated as a white solid in an 88% yield. GC/MS: ret. time = 4.49 min; m/z: 303/305/307. 1H NMR (d6-DMSO) δ: 8.36 (t, 1 H), 8.26 (s, 1 H), 7.35 (dd, 1H), 7.00-6.99 (m, 1H), 6.93 (dd, 1H), 4.67 (d, 2H) ppm.
A. 6-f5-Bromo-4-f(thiophen-2-ylmethyl)-amino1-pyrimidin-2-ylamino)-1 ,3-dihvdro- indol-2-one (Cr/H BrNgOS).
Figure imgf000104_0003
The title compound was isolated as a purple solid in a 27% yield. MS: 416.1/418.1 (MH+). 1H NMR (de-DMSO) δ: 10.32 (s, 1 H), 9.22 (s, 1 H), 8.00 (s, 1 H), 7.59 (t, 1 H), 7.36 (d, 1H), 7.29 (dd, 1 H), 7.19 (dd, 1 H), 7.00-6.97 (m, 2H), 6.91-6.88 (m, 1H), 4.74 (d, 2H), 3.34 (s,
2H) ppm.
Example 85
5-r5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2- one
A. (5-Bromo-2-chloro-pyrimidin-4-γl)-(2.3-dimethyl-benzyl)-amine
(CijjHiaBrCI j).
Figure imgf000105_0001
The title intermediate was isolated as a white solid in a 72% yield. GC/MS: ret. time = 5.16 min; m/z: 325/327/329. 1H NMR (d6-DMSO) δ: 8.25 (s, 1H), 8.13 (t, 1H), 7.03-6.95 (m, 3H), 4.52 (d, 2H), 2.21 (s, 3H), 2.18 (s, 3H) ppm.
B. 5-r5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylamino1-1 ,3-dihydro- indol-2-one (CTiHTnBrNgQ).
Figure imgf000105_0002
The title compound was isolated as a light pink solid in a 7.7% yield. MS:
438.1/440.1 (MH+). 1H NMR (d6-DMSO) δ: 10.12 (s, 1 H), 8.97 (s, 1 H), 7.98 (s, 1 H), 7.32 (s, 2H), 7.16 (d, 1 H), 7.02-6.91 (m, 3H), 6.47 (d, 1H), 4.54 (d, 2H), 3.21 (s, 2H), 2.26 (s, 3H), 2.16 (s, 3H) ppm. Example 86 6-[5-Bromo-4-(2.3-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihydro-indol-2- one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2,3-dimethyl-benzyl)-amine
(CisHiaBrONal
Figure imgf000106_0001
The title intermediate was isolated as a white solid in a 72% yield. GC/MS: ret. time = 5.16 min; m/z: 325/327/329. 1H NMR (d6-DMSO) δ: 8.25 (s, 1 H), 8.13 (t, 1H), 7.03-6.95 (m, 3H), 4.52 (d, 2H), 2.21 (s, 3H), 2.18 (s, 3H) ppm. B. 6-f5-Bromo-4-(2.3-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1.3-dihydro- indol-2-one (C^HgnBr gO).
Figure imgf000106_0002
The title compound was isolated as a purple solid in a 21 % yield. MS: 438.0/440.2 (MH+). H NMR (de-DMSO) δ: 10.24 (s, 1 H), 9.12 (s, 1 H), 8.01 (s, 1 H), 7.26 (t, 1 H), 7.18 (s, 1 H), 7.07 (dd, 1 H), 7.02-6.96 (m, 3H), 6.84 (d, 1 H), 4.58 (d, 2H), 3.30 (s, 2H), 2.23 (s, 3H), 2.17 (s, 3H) ppm.
Example 87 5-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1.3-dihydro-indol-2- one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2,5-dimethyl-benzyl)-amine (CiaHiaBrCINa).
Figure imgf000107_0001
The title intermediate was isolated as a white solid in an 84% yield. GC/MS: ret. time = 4.99 min; m/z: 325/327/329. 1H NMR (d6-DMSO) δ: 8.24 (s, 1H), 8.16 (t, 1H), 7.02-6.91 (m, 3H), 4.47 (d, 2H), 2.26 (s, 3H), 2.18 (s, 3H) ppm. B. 5-f5-Bromo-4-(2.5-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1.3-dihydro-
Figure imgf000107_0002
The title compound was isolated as a off white solid in a 9 % yield. MS: 438.1/440.1 (MH+). HPLC: ret. time = 6.48 min. 1H NMR (d6-DMSO) δ: 10.12 (s, 1H), 8.99 (s, 1H), 7.98 (s, 1 H), 7.35-7.32 (m, 2H), 7.23-7.21 (m, 1 H), 7.04-7.02 (m, 1 H), 6.91-6.87 (m, 2H), 6.52 (d, 1H), 4.50 (d, 2H), 3.25 (s, 2H), 2.22 (s, 3H), 2.14 (s, 3H) ppm.
Example 88 6-f5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylamino1-1.3-dihvdro-indol-2- one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2.5-dimethyl-benzyl)-amine (CigHjgBrCINg).
Figure imgf000108_0001
The title intermediate was isolated as a white solid in an 84% yield. GC/MS: ret. time = 4.99 min; m/z: 325/327/329. 1H NMR (d6-DMSO) δ: 8.24 (s, 1 H), 8.16 (t, 1 H), 7.02-6.91 (m, 3H), 4.47 (d, 2H), 2.26 (s, 3H), 2.18 (s, 3H) ppm.
B. 6-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylaminol-1.3-dihvdro-
Figure imgf000108_0002
The title compound was isolated as a purple solid in a 4 % yield. MS: 438.1/440.1 (MH+). HPLC: ret. time = 6.86 min. H NMR (d6-DMSO) δ: 10.26 (s, 1H), 9.13 (s, 1H), 8.01 (s, 1 H), 7.28 (t, 1 H), 7.20-7.18 (m, 1 H), 7.12-7.09 (m, 1 H), 7.03-7.01 (m, 1 H), 6.95-6.86 (m, 3H), 4.54 (d, 2H), 3.31 (s, 2H), 2.23 (s, 3H), 2.14 (s, 3H) ppm.
Example 89 6-r5-Bromo-4-(2-fluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihydro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-fluoro-benzyl)-amine (C-πHaBrCIFNj).
Figure imgf000108_0003
The title intermediate was isolated as a white solid in a 68% yield. GC/MS: ret. time = 4.75 min; m/z: 315/317/319. 1H NMR (d6-DMSO) δ: 8.28-8.25 (m, 2H), 7.31-7.22 (m, 2H), 7.18-7.10 (m, 2H), 4.58 (d, 2H) ppm.
B. 6-[5-Bromo-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino1-1 ,3-dihvdro-indol-2- one (CiflHigBrFNgO).
Figure imgf000109_0001
The title compound was isolated as a purple solid in a 6.5% yield. MS: 428.1/430.1 (MH+). 1H NMR (de-DMSO) δ: 10.26 (s, 1 H), 9.15 (s, 1 H), 8.03 (s, 1 H), 7.48 (t, 1 H), 7.26-7.09 (m, 6H), 6.87 (d, 1 H), 4.65 (d, 2H), 3.31 (s, 2H) ppm. Example 90
6-r5-Bromo-4-(2-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino1-1.3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-trifluoromethoxy-benzyl)-amine
(C^HgBrCIFgNgO).
Figure imgf000109_0002
The title intermediate was isolated as a white solid in a 66% yield. GC/MS: ret. time =
4.55 min; m/z: 381/383/385. 1H NMR (d6-DMSO) δ: 8.28 (m, 2H), 7.40-7.30 (m, 4H), 4.63- 4.62 (d, 2H) ppm.
B. 6-f5-Bromo-4-(2-trifluoromethoxy-benzylamino)-pyrimidin-2-ylaminol-1 ,3- dihydro-indol^-one fdnHjgBrFgNgO?).
Figure imgf000109_0003
The title compound was isolated as a dark purple solid in a 2% yield. MS: 494.1/496.0 (MH+). 1H NMR (CD3OD) δ: 8.00 (s, 1 H), 7.41-7.31 (m, 4H), 7.15-7.09 (m, 2H), 7.02-6.99 (m, 1 H), 4.81 (s, 2H), 3.46 (s, 2H) ppm.
Example 91
5-f5-Bromo-4-(3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylaminol-1.3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-trifluoromethoxy-benzyl)-amine
{CjzHβBrCIFaNaOl
Figure imgf000110_0001
The title intermediate was isolated as a colorless oil in a 68% yield. GC/MS: ret. time
= 4.75 min; m/z: 381/383/385. 1H NMR (d6-DMSO) δ: 8.35 (t, 1H), 8.26 (s, 1 H), 7.45-7.41 (m, 1H), 7.31-7.20 (m, 3H), 4.56 (d, 2H) ppm.
B. 5-[5-Bromo-4-(3-trifluoromethoxy-benzylamino)-py midin-2-ylamino'|-1 ,3- dihvdro-indol^-one fCynHigBrFgNgO?).
Figure imgf000110_0002
The title compound was isolated as a pink solid in a 38% yield. MS: 494.1/496.1 (MH+). 1H NMR (de-DMSO) δ: 10.16 (s, 1H), 9.02 (s, 1H), 7.98 (s, 1H), 7.61 (t, 1H), 7.44-7.39 (m, 2H), 7.32-7.17 (m, 4H), 6.57 (d, 2H), 4.59 (d, 2H), 3.29 (s, 2H) ppm. Example 92 6-f5-Bromo-4-(3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylaminol-1.3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-trifluoromethoxy-benzyl)-amine (C^HsBrCIFgN.O).
Figure imgf000111_0001
The title intermediate was isolated as a colorless oil in a 68% yield. GC/MS: ret. time = 4.75 min; m/z: 381/383/385. H NMR (d6-DMSO) δ: 8.35 (t, 1 H), 8.26 (s, 1 H), 7.45-7.41 (m, 1 H), 7.31-7.20 (m, 3H), 4.56 (d, 2H) ppm. B. 6-f5-Bromo-4-(3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino1-1 ,3- dihydro-indol-2-one (CgnHigBrFgNgO?).
Figure imgf000111_0002
The title compound was isolated as a purple solid in a 4% yield. MS: 494.2/496.2 (MH+). 1H NMR (de-DMSO) δ: 10.32 (s, 1 H), 9.17 (s, 1 H), 8.01 (s, 1H), 7.65 (t, 1H), 7.42-7.28 (m, 4H), 7.17-7.15 (m, 1 H), 7.07 (dd, 1 H), 6.92 (d, 1 H), 4.62 (d, 2H), 3.31 (s, 2H) ppm.
Example 93 5-f5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(4-trifluoromethoxy-benzyl)-amine (C„H,BrCIF3N3OV
Figure imgf000111_0003
The title intermediate was isolated as a colorless oil in a 76% yield. GC/MS: ret. time = 4.88 min; m/z: 381/383/385. 1H NMR (d6-DMSO) δ: 8.34 (t, 1 H), 8,25 (s, 1H), 7.41-7.37 (m, 2H), 7.30-7.27 (m, 2H), 4.56 (d, 2H) ppm.
B. 5-f5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino1-1.3- dihvdro-indol-2-one (C?nHifiBrFgNgθ2).
Figure imgf000112_0001
The title compound was isolated as a light gray solid in a 23% yield. MS: 494.0/496.0 (MH+). 1H NMR (de-DMSO) δ: 10.14 (s, 1H), 9.01 (s, 1H), 7.98 (s, 1H), 7.59 (t, 1H), 7.40-7.21 (m, 6H), 6.57 (d, 1 H), 4.58 (d, 2H), 3.29 (s, 2H) ppm.
Example 94
6-[5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihvdro- indol-2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(4-trifluoromethoxy-benzyl)-amine
(C^HgBrCIFaNgO).
Figure imgf000112_0002
The title intermediate was isolated as a colorless oil in a 76% yield. GC/MS: ret. time = 4.88 min; m/z: 381/383/385. 1H NMR (d6-DMSO) δ: 8.34 (t, 1H), 8,25 (s, 1H), 7.41-7.37 (m, 2H), 7.30-7.27 (m, 2H), 4.56 (d, 2H) ppm. B. 6-[5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylaminol-1 ,3- dihydro-indol^-one fCTnHigBrFjNsQg)-
Figure imgf000113_0001
The title compound was isolated as a purple solid in a 25% yield. MS: 494.0/496.0 (MH+). 1H NMR (de-DMSO) δ: 10.31 (s, 1H), 9.16 (s, 1H), 8.01 (s, 1 H), 7.61 (t, 1 H), 7.42 (d, 2H), 7.28- 7.25 (m, 3H), 7.09 (dd, 1 H), 6.92 (d, 1 H), 4.61 (d, 2H), 3.32 (s, 2H) ppm.
Example 95 6-r5-Bromo-4-(2-methoxy-benzylamino)-pyrimidin-2-ylaminol-1.3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2-methoxy-benzyl)-amine
Figure imgf000113_0002
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 5.43 min; m/z: 327/329/331. 1H NMR (d6-DMSO) δ: 8.26 (s, 1 H), 8.05 (t, 1H), 7.23-7.19 (m, 1 H), 7.01-6.96 (m, 2H), 6.88-6.84 (m, 1 H), 4.52 (d, 2H), 3.80 (s, 3H) ppm. B. 6-f5-Bromo-4-(2-methoxy-benzylamino)-pyrimidin-2-ylamino1-1,3-dihvdro- indol-2-one (CynHigBrNgQ?).
Figure imgf000113_0003
The title compound was isolated as a gray solid in a 12% yield. MS: 440.1/442.1 (MH+). 1H NMR (d6-DMSO) δ: 10.31 (s, 1 H), 9.17 (s, 1 H), 8.00 (s, 1 H), 7.54 (t, 1 H), 7.29 (s, 1 H), 7.20-7.11 (m, 2H), 6.95-6.89 (m, 3H), 6.75-6.73 (m, 1 H), 4.56 (d, 2H), 3.63 (s, 3H), 3.32 (s, 2H) ppm.
Example 96 6-r5-Bromo-4-(3-methoxy-benzylamino)-pyrimidin-2-ylamino1-1 ,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-methoxy-benzyl)-amine
Figure imgf000114_0001
The title intermediate was isolated as a white solid in an 83% yield. GC/MS: ret. time = 5.56 min; m/z: 327/329/331. 1H NMR (d6-DMSO) δ: 8.28 (t, 1 H), 8.25 (s, 1 H), 7.21 (t, 1 H), 6.86-6.77 (m, 3H), 4.50 (d, 2H), 3.70 (s, 3H) ppm.
B. 6-[5-Bromo-4-(3-methoxy-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro- indol-2-one (dnHigBrNgO;).
Figure imgf000114_0002
The title compound was isolated as a pink solid in a 5% yield. MS: 440.0/442.0 (MH+). 1H NMR (d6-DMSO) δ: 10.23 (s, 1H), 9.11 (s, 1 H), 8.02 (s, 1H), 7.21-6.82 (m, 8H), 4.57 (d, 2H), 3.81 (s, 3H), 3.30 (s, 2H) ppm.
-114-
Example 97 6-f5-Bromo-4-(3-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino1-1 ,3-dihvdro-indol- 2-one
A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(3-trifluoromethyl-benzyl)-amine (C^HgBrCIF.N,).
Figure imgf000115_0001
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 4.77 min; m/z: 365/367/369. H NMR (d6-DMSO) δ: 8.38 (t, 1 H), 8.26 (s, 1H), 7.67 (s, 1 H), 7.59-7.51 (m, 3H), 4.60 (d, 2H) ppm. B. 6-r5-Bromo-4-(3-trifluoromethyl-benzylamino)-pyrimidin-2-ylaminoM ,3-dihvdro- indol-2-one (CpgHigBrFgNgO).
Figure imgf000115_0002
The title compound was isolated as a purple solid in a 10% yield. MS: 478.0/480.0 (MH+). 1H NMR (de-DMSO) δ: 10.33 (s, 1H), 9.18 (s, 1H), 8.01 (s, 1H), 7.71-7.67 (m, 2H), 7.62-6.60 (m, 1 H), 7.54-7.48 (m, 2H), 7.29 (d, 1 H), 7.05 (dd, 1 H), 6.91 (d, 1H), 4.66 (d, 2H), 3.31 (s, 2H) ppm. Example 98 5-(5-Bromo-4-f(thiazol-2-ylmethyl)-aminol-pyrimidin-2-ylamino)-1.3-dihydro-indol-2- one
A. Thiazole-2-carbaldehyde oxime ( H^PS).
Figure imgf000116_0001
The title intermediate was synthesized following the procedure by Dondoni (Dondoni, A., Fantin, G., Fogagnolo, M., Medici, A., Pedrini, P.; Synthesis 1987, 998-1001) and isolated as a light purple solid in a 50% yield. GC/MS: ret. time = 1.55 min and 1.70 min (cis and trans isomers); m/z: 128. B. C-Thiazol-2-yl-methylamine (dHgN?S).
Figure imgf000116_0002
The title intermediate was synthesized following the procedure by Dondoni (Dondoni, A., Merchan, F.L., Merino, P., Rojo, I., Tejero, T.; Synthesis, 1996, 641-646) and isolated as a crude sample in a 21 % yield. GC/MS: ret. time = 0.99 min; m/z: 114. 1H NMR (d6-DMSO) δ: 7.65 (d, 1 H), 7.52 (d, 1 H), 3.95 (s, 2H), 3.30 (s, 2H) ppm.
C. (5-Bromo-2-chloro-pyrimidin-4-yl)-thiazol-2-ylmethyl-amine (CsHgBrCIN S).
Figure imgf000116_0003
The title intermediate was isolated as a yellow solid in a 45% yield. GC/MS: ret. time = 4.91 min; m/z: 304/306/308. 1H NMR (d6-DMSO) δ: 8.55 (t, 1 H), 8.33 (s, 1 H), 7.71 (d, 1 H), 7.60 (d, 1 H), 4.81 (d, 2H) ppm. D. 5-(5-Bromo-4-f(thiazol-2-ylmethyl)-amino1-pyrimidin-2-ylamino)-1.3-dihvdro- indol-2-one (CigHigBrNgOS).
Figure imgf000117_0001
The title compound was isolated as a brown solid in a 43% yield. MS: 417.0/418.9 (MH+). . 1H NMR (d6-DMSO) δ: 10.15 (s, 1H), 9.10 (s, 1H), 8.02 (s, 1H), 7.82 (sb, 1H), 7.72 (d, 1H), 7.54 (d, 1 H), 7.40 (s, 1 H), 7.22 (d, 1 H), 6.56 (d, 1 H), 4.81 (d, 2H), 3.33 (s, 2H) ppm.
Example 99 5-f5-Bromo-4-r(5-methanesulfonyl-thiophen-2-ylmethyl)-amino1-pyhmidin-2-ylamino)- 1 ,3-dihydro-indol-2-one A 5-Methanesulfonyl-thiophene-2-carbaldehvde (CgHgQ3S7).
Figure imgf000117_0002
The title intermediate was prepared by adapting the procedure by Archer (Archer, W.J., Cook, R., Taylor, R.; J. Chem. Soc. Perkin Trans. //; 1983, 813-819) and isolated as a light yellow solid in a 26% yield. GC/MS: ret. time = 2.96 min; m/z: 190. 1H NMR (d6-DMSO) δ: 10.01 (s, 1H), 8.08 (d, 1H), 7.94 (d, 1H), 3.42 (s, 3H) ppm.
B. (5-Methanesulfonyl-thiophen-2-yl)-methanol (CgHgOgS?).
Figure imgf000117_0003
The title intermediate was prepared by adapting the procedure by Lee (Lee, Y. and Silverman, R.B.; Tetrahedron, 2001 , 53, 5339-5352) and isolated as a yellow oil in a 74% yield. GC/MS: ret. time = 3.55 min; m/z: 192. 1H NMR (d6-DMSO) δ: 7.61 (d, 1 H), 7.04 (d, 1 H), 5.83 (t, 1 H), 4.67 (d, 2H), 3.27 (s, 3H) ppm. C. 2-Chloromethyl-5-methanesulfonyl-thiophene (CnH^OgS
Figure imgf000118_0001
The title intermediate was isolated as a white solid in a 52% yield. GC/MS: ret. time = 3.31 min; m/z: 210/212. 1H NMR (d6-DMSO) δ: 7.65 (d, 1 H), 7.29 (d, 1H), 5.08 (s, 2H), 3.32 (s, 3H) ppm. a. C-(5-Methanesulfonyl-thiophen-2-yl)-methylamine (CgHgNQyS?)
Figure imgf000118_0002
The title intermediate was isolated as a white solid in the TFA salt form in a 75% yield. GC/MS: ret. time = 3.53 min; m/z: 191. 1H NMR (d6-DMSO) δ: 8.36 (s, 2H), 7.73 (d, 1H), 7.32 (d, 1 H), 4.32 (s, 2H), 3.32 (s, 3H) ppm.
E. (5-Bromo-2-chloro-pyrimidin-4-yl)-(5-methanesulfonyl-thiophen-2-ylmethyl)- amine (doHgBrCINgOgS?),
Figure imgf000118_0003
The title intermediate was isolated as a light yellow solid in a 74% yield. GC/MS: ret. time = 7.00 min; m/z: 381/383/385. 1H NMR (d6-DMSO) δ: 8.49 (t, 1H), 8.31 (s, 1H), 7.62 (d, 1H), 7.14 (d, 1 H), 4.72 (d, 2H), 3.27 (s, 3H) ppm. F. 5- 5-Bromo-4-r(5-methanesulfonyl-thiophen-2-ylmethyl)-amino1-pyrimidin-2-
Figure imgf000119_0001
The title compound was isolated as a pink solid in an 18% yield. MS: 494.0/495.9 (MH+). H NMR (dβ-DMSO) δ: 10.18 (s, 1 H), 9.11 (s, 1 H), 8.01 (s, 1 H), 7.74 (t, 1 H), 7.61 (d, 1 H), 7.47 (s, 1 H), 7.34-7.31 (m, 1 H), 7.11 (d, 1 H), 6.63 (d, 1 H), 4.74 (d, 1 H), 3.37 (s, 2H), 3.30 (s, 3H) ppm.
Example 100 5-r5-Bromo-4-(2.3-difluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2.3-difluoro-benzyl)-amine
(dnH^BrCIF^Ng).
Figure imgf000119_0002
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 4.77 min; m/z: 333/335/337. 1H NMR (d6-DMSO) δ: 8.33 (t, 1 H), 8.28 (s, 1H), 7.33-7.26 (m, 1 H), 7.16-7.06 (m, 2H), 4.61 (d, 2H) ppm.
B. 5-f5-Bromo-4-(2.3-difluoro-benzylamino)-pyrimidin-2-ylamino1-1.3-dihvdro- indol-2-one (dgHuBrFgNgO).
Figure imgf000119_0003
04 0
-119-
The title compound was isolated as a pink solid in a 33% yield. MS: 446.1/448.0 (MH+). 1 H NMR (de-DMSO) δ: 10.16 (s, 1H), 9.05 (s, 1H), 8.00 (s, 1H), 7.58 (t, 1H), 7.32-7.21 (m, 3H), 7.13-7.11 (m, 1 H), 7.03-7.01 (m, 1 H), 6.54 (d, 1 H), 4.65 (d, 2H), 3.28 (s, 2H) ppm.
Example 101 6-f5-Bromo-4-(2,3-difluoro-benzylamino)-pyrimidin-2-ylamino1-1 ,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(213-difluoro-benzyl)-amine
(CιιHzBrCIF2Ng).
Figure imgf000120_0001
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 4.77 min; m/z: 333/335/337. 1H NMR (d6-DMSO) δ: 8.33 (t, 1H), 8.28 (s, 1H), 7.33-7.26 (m, 1 H), 7.16-7.06 (m, 2H), 4.61 (d, 2H) ppm.
B. 6-r5-Bromo-4-(2.3-difluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-
Figure imgf000120_0002
The title compound was isolated as a purple solid in an 8% yield. MS: 446.0/447.9 (MH+). 1H NMR (d6-DMSO) δ: 10.28 (s, 1H), 9.18 (s, 1 H), 8.04 (s, 1H), 7.57 (t, 1 H), 7.28-7.26 (m, 1 H), 7.13-7.06 (m, 4H), 6.87 (d, 1H), 4.68 (d, 1H), 3.32 (s, 2H) ppm.
Example 102 5-f5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihydro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2,4-difluoro-benzyl)-amine fCι HzBrCIF2N3).
Figure imgf000120_0003
-121 -
The title compound was isolated as a light purple solid in an 11 % yield. MS: 446.2/448.2. 1H NMR (d6-DMSO) δ: 10.28 (s, 1 H), 9.18 (s, 1 H), 8.03 (s, 1 H), 7.50 (t, 1 H), 7.32, 7.12 (m, 4H), 7.02-6.97 (m, 1 H), 6.90 (d, 1 H), 4.61 (d, 2H), 3.32 (s, 2H) ppm.
The following compounds were also prepared using the methods described in this application:
6-[5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one
5-Chloro-N2-(1-methyl-1H-indol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine 5-Chloro-N2-(1 H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine
5-Chloro-N2-(1 -methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
6-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
5-Chloro-N2-(1H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine 5-Chloro-N2-(1 H-indazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
(5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid tert-butyl ester
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-2-yl)-acetic acid tert-butyl ester 6-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one
N2-(1 -Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4- diamine
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid tert-butyl ester
N4-Pyridin-2-ylmethyl-N2-quinolin-5-yl-5-trifluoromethyl-pyrimidine-2,4-diamine
2-(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-N-(2- methoxy-ethyl)-acetamide
6-{5-Chloro-4-[(3-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid tert-butyl ester
N2-(1 H-lndazol-6-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid tert-butyl ester -120-
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 4.63 min; m/z: 333/335/337. 1H NMR (d6-DMSO) δ: 8.28-8.26 (m, 2H), 7.35-7.29 (m, 1H), 7.23-7.17 (m, 1 H), 7.04-6.99 (m, 1 H), 4.54 (d, 2H) ppm.
B. 5-r5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-
Figure imgf000122_0001
The title compound was isolated as a dark pink solid in a 13% yield. MS: 446.1/448.1 (MH+). 1H NMR (de-DMSO) δ: 10.15 (s, 1 H), 9.04 (s, 1 H), 8.00 (s, 1 H), 7.51 (t, 1 H), 7.39 (s, 1 H), 7.25-7.20 (m, 3H), 7.03-6.98 (m, 1 H), 6.56 (d, 1 H), 4.58 (d, 2H), 3.30 (s, 2H) ppm.
Example 103 6-r5-Bromo-4-(2.4-difluoro-benzylamino)-pyrimidin-2-ylaminol-1 ,3-dihvdro-indol-2-one A. (5-Bromo-2-chloro-pyrimidin-4-yl)-(2.4-difluoro-benzyl)-amine
Figure imgf000122_0002
The title intermediate was isolated as a white solid in a 78% yield. GC/MS: ret. time = 4.63 min; m/z: 333/335/337. 1H NMR (dβ-DMSO) δ: 8.28-8.26 (m, 2H), 7.35-7.29 (m, 1 H), 7.23-7.17 (m, 1H), 7.04-6.99 (m, 1 H), 4.54 (d, 2H) ppm.
B. 6-[5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylaminol-1.3-dihvdro- indol-2-one ((CιaH-uBrF2NgO).
Figure imgf000122_0003
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid
(5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid
5-{5-Chloro-4-[(3-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one
5-[5-Chloro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one 6-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 6-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 5-[5-Bromo-4-(2-methoxy-ethylamino)-pyhmidin-2-ylamino]-1 ,3-dihydro-indol-2-one 5-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 6-{5-Chloro-4-[(4-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one
5-(4-Benzylamino-5-chloro-pyhmidin-2-ylamino)-1 ,3-dihydro-indol-2-one
5-Bromo-N2-(1H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N2-(1H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine
5-Bromo-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1H-indazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1H-indol-4-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine N2-(1 H-lndol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
N2-(1 H-lndazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine N2-(1H-lndol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine N2-(1 H-lndazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine N2-(1 H-lndazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine N2-(1 H-lndazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- benzoimidazol-2-one
5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- benzoimidazol-2-one 5-{4-[(Pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1,3-dihydro-benzoimidazol-2- one
5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-benzoimidazol-2-one 5-Bromo-N2-(1 H-indazol-6-yl)-N4-pyhdin-2-ylmethyl-pyrimidine-2,4-diamine 5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine
N2-(2-Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine N2-(1 H-lndol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine2,4-diamine
N2-(1 H-Benzoimidazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine N2-(1 H-Benzoimidazol-5-yl)-5-bromo-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 3-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-yl]-3H-benzoimidazol-5-ylamine N2-(1H-Benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4- diamine
N2-(2-Methyl-1H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine- 2,4-diamine 5-Bromo-N2-(2,3-dihydro-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4- diamine
N2-(2,3-Dihydro-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine N2-(1 -Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N2-(2,3-dihydro-1 H-indol-5-yl)-N4-pyhdin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Fluoro-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine 5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indol-7-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N2-(1 H-indazol-4-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-6-yl-pyrimidine-2,4-diamine
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-5-yl-pyrimidine-2,4-diamine 5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-5-yl-pyrimidine-2,4-diamine 6-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-8-yl-pyrimidine-2,4-diamine
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-8-yl-pyrimidine-2,4-diamine
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 H-indole-2-carboxylic acid ethyl ester 6-[5-Bromo-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-
2-one
5-Bromo-N2-(1 H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1 H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine 5-Bromo-N2-(1 -methyl-1 H-indol-5-yl )-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine
5-Bromo-N2-(1 H-indazol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine
6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-3H-isobenzofuran-1- one N2-Benzothiazol-6-yl-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-2-methyl-1 H-indole-3- carbonitrile
5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1 H-indazol-5-yl)-pyrimidine-
2,4-diamine N2-(1 -Benzyl-1 H-indol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1 H-indol-5-yl)-pyrimidine-2,4- diamine
N2-(1-Benzyl-1 H-indazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-Bromo-N2-(1 -methyl-1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine
5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyhdin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine
5-Bromo-N4-cyclohexylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine
1 -{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3- (1 ,2,3,6-tetrahydro-pyridin-
4-yl)-1 H-indol-5-ylamine
1-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3-(1 ,2,3,6-tetrahydro-pyridin-
4-yl)-1 H-indol-5-ylamine 5-Fluoro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine
5-{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
5-Chloro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
5-Fluoro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine 5-Chloro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine
5-Fluoro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine
5-[5-Fluoro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-Chloro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine 5-[5-Chloro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one
5-{5-Methoxy-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one 5-[5-Methoxy-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one
5-[5-Methoxy-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one
5-{5-Bromo-4-[(cyclohex-1-enylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one
5-[5-Bromo-4-(methyl-pyridin-2-ylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one
5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one 5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one
5-[5-Bromo-4-(cyclohexylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-[5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol- 2-one 2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile
5-{5-Methyl-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
N2-(1 H-lndazol-5-yl)-5-methyl-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine 5-Fluoro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine
5-Chloro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine 2-(2-Oxo-2,3-dihydro-1 H-indol-5-ylamino)-4-(2-trifluoromethyl-benzylamino)- pyrimidine-5-carbonitrile
5-{4-[Methyl-(2-pyridin-2-yl-ethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2-one
5-Bromo-N4-cyclohex-1-enylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine
N2-(1 H-lndazol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine
5-[5-Trifluoromethyl-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one
6-{2-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-4-ylamino}-1 ,3-dihydro- indol-2-one
5-[5-Bromo-4-(piperidin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-[4-(1-Acetyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one
2-(2-Oxo-2,3-dihydro-1 H-indol-6-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile
5-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one
6-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one 4-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine-
1 -carboxylic acid tert-butyl ester
5-[5-Bromo-4-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one
5-[5-Bromo-4-(piperidin-3-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one 4-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine-
1 -carboxylic acid ethylamide
3-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine- 1 -carboxylic acid ethylamide
5-[4-(1-Benzoyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one
6-[4-(3-Methanesulfonyl-benzylamino)-5-methoxy-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one
6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one 6-[4-(3-Methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one
5-[4-(1-Benzenesulfonyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one 5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one
6-{5-Chloro-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one 6-{5-Chloro-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-
1 ,3-dihydro-indol-2-one
6-{5-Bromo-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one
6-{5-Bromo-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one
5-[5-Fluoro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one
5-{5-Bromo-4-[(1-hydroxy-cyclohexylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one. *
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
All patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated herein by reference in their entireties.

Claims

CLAIMS 1 A compound of the formula 1
Figure imgf000129_0001
1 or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R1 has the following formula 2
II I
Y
\ z— w
2 wherein each D is independently selected from the group consisting of CR8 and N, with the proviso that R1 is linked to NH group through a ring carbon atom, wherein E and G are independently selected from the group consisting of N and C, wherein X, W and Q are independently selected from the group consisting of N, O, S, S02, CO, NR3, CR2 and CR2R3, wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, O, S, S02, CO, NR3, CR2 and CR2R3, wherein A is present or absent, if present A is selected from the group consisting of O, S and NH and wherein B is present or absent, if present B is selected from the group consisting of
CO, S02, and NR6, with the proviso that when A is O or S that B is absent, wherein n is an integer from 1 to 3, wherein each R2 is independently selected from the group consisting of H, d-Cβ alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, Od-C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl,
NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2,
S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7,
NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR10, N(R 0)2, OR10, C Ce alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein each R3 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, CONR6R7 or R2 and R3 taken together with the carbon atom they are linked to can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring, wherein each methylene group present in said 3-7 membered cycloalkyl ring and said 4-7 membered heterocycloalkyl ring may be optionally replaced by a C=0 group, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NHR10, N(R 0)2, OR10, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein R4 is selected from the group consisting of H, Ci-Ce alkyl, C3-C7 cycloalkyl, C4- C7 heterocycloalkyl, C6-Cι0 aryl, and 5-10 membered heteroaryl, the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 subsitutents independently selected from the group consisting of H, halo, OH, N02, Ci- Ce alkyl, C(R6)=CR6R7, C≡CR6, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OC,-C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, C=N-OH, C=N-0(d-C6 alkyl), NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom; wherein R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, S02CH3, CONH2, cyclopropyl, cyclobutyl, C6H5, CONHR6, CONR6R7, C02R6, C(R9)=C(R9)2, and C≡CR9; wherein each R6 is independently selected from the group consisting of H, C C6 alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, and 5-10 membered heteroaryl, said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Ci-d alkyl, CN, NH2, NHR10, N(R10)2, OR10, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12 ; wherein each R7 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, and 5-10 membered heteroaryl, said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR11R12; wherein each R is independently selected from the group consisting of H, halo, cyano, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, OCι-C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, NH2, NHR6, NR6R7, SR6, SOR6, S02R6, COzR6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, said alkyl, cycloalkyl, and heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR3, N(R3)2, OR3, C Ce alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, and CONR6R7; and wherein each R9 is independently selected from the group consisting of H, CF3, and C C6 alkyl, said Cι-C6 alkyl is optionally substituted by 1 to 6 halo atoms; wherein each R10 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, CONR11R12, SOR11, S02R11, S02NH2, S02NHR11, S02NR11R12; said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR13, N(R13)2, OR13, C Cβ alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, and CONR14R15; wherein each R11 is independently selected from the group consisting of H, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR13, N(R13)2, OR13, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R14, CONH2, CONHR14, and CONR14R15; wherein each R12 is independently selected from the group consisting of H, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR13, N(R 3)2, PR13, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, CC2R14, CCNH2, CPNHR14, and CONR14R15; wherein each R13 is independently selected from the group consisting of H, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, CC2R14, CCNH2, CPNHR14, CPNR14R15, SOR14, S02R14, S02NH2, S02NHR14, S02NR14R15; wherein each R14 is independently selected from the group consisting of H, d-C6 alkyl,
C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-Cβ alkyl, CN, NH2, NH d-C6alkyl, N(d-C6alkyl)2, 0-C C6 alkyl; and wherein each R15 is independently selected from the group consisting of H, d-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C6-Cι0 aryl, C5-C10 membered heteroaryl; said alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, d-C6 alkyl, CN, NH2, NH d-C6alkyl, N(d-C6alkyl)2, 0-C C6 alkyl.
2. A compound according to claim 1 , wherein E and G are C; wherein X, W and Q are independently selected from the group consisting of N, NR3,
CR2 and CR R3; and wherein Y and Z are independently present or absent, if present Y and Z are selected from the group consisting of N, NR3, CR2 and CR2R3.
3. A compound according to any of the preceding claims, wherein R2 is selected from the group consisting of:
Figure imgf000132_0001
4. A compound according to any of the preceding claims, wherein R2 is selected from the group consisting of:
Figure imgf000133_0001
5. A compound according to any of the preceding claims, wherein R is selected from the group consisting of:
Figure imgf000134_0001
Figure imgf000134_0002
Figure imgf000134_0004
Figure imgf000134_0003
Figure imgf000134_0005
6. A compound according to any of the preceding claims, wherein R is selected from the group consisting of:
Figure imgf000135_0001
6. The compound according to any of the preceding claims, wherein wherein A is NH and wherein B is absent.
7. The compound according to any of the preceding claims wherein each R2 is independently selected from the group consisting of H, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, Od-C6 alkyl, OC3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, NH2, NHR6, NR6R7, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, C C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, Cι-C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR1 R12 ; and wherein each R3 is independently selected from the group consisting of H, C C6 alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R6, CONH2, CONHR6, CONR6R7 or R2 and R3 taken together with the carbon atom they are linked to can form a 3-7 membered cycloalkyl ring or 4-7 membered heterocycloalkyl ring, wherein each methylene group present in said 3-7 membered cycloalkyl ring and said 4-7 membered heterocycloalkyl ring may be optionally replaced by a C=0 group, said alkyl, cycloalkyl, heterocycloalkyl moieties of the foregoing groups are optionally substituted by 1 to 3 substituents independently selected from the group consisting of H, halo, Cι-C6 alkyl, CN, NH2, NHR10, N(R10)2, OR10, Ci-Ce alkyl, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, C02R11, CONH2, CONHR11, and CONR R12 .
8. The compound according to any of the preceding claims, wherein R4 is selected from the group consisting of H, Cι-C6 alkyl, and C6-Cι0 aryl, wherein the alkyl, and aryl moieties of the foregoing groups are optionally substituted by 1 to 3 subsitutents independently selected from the group consisting of H, halo, OH, N02, d-C6 alkyl, C(R6)=CR6R7, C≡CR6, C3-C7 cycloalkyl, C4-C7 heterocycloalkyl, Od-C6 alkyl, 0C3-C7 cycloalkyl, OC4-C7 heterocyloalkyl, C=N- OH, C=N-0(Cι-C6 alkyl), NH2, NHR6, NR6R7, SR6, SOR6, S02R6, C02R6, CONH2, CONHR6, CONR6R7, S02NH2, S02NHR6, S02NR6R7, NHCOR6, NR6CONR6, NHCONHR6, NR6CONHR6, NHCONR6R7, NR6CONR6R7, NHS02R6, NR6S02R6, with the proviso that O, N or S atom of the foregoing substituents may not be bound to a carbon atom bound to another heteroatom.
9. The compound according to any of the preceding claims, wherein R5 is selected from the group consisting of H, Br, Cl, CN, CF3, CH2F, CHF2, S02CH3, and CONH2.
10. A compound according to claim 1 selected from the group consisting of: 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-p-tolyl-pyrimidine-2,4- diamine;
5-Bromo-N4-pyridin-2-yl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
N4-Benzyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]-pyrimidine- 2,4-diamine; 5-Bromo-N4-(1 R-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(1 rac-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(1 S-phenyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indoi-5-yl]- pyrimidine-2,4-diamine;
4-({5-Bromo-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-ylamino]-pyrimidin-4- ylamino}-methyl)-benzenesulfonamide 5-Bromo-N2-[3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(4-trifluoromethyl- benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-methoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-(4-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-naphthalen-1 -ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-fluoro-3-trifluoromethyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)- 1 H-indol-5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(3-fluoro-5-trifluoromethyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)- 1 H-indol-5-yl]-pyrimidine-2,4-diamine; 5-Bromo-N4-(4-phenoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyhdin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3,4-difluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(3-trifluoromethoxy- benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(4-chloro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-thiophen-2-ylmethyl- pyrimidine-2,4-diamine; 5-Bromo-N4-furan-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-methyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3-methyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(4-methyl-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-fluoro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5-yl]- pyrimidine-2,4-diamine; N4-Biphenyl-2-ylmethyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
N4-Biphenyl-3-ylmethyl-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-(2-methoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(3-methoxy-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 3-({5-Bromo-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-ylamino]-pyrimidin-4- ylamino}-methyl)-N-methyl-benzamide
5-Bromo-N4-(2-chloro-benzyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-phenethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine- 2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-4-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-Bromo-N4-(2-pyridin-3-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(3-fluoro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-phenyl-cyclopropyl)-N -[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-phenyl-cyclopropyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; (homo-chiral)
5-Bromo-N4-(2-phenyl-cyclopropyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; (homo-chiral) 5-Bromo-N -[2-(4-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-
5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-thiophen-2-yl- ethyl)-pyhmidine-2,4-diamine;
5-Bromo-N4-[2-(2-fluoro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(2-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-[2-(2-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine; N4-(2-Benzo[1 ,3]dioxol-5-yl-ethyl)-5-bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-(3-phenyl-propyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 5-(5-Bromo-4-phenethylamino-pyrimidin-2-ylamino)-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2-chloro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-(4-Benzylamino-5-bromo-pyrimidin-2-ylamino)-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[5-Bromo-4-(3-phenyl-propylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-(2-methanesulfonyl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
N4-Benzyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine-2,4-diamine;
N4-Benzyl-N4-methyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-pyrimidine- 2,4-diamine;
N4-Methyl-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
[4-(2-Phenyl-morpholin-4-yl)-pyrimidin-2-yl]-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-amine 5-Methyl-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Bromo-N2-(3-piperidin-4-yl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4- diamine;
5-Bromo-N2-[1 -methanesulfonyl-3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4- (2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-[1-methanesulfonyl-3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4- pyridin-2-yl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2-pyridin-2-yl-ethyl)-N4-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine; 3-{4-(2-Pyridin-2-yl-ethylamino)-2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- ylamino]-pyrimidin-5-yl}-acrylic acid; ethyl ester;
5-{5-Bromo-4-[2-(3-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-Bromo-N4-[2-(3-chloro-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-Bromo-N -[2-(3-chloro-phenyl)-ethyl]-N2-t3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol- 5-yl]-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[2-(4-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; 5-Bromo-N -[2-(4-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[2-(3-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; 5-Bromo-N4-[2-(3-methoxy-phenyl)-ethyl]-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H- indol-5-yl]-pyhmidine-2,4-diamine;
5-[5-Bromo-4-(2-o-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-o-tolyl-ethyl)- pyrimidine-2,4-diamine;
5-[5-Bromo-4-(2-m-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-m-tolyl-ethyl)- pyrimidine-2,4-diamine;
5-[5-Bromo-4-(2-p-tolyl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-Bromo-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]-N4-(2-p-tolyl-ethyl)- pyrimidine-2,4-diamine;
[5-Bromo-2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-acetic acid;
5-{5-Bromo-4-[2-(3-trifluoromethyl-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one; 5-[4-(2-Biphenyl-4-yl-ethylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
5-{5-Bromo-4-[2-(3-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-{5-Bromo-4-[2-(2-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-{5-Bromo-4-[2-(2-methoxy-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-{5-Bromo-4-[2-(4-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one; 5-{5-Bromo-4-[2-(4-chloro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-
2-one;
5-{5-Bromo-4-[2-(2-fluoro-phenyl)-ethylamino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one;
5-[5-Bromo-4-(3-phenyl-allylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-{5-Bromo-4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
6-{5-Bromo-4-[(thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
6-[5-Bromo-4-(2,3-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 5-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
6-[5-Bromo-4-(2,5-dimethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 6-[5-Bromo-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(2-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one; 6-[5-Bromo-4-(3-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Bromo-4-(4-trifluoromethoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Bromo-4-(2-methoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(3-methoxy-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(3-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one; 5-[5-Bromo-4-[(thiazol-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-{5-Bromo-4-[(5-methanesulfonyl-thiophen-2-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2,3-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 6-[5-Bromo-4-(2,3-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Bromo-4-(2,4-difluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol- 2-one; 5-Chloro-N2-(1 -methyl-1 H-indol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine;
5-Chloro-N2-(1 H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Chloro-N2-(1 -methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
6-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Chloro-N2-(1 H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Chloro-N2-(1 H-indazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid; tert-butyl ester;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-2-yl)-acetic acid; tert-butyl ester; 6-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
N2-(1 -Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4- diamine;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; tert-butyl ester;
N4-Pyridin-2-ylmethyl-N2-quinolin-5-yl-5-trifluoromethyl-pyrimidine-2,4-diamine;
2-(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-N-(2- methoxy-ethyl)-acetamide;
6-{5-Chloro-4-[(3-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid; tert-butyl ester;
N2-(1 H-lndazol-6-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine; (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; tert-butyl ester;
(6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid;
(5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indol-1-yl)-acetic acid; (5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-indazol-1-yl)-acetic acid;
5-{5-Chloro-4-[(3-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-[5-Chloro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
6-[5-Chloro-4-(2-fluoro-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[5-Bromo-4-(2-methoxy-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[5-Chloro-4-(3-methyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol-2-one;
6-{5-Chloro-4-[(4-methyl-pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-(4-Benzylamino-5-chloro-pyrimidin-2-ylamino)-1 ,3-dihydro-indol-2-one; 5-Bromo-N2-(1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 H-indazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-4-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndol-5-yl)-N4-pyridin-2-ylmethyl-pyhmidine-2,4-diamine;
N2-(1H-lndazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; N2-(1 H-lndol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1H-lndazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- benzoimidazol-2-one;
5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- benzoim idazol-2-one;
5-{4-[(Pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-benzoimidazol-2- one; 5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-benzoimidazol-2-one;
5-Bromo-N2-(1 H-indazol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[4-(2-Pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(2-Methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-lndol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2-methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 H-indol-6-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indol-6-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine2,4-diamine;
N2-(1H-Benzoimidazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
N2-(1 H-Benzoimidazol-5-yl)-5-bromo-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
3-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-yl]-3H-benzoimidazol-5-ylamine N2-(1H-Benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4- diamine;
N2-(2-Methyl-1 H-benzoimidazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; , _„„^ 04/056786
-143-
5-Bromo-N2-(2-methyl-1 H-benzoimidazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine- 2,4-diamine;
5-Bromo-N2-(2,3-dihydro-1 H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4- diamine; N2-(2,3-Dihydro-1 H-indol-5-yl)-N4-pyridin-2-yimethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1-methyl-1H-indol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
N2-(1-Methyl-1H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(2,3-dihydro-1H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-pyridin-2-ylmethyl-pyrirnidine-2,4-diamine; 5-Fluoro-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-6-yl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indol-7-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indazol-4-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-6-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-5-yl-pyrimidine-2,4-diamine; 5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-5-yl-pyrimidine-2,4-diamine;
6-[5-Bromo-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-pyridin-2-ylmethyl-N2-quinolin-8-yl-pyrimidine-2,4-diamine;
5-Bromo-N4-(2-pyridin-2-yl-ethyl)-N2-quinolin-8-yl-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 H-indole-2-carboxylic acid; ethyl ester;
6-[5-Bromo-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one;
5-Bromo-N2-(1H-indazol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
5-Bromo-N2-(1H-indazol-6-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 -methyl-1 H-indol-5-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4- diamine;
5-Bromo-N2-(1H-indazol-7-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-Bromo-N2-(1 H-indazol-4-yl)-N4-(2-trifluoromethyl-benzyl)-pyrimidine-2,4-diamine;
6-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-3H-isobenzofuran-1- one;
N2-Benzothiazol-6-yl-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine;
5-{5-Bromo-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-2-methyl-1 H-indole-3- carbonitrile 5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1 H-indazol-5-yl)-pyrimidine- 2,4-diamine;
N2-(1-Benzyl-1 H-indol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N4-pyridin-2-ylmethyl-N2-(1-pyridin-2-ylmethyl-1 H-indol-5-yl)-pyrimidine-2,4- diamine;
N2-(1-Benzyl-1 H-indazol-5-yl)-5-bromo-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N2-(1 -methyl-1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine; 5-Bromo-N4-(4-methyl-cyclohexyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5- yl]-pyrimidine-2,4-diamine;
5-Bromo-N4-cyclohexylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
1 -{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3- (1 ,2,3,6-tetrahydro-pyridin- 4-yl)-1 H-indol-5-ylamine
1-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-yl}-3-(1 ,2,3,6-tetrahydro-pyridin- 4-yl)-1 H-indol-5-ylamine
5-Fluoro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-{5-Fluoro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Chloro-N2-(1 H-indazol-5-yl)-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-{5-Chloro-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-Fluoro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Chloro-N4-(2-pyridin-2-yl-ethyl)-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Fluoro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine; 5-[5-Fluoro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-Chloro-N2-(1 H-indazol-5-yl)-N4-(2-pyridin-2-yl-ethyl)-pyrimidine-2,4-diamine;
5-[5-Chloro-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-{4-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one;
5-{5-Methoxy-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
5-[5-Methoxy-4-(2-pyridin-2-yl-ethylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one; 4/056786
-145-
5-[5-Methoxy-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one;
5-{5-Bromo-4-[(cyclohex-1-enylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol- 2-one; 5-[5-Bromo-4-(methyl-pyridin-2-ylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(4-methyl-cyclohexylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
5-[5-Bromo-4-(cyclohexylmethyl-amino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-t5-Chloro-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3-dihydro-indol- 2-one;
2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile
5-{5-Methyl-4-[(pyridin-2-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
N2-(1H-lndazol-5-yl)-5-methyl-N4-pyridin-2-ylmethyl-pyrimidine-2,4-diamine; 5-Fluoro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
5-Chloro-N4-pyridin-2-ylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1 H-indol-5-yl]- pyrimidine-2,4-diamine;
2-(2-Oxo-2,3-dihydro-1H-indol-5-ylamino)-4-(2-trifluoromethyl-benzylamino)- pyrimidine-5-carbonitrile 5-{4-[Methyl-(2-pyridin-2-yl-ethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2-one;
5-Bromo-N4-cyclohex-1-enylmethyl-N2-[3-(1 ,2,3,6-tetrahydro-pyridin-4-yl)-1H-indol-5- yl]-pyrimidine-2,4-diamine;
N2-(1 H-lndazol-5-yl)-N4-pyridin-2-ylmethyl-5-trifluoromethyl-pyrimidine-2,4-diamine; 5-[5-Trifluoromethyl-4-(2-trifluoromethyl-benzylamino)-pyrimidin-2-ylamino]-1,3- dihydro-indol-2-one;
6-{2-[(Pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-4-ylamino}-1 ,3-dihydro- indol-2-one;
5-[5-Bromo-4-(pipehdin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 5-[4-(1-Acetyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2- one;
2-(2-Oxo-2,3-dihydro-1 H-indol-6-ylamino)-4-[(pyridin-2-ylmethyl)-amino]-pyrimidine-5- carbonitrile 5-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one;
6-{4-[(3-Methyl-pyridin-2-ylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1 ,3- dihydro-indol-2-one; 4-[5-Bromo-2-(2-oxo-2,3-dihydro-1 H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine-
1 -carboxylic acid; tert-butyl ester;
5-[5-Bromo-4-(1-methanesulfonyl-piperidin-4-ylamino)-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one;
5-[5-Bromo-4-(piperidin-3-ylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one; 4-[5-Bromo-2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine-
1 -carboxylic acid; ethylamide
3-[5-Bromo-2-(2-oxo-2,3-dihydro-1H-indol-5-ylamino)-pyrimidin-4-ylamino]-piperidine- 1 -carboxylic acid; ethylamide
5-[4-(1-Benzoyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3-dihydro-indol- 2-one;
6-[4-(3-Methanesulfonyl-benzylamino)-5-methoxy-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one;
6-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one; 6-[4-(3-Methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro-indol-2-one;
5-[4-(1-Benzenesulfonyl-piperidin-4-ylamino)-5-bromo-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one;
5-[4-(3-Methanesulfonyl-benzylamino)-5-trifluoromethyl-pyrimidin-2-ylamino]-1 ,3- dihydro-indol-2-one; 6-{5-Chloro-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
6-{5-Chloro-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one;
6-{5-Bromo-4-[(piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro-indol-2- one;
6-{5-Bromo-4-[(1-methanesulfonyl-piperidin-3-ylmethyl)-amino]-pyrimidin-2-ylamino}- 1 ,3-dihydro-indol-2-one;
5-[5-Fluoro-4-(3-methanesulfonyl-benzylamino)-pyrimidin-2-ylamino]-1 ,3-dihydro- indol-2-one; 5-{5-Bromo-4-[(1-hydroxy-cyclohexylmethyl)-amino]-pyrimidin-2-ylamino}-1 ,3-dihydro- indol-2-one; and pharmaceutically acceptable salt, prodrug, hydrate or solvate of the aforementioned compounds.
11. A method for the treatment of abnormal cell growth in a mammal comprising administering to said mammal an amount of a compound of claim 1 that is effective in treating abnormal cell growth.
12. A method according to claim 11 wherein said abnormal cell growth is cancer.
13. A method according to claim 12 wherein said cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers.
14. A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.
PCT/IB2003/006055 2002-12-20 2003-12-17 Pyrimidine derivates for the treatment of abnormal cell growth WO2004056786A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004561885A JP2006515298A (en) 2002-12-20 2003-12-17 Pyrimidine derivatives for treating abnormal cell proliferation
BR0317435-2A BR0317435A (en) 2002-12-20 2003-12-17 Pyrimidine Derivatives for the Treatment of Abnormal Cell Growth
CA002510848A CA2510848A1 (en) 2002-12-20 2003-12-17 Pyrimidine derivates for the treatment of abnormal cell growth
MXPA05006420A MXPA05006420A (en) 2002-12-20 2003-12-17 Pyrimidine derivates for the treatment of abnormal cell growth.
EP03780443A EP1578732A2 (en) 2002-12-20 2003-12-17 Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003288603A AU2003288603A1 (en) 2002-12-20 2003-12-17 Pyrimidine derivates for the treatment of abnormal cell growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43567002P 2002-12-20 2002-12-20
US60/435,670 2002-12-20

Publications (2)

Publication Number Publication Date
WO2004056786A2 true WO2004056786A2 (en) 2004-07-08
WO2004056786A3 WO2004056786A3 (en) 2004-10-21

Family

ID=32682276

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/006055 WO2004056786A2 (en) 2002-12-20 2003-12-17 Pyrimidine derivates for the treatment of abnormal cell growth

Country Status (17)

Country Link
US (1) US20040220177A1 (en)
EP (1) EP1578732A2 (en)
JP (1) JP2006515298A (en)
AR (1) AR042531A1 (en)
AU (1) AU2003288603A1 (en)
BR (1) BR0317435A (en)
CA (1) CA2510848A1 (en)
GT (2) GT200300292A (en)
HN (1) HN2003000422A (en)
MX (1) MXPA05006420A (en)
NL (1) NL1025071C2 (en)
PA (1) PA8593101A1 (en)
PE (1) PE20040934A1 (en)
TW (1) TW200413330A (en)
UA (1) UA80767C2 (en)
UY (1) UY28135A1 (en)
WO (1) WO2004056786A2 (en)

Cited By (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
WO2005030716A1 (en) * 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
WO2005111023A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111016A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7060827B2 (en) 2002-02-01 2006-06-13 Rigel Pharmaceuticals, Inc. Intermediates useful for making 2,4-pyrimidinediamine compounds
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2006117560A1 (en) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
WO2007072158A2 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2007126128A1 (en) 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivative
DE102007010801A1 (en) 2007-03-02 2008-09-04 Bayer Cropscience Ag Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi
JP2008544972A (en) * 2005-07-01 2008-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2,4-Diamino-pyrimidine as an aurora inhibitor
WO2009054332A1 (en) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2010064737A1 (en) * 2009-02-16 2010-06-10 Nishio Tetsuya Heterocyclic compound and use of the same
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
WO2011008487A1 (en) 2009-06-29 2011-01-20 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011018518A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US7893074B2 (en) 2003-08-15 2011-02-22 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US7943627B2 (en) 2002-03-15 2011-05-17 Novartis Ag 2,4-diaminopyrimidine derivatives
US7964592B2 (en) 2003-03-14 2011-06-21 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2343298A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
WO2011112662A1 (en) 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
WO2011146808A2 (en) 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
US8076343B2 (en) * 2005-07-26 2011-12-13 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as inhibitors of protein kinases
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
WO2012041796A1 (en) 2010-09-28 2012-04-05 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with ptk2 inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012085126A1 (en) * 2010-12-21 2012-06-28 Boehringer Ingelheim International Gmbh Oxindolopyrimidine as igf1r receptor inhibitors
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
WO2013026025A1 (en) 2011-08-18 2013-02-21 Incyte Corporation Cyclohexyl azetidine derivatives as jak inhibitors
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
WO2013151930A1 (en) 2012-04-02 2013-10-10 Incyte Corporation Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8609679B2 (en) 2008-06-27 2013-12-17 Celgene Avilomics Research, Inc. 2,4-diaminopyrimidines useful as kinase inhibitors
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US8710222B2 (en) 2008-06-27 2014-04-29 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
WO2014134426A1 (en) 2013-03-01 2014-09-04 Incyte Corporation USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US8993585B2 (en) 2007-07-17 2015-03-31 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
WO2015131031A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2015157257A1 (en) 2014-04-08 2015-10-15 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
EP3042655A1 (en) 2008-10-02 2016-07-13 Incyte Holdings Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020159905A1 (en) 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020168178A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021041360A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021211864A1 (en) 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2021247668A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022061351A1 (en) 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
WO2022199561A1 (en) * 2021-03-23 2022-09-29 杭州阿诺生物医药科技有限公司 Hpk1 kinase inhibitor compound
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
US11590138B2 (en) 2019-06-10 2023-02-28 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023122134A1 (en) 2021-12-22 2023-06-29 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
EP3998254A4 (en) * 2019-07-04 2023-08-09 Shenyang Pharmaceutical University 2-aminopyrimidine compound and application thereof
WO2023172921A1 (en) 2022-03-07 2023-09-14 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11833152B2 (en) 2018-02-16 2023-12-05 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632149C (en) * 2005-12-01 2011-11-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
NZ601683A (en) 2007-01-16 2012-11-30 Shionogi & Co Heterocyclic-substituted piperidine compounds for modulating ORL-1 receptor function in a cell
UA97834C2 (en) 2007-04-18 2012-03-26 Пфайзер Продактс Инк. Sulfonyl amide derivatives for the treatment of abnormal cell growth
KR101294731B1 (en) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 Array substrate, display panel having the array substrate and method of manufacturing the array substrate
KR20100053626A (en) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 3' substituted compounds having 5-ht6 receptor affinity
WO2009027820A2 (en) 2007-08-31 2009-03-05 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
JP5781943B2 (en) 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド N2- (3-pyridyl or phenyl) -N4- (4-piperidyl) -2,4-pyrimidinediamine derivatives useful for the treatment of inflammatory diseases, autoimmune diseases or proliferative diseases
KR101771401B1 (en) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
DE102010034699A1 (en) * 2010-08-18 2012-02-23 Merck Patent Gmbh pyrimidine derivatives
PT2646448T (en) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Macrocyclic kinase inhibitors
JP6116554B2 (en) * 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Substituted azaheterocycles for the treatment of cancer
EP2785709B1 (en) * 2011-11-29 2017-05-10 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP4070795A1 (en) 2014-08-25 2022-10-12 Salk Institute for Biological Studies Novel ulk1 inhibitors and methods using same
BR112017028519A2 (en) 2015-06-29 2018-08-28 Verastem Inc therapeutic compositions, combinations and methods of use
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
US20210030703A1 (en) 2018-03-12 2021-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2000012485A1 (en) * 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
WO2002096888A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003032997A1 (en) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
WO2003063794A2 (en) * 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
WO2004046118A2 (en) * 2002-05-06 2004-06-03 Bayer Pharmaceuticals Corporation 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
US4983608A (en) * 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
IL123581A (en) * 1995-10-02 2001-09-13 Hoffmann La Roche PYRIMIDINE DERIVATIVES AS 5HT2c-RECEPTOR ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2002102313A2 (en) * 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
EP1453516A2 (en) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG Novel tri-substituted pyrimidines, method for production and use thereof as medicament
ES2337782T3 (en) * 2002-07-29 2010-04-29 Rigel Pharmaceuticals, Inc. METHODS TO TREAT OR PREVENT AUTOIMMUNITY DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS.
NZ539823A (en) * 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
WO1997019065A1 (en) * 1995-11-20 1997-05-29 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2000012485A1 (en) * 1998-08-29 2000-03-09 Astrazeneca Ab Pyrimidine compounds
WO2000039101A1 (en) * 1998-12-24 2000-07-06 Astrazeneca Ab Pyrimidine compounds
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
WO2002096888A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003032997A1 (en) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same
WO2003063794A2 (en) * 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
WO2004046118A2 (en) * 2002-05-06 2004-06-03 Bayer Pharmaceuticals Corporation 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATH J C: "PATENT FOCUS: INHIBITORS OF TUMOUR CELL GROWTH" EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 6, 2000, pages 803-818, XP000919385 ISSN: 1354-3776 *

Cited By (437)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334296B2 (en) 2002-02-01 2012-12-18 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7906644B2 (en) 2002-02-01 2011-03-15 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7655797B2 (en) 2002-02-01 2010-02-02 Rigel Pharmaceuticals, Inc. Intermediates for making 2,4-pyrimidinediamine compounds
US7803939B2 (en) 2002-02-01 2010-09-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7060827B2 (en) 2002-02-01 2006-06-13 Rigel Pharmaceuticals, Inc. Intermediates useful for making 2,4-pyrimidinediamine compounds
US7820819B2 (en) 2002-02-01 2010-10-26 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10709703B2 (en) 2002-02-01 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US10682350B2 (en) 2002-02-01 2020-06-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US7943627B2 (en) 2002-03-15 2011-05-17 Novartis Ag 2,4-diaminopyrimidine derivatives
US8431589B2 (en) 2002-03-15 2013-04-30 Novartis Ag 2,4-diaminopyrimidine derivatives
US7812029B1 (en) 2002-07-29 2010-10-12 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7825116B2 (en) 2002-07-29 2010-11-02 Rigel Pharmaceuticals, Inc. N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
US7674796B2 (en) 2002-12-20 2010-03-09 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7351712B2 (en) 2002-12-20 2008-04-01 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7741336B2 (en) 2002-12-20 2010-06-22 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109335B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7964592B2 (en) 2003-03-14 2011-06-21 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US8263590B2 (en) 2003-03-14 2012-09-11 Carlos Garcia-Echeverria Pyrimidine derivatives
US9751893B2 (en) 2003-07-30 2017-09-05 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7893074B2 (en) 2003-08-15 2011-02-22 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP2266977A1 (en) * 2003-09-16 2010-12-29 Novartis AG 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors
AU2004272283B9 (en) * 2003-09-16 2008-10-23 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors
AU2004272283B2 (en) * 2003-09-16 2008-10-02 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors
US8283356B2 (en) 2003-09-16 2012-10-09 Novartis Ag 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors
WO2005026158A1 (en) * 2003-09-16 2005-03-24 Novartis Ag 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
US7671063B2 (en) 2003-09-16 2010-03-02 Novartis Ag 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors
WO2005026130A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2005030716A1 (en) * 2003-09-25 2005-04-07 Wyeth Heterocyclic- or aryloxy, -thio or -amino substituted indoles-2-carboxylic acids or esters as pai-1
US8481536B2 (en) 2004-04-08 2013-07-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US7208499B2 (en) 2004-05-14 2007-04-24 Pfizer Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111016A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
WO2005111023A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CN102127058A (en) * 2004-05-14 2011-07-20 辉瑞产品有限公司 Pyrimidine derivatives for the treatment of abnormal cell growth
US7235562B2 (en) 2004-05-14 2007-06-26 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) 2004-05-14 2006-12-05 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8372971B2 (en) 2004-08-25 2013-02-12 Targegen, Inc. Heterocyclic compounds and methods of use
US7851480B2 (en) 2004-11-24 2010-12-14 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US10577381B2 (en) 2005-01-19 2020-03-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006117560A1 (en) * 2005-05-05 2006-11-09 Astrazeneca Ab Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
US11192868B2 (en) 2005-05-10 2021-12-07 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
AU2006264958B2 (en) * 2005-07-01 2012-05-03 Boehringer Ingelheim International Gmbh 2,4-diamino-pyrimidines used as aurora inhibitors
JP2008544972A (en) * 2005-07-01 2008-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2,4-Diamino-pyrimidine as an aurora inhibitor
US8076343B2 (en) * 2005-07-26 2011-12-13 Vertex Pharmaceuticals Incorporated Benzimidazoles useful as inhibitors of protein kinases
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
US8835423B2 (en) 2005-09-22 2014-09-16 Incyte Corporation Azepine inhibitors of janus kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3838903A1 (en) 2005-12-13 2021-06-23 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2474545A1 (en) 2005-12-13 2012-07-11 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
EP2343298A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2343299A1 (en) 2005-12-13 2011-07-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3466953A1 (en) 2005-12-13 2019-04-10 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
EP2348023A1 (en) 2005-12-13 2011-07-27 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP2455382A1 (en) 2005-12-13 2012-05-23 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3184526A1 (en) 2005-12-13 2017-06-28 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor
EP2426129A1 (en) 2005-12-13 2012-03-07 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007072158A2 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
NL2000375C2 (en) * 2005-12-21 2008-01-03 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth.
WO2007072158A3 (en) * 2005-12-21 2007-12-27 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EA014551B1 (en) * 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Pyrimidine derivatives for the treatment of abnormal cell growth
US7834019B2 (en) 2006-04-27 2010-11-16 Banyu Pharmaceutical Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidinone derivatives
JPWO2007126128A1 (en) * 2006-04-27 2009-09-17 萬有製薬株式会社 Dihydropyrazolopyrimidinone derivatives
JP4513919B2 (en) * 2006-04-27 2010-07-28 萬有製薬株式会社 Dihydropyrazolopyrimidinone derivatives
US7935708B2 (en) 2006-04-27 2011-05-03 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2007126128A1 (en) 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivative
CN101432284B (en) * 2006-04-27 2012-08-15 Msdk.K.公司 Dihydropyrazolopyrimidinone derivative
US8372858B2 (en) 2006-12-08 2013-02-12 Irm Llc Compounds and compositions as protein kinase inhibitors
US8377921B2 (en) 2006-12-08 2013-02-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8957081B2 (en) 2006-12-08 2015-02-17 Irm Llc Compounds and compositions as protein kinase inhibitors
US8039479B2 (en) 2006-12-08 2011-10-18 Irm Llc Compounds and compositions as protein kinase inhibitors
US8399450B2 (en) 2006-12-08 2013-03-19 Irm Llc Compounds and compositions as protein kinase inhibitors
US8841318B2 (en) 2006-12-22 2014-09-23 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
DE102007010801A1 (en) 2007-03-02 2008-09-04 Bayer Cropscience Ag Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi
US8889697B2 (en) 2007-06-13 2014-11-18 Incyte Corporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP4011883A1 (en) 2007-06-13 2022-06-15 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2740731A1 (en) 2007-06-13 2014-06-11 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP3070090A1 (en) 2007-06-13 2016-09-21 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP3495369A1 (en) 2007-06-13 2019-06-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10463667B2 (en) 2007-06-13 2019-11-05 Incyte Incorporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8993585B2 (en) 2007-07-17 2015-03-31 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
US8329711B2 (en) 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2009054332A1 (en) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8461147B2 (en) 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011505407A (en) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Diaminopyridine for treating diseases characterized by excessive or abnormal cell proliferation
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
US8420629B2 (en) 2008-03-11 2013-04-16 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
EA018282B1 (en) * 2008-04-07 2013-06-28 Айрм Ллк Compounds and compositions as protein kinase inhibitors
WO2009126515A1 (en) * 2008-04-07 2009-10-15 Irm Llc Compounds and compositions as protein kinase inhibitors
US8592432B2 (en) 2008-04-07 2013-11-26 Bei Chen Compounds and compositions as protein kinase inhibitors
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9296737B2 (en) 2008-06-27 2016-03-29 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9987276B2 (en) 2008-06-27 2018-06-05 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US8609679B2 (en) 2008-06-27 2013-12-17 Celgene Avilomics Research, Inc. 2,4-diaminopyrimidines useful as kinase inhibitors
US10010548B2 (en) 2008-06-27 2018-07-03 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8710222B2 (en) 2008-06-27 2014-04-29 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10828300B2 (en) 2008-06-27 2020-11-10 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10596172B2 (en) 2008-06-27 2020-03-24 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11207302B2 (en) 2008-07-08 2021-12-28 Incyte Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP3042655A1 (en) 2008-10-02 2016-07-13 Incyte Holdings Corporation Janus kinase inhibitors for treatment of dry eye and other eye related diseases
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2010064737A1 (en) * 2009-02-16 2010-06-10 Nishio Tetsuya Heterocyclic compound and use of the same
US8895565B2 (en) 2009-02-16 2014-11-25 Tetsuya Nishio Heterocyclic compound and use of the same
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US10428087B2 (en) 2009-06-29 2019-10-01 Incyte Corporation Pyrimidinones as PI3K inhibitors
US11401280B2 (en) 2009-06-29 2022-08-02 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
WO2011008487A1 (en) 2009-06-29 2011-01-20 Incyte Corporation Pyrimidinones as pi3k inhibitors
US9975907B2 (en) 2009-06-29 2018-05-22 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
US10829502B2 (en) 2009-06-29 2020-11-10 Incyte Corporation Pyrimidinones as PI3K inhibitors
WO2011018518A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2 -amino-5-trifluoromethylpyrimidine derivatives
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2473486B1 (en) 2009-09-02 2015-10-28 Vifor (International) Ag Pyrimidines as hepcidine antagonists
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011103423A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP3354652A1 (en) 2010-03-10 2018-08-01 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
EP4036088A1 (en) 2010-03-10 2022-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3050882A1 (en) 2010-03-10 2016-08-03 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2011112662A1 (en) 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3715347A1 (en) 2010-03-10 2020-09-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
WO2011146808A2 (en) 2010-05-21 2011-11-24 Incyte Corporation Topical formulation for a jak inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
WO2012041796A1 (en) 2010-09-28 2012-04-05 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with ptk2 inhibitors
US10081606B2 (en) 2010-11-01 2018-09-25 Celgene Car Llc Heteroaryl compounds and uses thereof
US9765038B2 (en) 2010-11-01 2017-09-19 Celgene Car Llc Heteroaryl compounds and uses thereof
US11096942B2 (en) 2010-11-01 2021-08-24 Celgene Car Llc Heterocyclic compounds and uses thereof
US9375431B2 (en) 2010-11-01 2016-06-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
US10434101B2 (en) 2010-11-01 2019-10-08 Celgene Car Llc Heterocyclic compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9867824B2 (en) 2010-11-01 2018-01-16 Celgene Car Llc Heterocyclic compounds and uses thereof
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US9868723B2 (en) 2010-11-10 2018-01-16 Celgene Car Llc Mutant-selective EGFR inhibitors and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9815839B2 (en) 2010-12-20 2017-11-14 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012085126A1 (en) * 2010-12-21 2012-06-28 Boehringer Ingelheim International Gmbh Oxindolopyrimidine as igf1r receptor inhibitors
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US9120761B2 (en) 2011-02-17 2015-09-01 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US9421205B2 (en) 2011-02-17 2016-08-23 Cancer Therapeutics CRC Pty Ltd. FAK inhibitors
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
US9012461B2 (en) 2011-02-17 2015-04-21 Cancer Therapeutics Crc Pty Ltd FAK inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
WO2013026025A1 (en) 2011-08-18 2013-02-21 Incyte Corporation Cyclohexyl azetidine derivatives as jak inhibitors
US9730939B2 (en) 2011-09-02 2017-08-15 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US10092570B2 (en) 2011-09-02 2018-10-09 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
EP3513793A1 (en) 2011-09-02 2019-07-24 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
WO2013033569A1 (en) 2011-09-02 2013-03-07 Incyte Corporation Heterocyclylamines as pi3k inhibitors
US11819505B2 (en) 2011-09-02 2023-11-21 Incyte Corporation Heterocyclylamines as PI3K inhibitors
US10376513B2 (en) 2011-09-02 2019-08-13 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US10646492B2 (en) 2011-09-02 2020-05-12 Incyte Corporation Heterocyclylamines as PI3K inhibitors
EP3196202A1 (en) 2011-09-02 2017-07-26 Incyte Holdings Corporation Heterocyclylamines as pi3k inhibitors
US11433071B2 (en) 2011-09-02 2022-09-06 Incyte Corporation Heterocyclylamines as PI3K inhibitors
US9707233B2 (en) 2011-09-02 2017-07-18 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
WO2013092854A1 (en) 2011-12-23 2013-06-27 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9944646B2 (en) 2012-04-02 2018-04-17 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
WO2013151930A1 (en) 2012-04-02 2013-10-10 Incyte Corporation Bicyclic azaheterocyclobenzylamines as pi3k inhibitors
US10259818B2 (en) 2012-04-02 2019-04-16 Incyte Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014044754A1 (en) 2012-09-21 2014-03-27 Chemilia Ab 4-indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US9908895B2 (en) 2012-11-01 2018-03-06 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10370387B2 (en) 2012-11-01 2019-08-06 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US11161855B2 (en) 2012-11-01 2021-11-02 Incyte Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
WO2014071031A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
US9181271B2 (en) 2012-11-01 2015-11-10 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US9777017B2 (en) 2012-11-01 2017-10-03 Incyte Holdings Corporation Tricyclic fused thiophene derivatives as JAK inhibitors
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US9549927B2 (en) 2012-12-21 2017-01-24 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
WO2014134426A1 (en) 2013-03-01 2014-09-04 Incyte Corporation USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
EP4233869A2 (en) 2013-03-01 2023-08-30 Incyte Holdings Corporation Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
US9932341B2 (en) 2013-03-01 2018-04-03 Incyte Corporation Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
EP3632442A1 (en) 2013-03-01 2020-04-08 Incyte Holdings Corporation Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9926301B2 (en) 2013-05-17 2018-03-27 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
US11591318B2 (en) 2013-05-17 2023-02-28 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
US9382231B2 (en) 2013-05-17 2016-07-05 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
EP3786162A1 (en) 2013-05-17 2021-03-03 Incyte Corporation Bipyrazole derivatives as jak inhibitors
US10435392B2 (en) 2013-05-17 2019-10-08 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
US11001571B2 (en) 2013-05-17 2021-05-11 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
EP3527263A1 (en) 2013-05-17 2019-08-21 Incyte Corporation Bipyrazole derivatives as jak inhibitors
US11905275B2 (en) 2013-05-17 2024-02-20 Incyte Corporation Bipyrazole derivatives as JAK inhibitors
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
EP3231801A1 (en) 2013-05-17 2017-10-18 Incyte Corporation Bipyrazole salt as jak inhibitor
EP4275756A2 (en) 2013-05-17 2023-11-15 Incyte Holdings Corporation Bipyrazole derivatives as jak inhibitors
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
WO2015026818A1 (en) 2013-08-20 2015-02-26 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015131031A1 (en) 2014-02-28 2015-09-03 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
US10675284B2 (en) 2014-04-08 2020-06-09 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
EP3795152A1 (en) 2014-04-08 2021-03-24 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US10064866B2 (en) 2014-04-08 2018-09-04 Incyte Corporation Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors
WO2015157257A1 (en) 2014-04-08 2015-10-15 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
US10450325B2 (en) 2014-04-30 2019-10-22 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
US9802957B2 (en) 2014-04-30 2017-10-31 Incyte Corporation Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015168246A1 (en) 2014-04-30 2015-11-05 Incyte Corporation Processes of preparing a jak1 inhibitor and new forms thereto
US11130767B2 (en) 2014-06-11 2021-09-28 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10479803B2 (en) 2014-06-11 2019-11-19 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
US10596184B2 (en) 2015-02-09 2020-03-24 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10022387B2 (en) 2015-02-09 2018-07-17 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP4183789A1 (en) 2015-02-27 2023-05-24 Incyte Holdings Corporation Salts of pi3k inhibitor and processes for their preparation
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
US10336759B2 (en) 2015-02-27 2019-07-02 Incyte Corporation Salts and processes of preparing a PI3K inhibitor
EP3831833A1 (en) 2015-02-27 2021-06-09 Incyte Corporation Processes for the preparation of a pi3k inhibitor
US11084822B2 (en) 2015-02-27 2021-08-10 Incyte Corporation Salts and processes of preparing a PI3K inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US10125150B2 (en) 2015-05-11 2018-11-13 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US11091491B2 (en) 2015-11-06 2021-08-17 Incyte Corporation Heterocyclic compounds as PI3K-y inhibitors
EP4086259A1 (en) 2015-11-06 2022-11-09 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
US11773102B2 (en) 2015-11-06 2023-10-03 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
US10472368B2 (en) 2015-11-06 2019-11-12 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
EP3792256A1 (en) 2016-01-05 2021-03-17 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US11352340B2 (en) 2016-01-05 2022-06-07 Incyte Corporation Pyridine and pyridimine compounds as PI3K-gamma inhibitors
WO2017120194A1 (en) 2016-01-05 2017-07-13 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
US10479795B2 (en) 2016-06-24 2019-11-19 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors
US10975088B2 (en) 2016-06-24 2021-04-13 Incyte Corporation Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11926630B2 (en) 2017-10-18 2024-03-12 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
EP4006034A1 (en) 2017-10-18 2022-06-01 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US10738057B2 (en) 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
US11225486B2 (en) 2017-10-18 2022-01-18 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019126505A1 (en) 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
US11306079B2 (en) 2017-12-21 2022-04-19 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11833152B2 (en) 2018-02-16 2023-12-05 Incyte Corporation JAK1 pathway inhibitors for the treatment of cytokine-related disorders
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US10669262B2 (en) 2018-03-08 2020-06-02 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
WO2019226213A2 (en) 2018-03-08 2019-11-28 Incyte Corporation AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
EP4056560A1 (en) 2018-03-08 2022-09-14 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2019227007A1 (en) 2018-05-25 2019-11-28 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US11713317B2 (en) 2018-05-25 2023-08-01 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US10947227B2 (en) 2018-05-25 2021-03-16 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
US11912722B2 (en) 2018-07-31 2024-02-27 Incyte Corporation Tricyclic heteroaryl compounds as sting activators
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11427597B2 (en) 2018-07-31 2022-08-30 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
US11186580B2 (en) 2018-09-05 2021-11-30 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor
EP4338801A2 (en) 2018-09-05 2024-03-20 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11396502B2 (en) 2018-11-13 2022-07-26 Incyte Corporation Substituted heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2020159905A1 (en) 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020168178A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
US11590138B2 (en) 2019-06-10 2023-02-28 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
EP3998254A4 (en) * 2019-07-04 2023-08-09 Shenyang Pharmaceutical University 2-aminopyrimidine compound and application thereof
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021041360A1 (en) 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2021211864A1 (en) 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
US11685731B2 (en) 2020-06-02 2023-06-27 Incyte Corporation Processes of preparing a JAK1 inhibitor
WO2021247668A1 (en) 2020-06-02 2021-12-09 Incyte Corporation Processes of preparing a jak1 inhibitor
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022061351A1 (en) 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022199561A1 (en) * 2021-03-23 2022-09-29 杭州阿诺生物医药科技有限公司 Hpk1 kinase inhibitor compound
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
WO2023056421A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2023122134A1 (en) 2021-12-22 2023-06-29 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023172921A1 (en) 2022-03-07 2023-09-14 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
WO2023245053A1 (en) 2022-06-14 2023-12-21 Incyte Corporation Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en) 2022-06-22 2023-12-28 Incyte Corporation Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors

Also Published As

Publication number Publication date
UA80767C2 (en) 2007-10-25
HN2003000422A (en) 2008-06-24
NL1025071C2 (en) 2004-12-30
EP1578732A2 (en) 2005-09-28
NL1025071A1 (en) 2004-06-22
BR0317435A (en) 2005-11-16
UY28135A1 (en) 2004-07-30
GT200300292A (en) 2004-08-13
AU2003288603A1 (en) 2004-07-14
PA8593101A1 (en) 2004-09-16
US20040220177A1 (en) 2004-11-04
AR042531A1 (en) 2005-06-22
GT200300296A (en) 2004-08-13
MXPA05006420A (en) 2006-03-08
AU2003288603A8 (en) 2004-07-14
CA2510848A1 (en) 2004-07-08
WO2004056786A3 (en) 2004-10-21
TW200413330A (en) 2004-08-01
PE20040934A1 (en) 2005-01-18
JP2006515298A (en) 2006-05-25

Similar Documents

Publication Publication Date Title
US20040220177A1 (en) Compound for the treatment of abnormal cell growth
US7674796B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7585869B2 (en) Substituted heterocylces for the treatment of abnormal cell growth
US7071337B2 (en) Benzoimidazole derivatives useful as antiproliferative agents
US7332493B2 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
KR100479401B1 (en) Novel Benzoimidazole Derivatives Useful As Antiproliferative Agents
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO334841B1 (en) Pyrimidine derivatives, processes for their preparation, pharmaceutical compositions comprising such and such compounds for the treatment of abnormal cell growth
ZA200501353B (en) Novel benzoimidazole derivatives useful as antiproliferative agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003780443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006420

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2510848

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004561885

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003780443

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317435

Country of ref document: BR